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ABSTRACT 
Induction of Immunogenic Cell Death with Non-Thermal Plasma for 
Cancer Immunotherapy 
 
Abraham G. Lin 
Vandana Miller, MD. 
 
 
 
 
Even with the recent advancements in cancer immunotherapy, treatments are still 
associated with debilitating side effects and unacceptable fail rates. Induction of 
immunogenic cell death (ICD) in tumors is a promising approach to cancer treatment that 
may overcome these deficiencies. Cells undergoing ICD pathways enhance the interactions 
between cancerous cells and immune cells of the patient, resulting in the generation of anti-
cancer immunity. The goal of this therapy relies on the engagement and reestablishment of 
the patient’s natural immune processes to target and eliminate cancerous cells systemically. 
The main objective of this research was to determine if non-thermal plasma could be used 
to elicit immunogenic cancer cell death for cancer immunotherapy. My hypothesis was that 
plasma induces immunogenic cancer cell death through oxidative stress pathways, 
followed by development of a specific anti-tumor immune response. This was tested by 
investigating the interactions between plasma and multiple cancerous cells in vitro and 
validating anti-tumor immune responses in vivo. Following plasma treatment, two 
surrogate ICD markers, secreted adenosine triphosphate (ATP) and surface exposed 
calreticulin (ecto-CRT), were emitted from all three cancerous cell lines tested: A549 lung 
carcinoma cell line, CNE-1 radiation-resistant nasopharyngeal cell line and CT26 
colorectal cancer cell line. When these cells were co-cultured with macrophages, cells of 
the innate immune system, the tumoricidal activity of macrophages was enhanced, thus 
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demonstrating the immunostimulatory activity of cells undergoing ICD. The underlying 
mechanisms of plasma-induced ICD were also evaluated. When plasma is generated, four 
major components are produced: electromagnetic fields, ultraviolet radiation, and charged 
and neutral reactive species. Of these, we determined that plasma-generated charged and 
short-lived reactive oxygen species (ROS) were the major effectors of ICD. Following 
plasma treatment, ROS immediately increased. When chemical attenuators of ROS were 
used, intracellular ROS was abrogated and emission of ICD markers were attenuated. This 
strongly suggests that plasma-induced ICD is associated with increased intracellular ROS. 
The gold-standard approach to evaluating whether a stimulus can elicit genuine ICD relies 
on a vaccination assay. CT26 colorectal cancer cells were treated at ICD-inducing regimes 
of plasma and injected into syngeneic Balb/c mice. One week later, mice were challenged 
with live CT26 cancer cells. Tumor progression was moderated in animals immunized with 
plasma-treated CT26 cells. Altogether, these provide strong evidence that plasma regimes 
can be adapted for a new application: ICD induction. Next, a study was conducted to test 
the potential of plasma to induce ICD in tumors in animals. Plasma treatment of 
subcutaneous tumors in mice elicited the emission of ecto-CRT and high mobility group 
box 1 (HMGB1), another marker of ICD, in the tumor and also recruited CD11c+ and 
CD45+ immune cells locally. This was followed by development of cancer-specific splenic 
T cells, indicating that a systemic anti-tumor response was elicited from localized plasma 
treatment of the tumor. Overall, this work demonstrates the development of non-thermal 
plasma as a novel method of inducing immunogenic cell death for cancer immunotherapy. 
The obtained results further our understanding of plasma-cellular interaction mechanisms 
and highlight the potential for clinical translation.
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CHAPTER 1: INTRODUCTION 
1. BACKGROUND AND MOTIVATION 
Cancer is the second leading cause of death with 8.2 million deaths worldwide, and 
in the US alone, it was anticipated that there would be 1.7 million new cases and 0.6 million 
deaths in 2016 [1]. While improved diagnostics and new therapeutic approaches have led 
to higher rates of cancer survival, they are often accompanied by debilitating short- and 
long-term side effects and high cost of care [2-4]. The associated economic burden of long-
term care has also increased over the years with the total projected cost estimated at $120 
billion in 2020 [5]. Moreover, in certain cancers, development of resistance to therapy has 
led to inevitable failure of treatment [6-8]. Even patients successfully treated for cancer 
may experience relapse [9, 10]. Therefore, it is altogether clear that new treatment 
methodology and novel therapeutic modalities are required to address the ongoing 
healthcare and economic burden. 
Clinical treatment of cancers have typically relied on surgery or the delivery of 
cytotoxic agents, locally with radiation or systemically with chemotherapy. The aim of 
these strategies has been focused on eliminating cancer cells in the patient, but is not 
usually tumor-specific; there is significant, yet reversible, toxicity to non-cancerous tissue 
[11]. For these treatments to be effective, the ability of normal tissue to repair therapy-
associated damage is critical to enable patients to tolerate and continue treatment [11]. 
The success of these anti-cancer therapies, is often limited by their inability to 
eliminate all cancerous cells; cells surviving treatment continue to grow and can even 
develop resistance to treatment [12-15]. In recent years, cancer immunotherapy has been 
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emerging to overcome this deficiency and a promising approach is to initiate immunogenic 
cell death (ICD) in tumor cells [16]. Cells undergoing ICD pathways help increase the 
affinity between cancerous cells and patient immune cells, which results in the subsequent 
generation of a specific, anti-cancer immune response [17]. The goal of this therapy does 
not rely only on differential toxicity against tumor and healthy cells, but also on 
engagement and reestablishment of the patient’s natural immune processes to target and 
eliminate cancerous cells systemically [18]. Therefore, reduced side-effects and long-term 
protection against cancer may be achieved [19-22]. ICD of tumor cells have been achieved 
using certain chemotherapeutic drugs (e.g. doxorubicin and mitoxantrone) or through 
direct physical methods (e.g. radiation and UV C light) [22-26]. While results in both the 
lab and clinical settings appear promising, cytotoxicity to healthy tissue is still prevalent as 
chemotherapeutics leave behind active drug residuals and radiation is penetrating and non-
specific [25, 27, 28]. As a result, there is a need for the development of novel ICD-inducers 
that deliver maximal therapeutic effects while minimizing toxicity to surrounding healthy 
tissue [26].  
II. HYPOTHESIS, OBJECTIVES, AND SPECIFIC AIMS 
Non-thermal plasma is a technology that is being explored for medical research in 
a rapidly growing field known as plasma medicine [29-32]. The ability of non-thermal 
plasma to destroy cancerous cells, both in vitro and in vivo, has been well documented 
throughout scientific literature [33-38]. However, the involvement of the immune system 
in the resolution of cancers with plasma has largely been ignored and the ability to induce 
ICD has never been investigated. Though the pathways that lead to ICD are not fully 
understood, ICD has been associated with 1) increased intracellular reactive oxygen 
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species (ROS), 2) endoplasmic reticulum (ER) stress and 3) emission of danger signals 
known as damage associated molecular patterns (DAMPs) [39-41]. Since multiple groups 
have reported on the ability of non-thermal plasma to elicit oxidative stress [38, 42-45], my 
hypothesis is that plasma induces immunogenic cancer cell death through oxidative stress 
pathways, initiating antigen presenting cell recruitment followed by specific anti-tumor T 
cell development. 
The goal of my study is to 1) explore the potential of non-thermal plasma induction 
of immunogenic cell death, 2) determine the underlying mechanisms of plasma-induced 
ICD and 3) evaluate the downstream protective immune responses. This would find 
application in cancer immunotherapy. To this end, the following specific aims are defined. 
Specific Aim 1: Evaluate the capacity of plasma to elicit immunogenic cell death in 
vitro. This aim will be broken down to answer the following questions.  
Question 1: Can plasma stimulate emission of DAMP signals characteristic of ICD? 
Although it is well established that plasma can induce apoptosis and necrosis in 
various cell types [44-48], the potential for plasma to stimulate ICD has not been 
explored. Presently, several surrogate markers of ICD (DAMPs) have been 
established as in vitro indicators of whether a stimulus can elicit ICD [39]. 
Calibration of plasma treatment to elicit DAMP emission from multiple cancer cell 
lines will be performed. This will not only define previously unknown biological 
outcomes following plasma exposure, but may also be exploited for cancer 
immunotherapy. 
Question 2: Is plasma-induced DAMP emission immunostimulatory? 
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Not all emitted DAMPs can trigger an immune response [49, 50], therefore, it is 
crucial to determine whether plasma-induced DAMP emission can enhance 
existing immune responses. Co-culturing plasma-treated cancer cells with 
macrophages, cells of the innate immune system, will be performed to assess 
immunostimulatory effects of plasma-induced ICD. This will help establish the 
immunogenic capacity of plasma treatment for further development in cancer 
immunotherapy. 
Question 3: Can mice immunized with cancer cells treated with ICD-inducing 
plasma develop protection against tumor challenge? 
While there is an ample panel of surrogate ICD-associated markers, presently, the 
most accepted approach to assess whether a stimulus can cause bona fide ICD relies 
on a vaccination assay [22, 51]. This assay will be performed following protocols 
defined by the ICD community and will provide insight into the degree of 
immunogenicity of plasma-elicited cell death. This will further establish whether 
plasma is a genuine ICD inducer. 
Specific Aim 2: Determine the underlying mechanisms of plasma-induced ICD. This 
aim will be broken down into two parts to elucidate both plasma (extracellular) 
mechanisms and intracellular mechanisms. 
Question 1: Which components of plasma are predominantly responsible for 
eliciting ICD? 
When plasma is generated directly onto cells, cells are exposed to four major 
plasma components: electromagnetic fields, UV radiation, charges, and neutral 
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species [52-55]. These components will be strategically isolated and removed from 
cancer cell treatment, with physical and gas barriers, and their effect on cell 
viability and DAMP emission will be assessed. Since each of the four plasma 
elements are known to independently influence cell death, both immunogenic and 
non-immunogenic [56-60], delineation of the major plasma components that are 
responsible for ICD induction will help further our understanding of fundamental 
plasma-cell interactions and help optimize a plasma delivery system most suited 
for onco-immunological studies.  
Question 2: Is plasma-induced ICD associated with oxidative stress? 
There is mounting evidence in scientific literature that plasma treatment alters the 
oxidation and reduction (redox) environment of cells [31, 43, 61]. The redox state 
is tightly controlled by the production and removal of reactive oxygen species 
(ROS) and is known to regulate cell processes from proliferation and quiescence to 
cell death [33, 62, 63]. Although the mechanisms which promote ICD are not fully 
understood, elevated ROS levels have been identified in association with cells 
undergoing ICD [40, 41]. Following plasma treatment in our previously defined 
ICD-inducing regime, the intracellular ROS levels will be measured. Chemical 
agents that attenuate intracellular ROS will then be used to determine the 
association between increased ROS and plasma-induced ICD. Studying this 
relationship will help further our understanding of the underlying mechanisms by 
which plasma can initiate ICD.  
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Specific Aim 3: Determine the efficacy of plasma-induced ICD to stimulate anti-
cancer immunity in vivo. In order to validate whether plasma-induced ICD observed in 
vitro can generate an anti-cancer immune response in live organisms, experiments will be 
performed in mice and the following two questions will be addressed. 
Question 1: Does plasma treatment of tumors elicit DAMP emission? 
While direct treatment of cancerous cells in vitro with plasma may induce ICD, the 
capacity of plasma to elicit ICD and trigger a therapeutic immune response in 
animal tumor models requires investigation. Validation that plasma treatment of 
tumors can induce emission of DAMP signals is critical to assess the feasibility of 
plasma technology for clinical use, as treatment will likely require overcoming 
barriers (i.e. epidermal or endothelial layers) to reach tumors. This will also help 
establish the temporal development of DAMP signals following plasma exposure, 
for optimization of treatment. 
Question 2: Can plasma-induced ICD initiate a specific T cell response against 
tumor antigens? 
A specific T cell response against tumor cell antigens is required to both eliminate 
tumor cells and reduce the incidence of cancer recurrence following treatment [64]. 
Following plasma treatment of tumors in mice, mice will be monitored for a period 
of 3 weeks to allow for the development a specific anti-cancer immune response. 
This response will be evaluated by resecting mice spleens at the end of the 
experiment and quantifying the number of cancer-specific effector T cells that have 
developed [65]. This will establish whether local treatment of tumors with plasma 
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can generate a systemic immune response for potential control and eradication of 
cancer. 
III. THESIS ORGANIZATION 
 This thesis is organized in the following sections. First, as shown above, the 
overall objectives, hypothesis and specific aims are defined. Chapter 2 consists of a review 
of immunogenic cell death characteristics and the known physical inducers. Chapter 3 
provides the background of plasma medicine with a focus on the present state of non-
thermal plasma application for cancer treatment. The following chapters are adapted from 
manuscripts that have been published or are under review. Chapter 4 reports the first 
experiments performed to determine whether plasma can induce emission of the danger 
signal, ATP, and subsequent immune cell stimulation. Insight into the involvement of ER 
stress response is also included. Chapter 5 describes the physical and gas barriers 
engineered to isolate and remove plasma constituents from treatment. This was done to 
elucidate the components of plasma that are important for cell death. Chapter 6 further 
expands on the previous study for identification of plasma components that elicit ICD 
specifically. Furthermore, chemical attenuators of intracellular ROS were used to delineate 
the association of plasma-induced oxidative stress with induced ICD. Chapter 7 reports on 
the in vivo investigation, including the ‘gold standard test’ for ICD, validation of plasma-
induced ICD in tumors and the development of cancer-specific splenic T cells in mice. 
Chapter 8 discusses the selectivity of plasma against tumor cells and direct augmentation 
of immune cell function. Since the immune system is designed to discriminate between 
self and non-self, this property must be retained following plasma treatment to avoid any 
autoimmune responses. Furthermore, direct enhancement of existing immune cell function 
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could be exploited for cancer immunotherapy and may contribute to additional advantages 
of plasma treatment compared to current ICD-inducing modalities, both physical and 
chemical. Finally, chapter 9 will detail the overall conclusions and proposed future work.  
Specific Aim 1: Evaluate the capacity of plasma to elicit immunogenic cell death in 
vitro. 
 Chapter 4- 1) First detection of a DAMP signal (secreted ATP) in vitro in a CNE-
1 radiation resistant nasopharyngeal cell line; 2) Evaluated immunostimulatory 
response of plasma induced-ICD via co-culture with macrophages. 
 Chapter 6- 1) Detected DAMPs (secreted ATP and ecto-CRT) in vitro in an A549 
lung carcinoma cell line; 2) Evaluated immunostimulatory response of plasma 
induced-ICD via co-culture with macrophages. 
 Chapter 7- 1) Detected DAMPs (secreted ATP and ecto-CRT) in vitro in a CT26 
colorectal cancer cell line; 2) Evaluated immunostimulatory response of plasma 
induced-ICD via co-culture with macrophages. 3) Established plasma as a bona fide 
ICD inducer via the ‘gold standard test’ for ICD 
Specific Aim 2: Determine the underlying mechanisms of plasma-induced ICD. 
 Chapter 4- Detected ER stress following plasma treatment in the ICD-inducing 
regime. 
 Chapter 5- 1) Engineered the physical and gas barriers used to isolate and remove 
plasma components from treatment. 2) Evaluated the contribution of each plasma 
component on cell death. 
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 Chapter 6- 1) Using barriers described in chapter 5, evaluated the contribution of 
each plasma component on ICD. 2) Determined relationship between increased 
intracellular ROS with plasma-induced ICD.  
Specific Aim 3: Determine the efficacy of plasma-induced ICD to stimulate anti-
cancer immunity in vivo. 
 Chapter 7- 1) Evaluated plasma-induced ICD in vivo and local recruitment of 
immune cells. 2) Assessed cancer-specific splenic T cell development.   
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CHAPTER 2: IMMUNOGENIC CELL DEATH FOR CANCER 
IMMUNOTHERAPY 
I. CANCER IMMUNOTHERAPY 
It has long been a goal in immunology and oncology to activate the patient’s 
immune system for therapeutic benefit and resolution of cancer [19]. Most advances have 
been passive immunotherapy strategies; anti-cancer monoclonal antibodies or T cells are 
grown and expanded in vitro and then transferred into patients with cancer to induce an 
immune reaction [66, 67]. Presently, monoclonal antibodies have been approved for 
treatment of solid and hematological malignances, targeting six cancer-associated proteins 
(Her2/neu, EGFR, VEGF, CD20, CD52 and CD33) [68-73]. While patients have benefited 
from these treatment, several barriers still stand in the way for this to be a practical and 
effective strategy. First, the process of harvesting and expanding antibodies and T cells for 
transfer is typically very expensive and labor intensive. Second, tumor-associated antigens 
are often closely related, sometimes identical to self-antigens; therefore, development of 
autoimmune responses and side effects has been associated with treatment [70, 72].  
Contrary to the passive strategies that bypass required steps to activate endogenous 
immunity, active stimulation of an adaptive, anti-cancer immunity is preferred for 
obtaining a robust immune response [19]. There are three main milestones that must be 
achieved to mount an effect adaptive immune response. First, antigen presenting cells 
(APCs), cells of the innate immune system such as dendritic cells (DCs), must recognize 
and engulf cancerous cells in order to process the tumor antigens [74, 75]. In the presence 
of immunogenic activation signals, DCs will mature and differentiate. Next, these activated 
DCs must migrate to the lymph organs, to present the captured and processed antigen to T 
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cells in order to generate protective T-cell responses [75-77]. Upon interaction with a T 
cell that recognizes the presented antigen, effector T cells and memory T cells are produced 
[78]. Effector T cells have cytotoxic potential against the specific tumor-antigen. These 
cells are the main ‘killers’ for eliminating cancerous cells though out the body [75, 79]. 
Memory T cells, on the other hand, do no directly respond to the present threat of cancer 
in the patient, but are required for long-term protection against cancer recurrence [80, 81]. 
The last milestone is that tumor-specific, effector T cells must leave the lymph organs and 
enter the tumor bed to perform their tumoricidal function [82]. 
Active immunotherapy strategies in the past first involved the introduction of a live 
or inactivated bacteria into cancer patients. This stimulates anti-bacterial phagocytes which 
are thought to subsequently kill bystander tumor cells [83, 84]. Based on these initial 
experiments, more effective agents have been developed including free peptides and whole 
or partial tumor cells [85-87]. However, due to the risks associated with introducing 
potentially infectious agents into cancer patients with already weakened immune systems, 
oncologists did not embrace this new method. Furthermore, poor understanding of 
immunization mechanisms, particularly the role of dendritic cells, resulted in limited and 
irreproducible success. It is now well known that DCs are critical for stimulating adaptive 
responses, and therefore, cancer vaccines and vaccination strategies have improved and 
even include dendritic-cell-based vaccines [88-90]. The DC-based vaccine uses DCs 
isolated from cancer patients and load them with cancer antigens ex vivo [89]. The DCs are 
then activated and reintroduced into the patient to go through the subsequent adaptive 
immunity pathways [89]. While there are promising responses, this approach has not 
gained extensive support, again due to the complexities of cell isolation, manipulation, and 
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reintroduction [19, 83]. Furthermore, several cancer vaccines are in clinical trials, often in 
combination with other therapies, but therapeutic responses have mostly been marginal 
[91, 92]. Therapies that failed highlight the importance of vaccine manufacturing methods 
and the need to adequately address a spectrum of tumor antigens for a robust therapeutic 
response. 
 Another active immunotherapy strategy that has been emerging is the use of agents 
that directly modulate T cell function [93-96]. Most important has been the development 
and use of ipilimumab which has been shown in a phase III clinical trial, to improve 
survival in patients with late-stage metastatic melanoma, a deadly disease with no other 
therapeutic option [93]. Ipilimumab is a monoclonal antibody to cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4), a protein receptor on T cells that inhibits activation and 
expansion [97, 98]. The use of ipilimumab blocks CTLA-4 so that protective T cells 
already present in the patient can exert their anti-cancer activity. The FDA has granted 
approval for the use of ipilimumab in patients with metastatic melanoma in 2011 due to its 
clear therapeutic efficacy, but there are still several clinical and scientific challenges 
associated with the drug. Firstly, some ipilimumab-treated patients develop autoimmune 
responses manifested as serious side effects (e.g. colitis, hepatitis and hypophysitis) [93, 
98]. Another challenge relates to the rate of anti-cancer response. While conventional 
chemotherapies can trigger rapid tumor reduction due to direct cytotoxic effects on cancer 
cells, T cell responses following ipilimumab treatment may take several months to occur, 
and evaluation of tumor progression with conventional methods may be inaccurate [99]. 
Improved endpoints for cancer immunotherapy trials are being developed to more 
accurately evaluate efficacy of these treatments [99, 100]. Despite these limitations, the 
13 
 
 
 
development of ipilimumab attests to the progress of active immunotherapies for cancers 
previously without treatment option. 
Overall, it is clear that cancer immunotherapy has been rapidly progressing over 
the past few decades, due to growth in present understanding of immunology. However, 
these therapies are expensive and the procedures are laborious and complex. Furthermore, 
introduction of vaccines or modulation of existing immune function have either had 
marginal effects or are associated with significant toxic side-effects. More recently, another 
avenue for cancer immunotherapy, induction of immunogenic cell death (ICD), has been 
emerging as a promising and effective approach for cancer treatment without associated 
side-effects. 
II. IMMUNOGENIC CELL DEATH 
Initially described by Zitvogel, Kroemer and co-workers, ICD is a modality of cell 
death in which dying cells stimulate immune responses against dead-cell antigens [17, 25, 
101]. In cancer therapy, this is advantageous since tumor cells undergoing ICD activate an 
adaptive anti-tumor immune response. The induction of ICD facilitates the front-end of the 
adaptive immune response by promoting cancer recognition and antigen capture by DCs. 
While the circumstances that trigger ICD are not fully understood, “danger signals” 
characteristic of ICD have been identified. They are known as damage associated 
molecular patterns (DAMPs) [21]. 
II.1 DAMP SIGNALS 
DAMPs associated with ICD include changes to the surface composition of the cell 
and secretion of soluble factors. These signals that recruit and activate APCs include: 
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surface exposure of calreticulin (ecto-CRT), heat shock protein 70 (HSP70) and HSP90 
and secretion of adenosine triphosphate (ATP) and high mobility group box 1 (HMGB1) 
[102-105].  
II.1.1 Calreticulin 
CRT is a protein located on the endoplasmic reticulum, where it acts as a molecular 
chaperone and regulates calcium homeostasis and signaling [106, 107]. CRT is translocated 
to the plasma membrane when cells undergo ER stress with concomitant oxidative stress 
[41, 106]. On the cell surface, exposed CRT acts as an ‘eat me’ DAMP signal that facilitates 
recognition, engulfment and processing of tumor cells by APCs [105, 108], a critical step 
for the initiation of an adaptive anti-cancer response [75]. CRT is considered the most 
important DAMP signal, as Obeid et al have reported that surface CRT dictates the 
immunogenicity of cancer cell death and the ability of a treatment to elicit an adaptive anti-
cancer response [60]. 
II.1.2 Adenosine Triphosphate 
ATP, the most abundant intracellular molecule required for metabolism, is secreted 
from cells undergoing ICD [103, 109]. Although the precise mechanism leading to ATP 
secretion is not fully understood, it is known to be facilitated by autophagy and considered 
pre-apoptotic [110-112]. Reports have also suggested that secretion of ATP follows 
overlapping pathways with CRT externalization [112]. Once ATP reaches the extracellular 
milieu, it becomes another hallmark of ICD and can increase the immunogenicity of dying 
cells, by functioning as a chemoattractant, ‘find me’ DAMP signal, for recruitment and 
activation of APCs [111-113]. Furthermore, extracellular ATP is known to stimulate the 
release of anti-tumor factors [e.g. tumor necrosis factor alpha (TNFα), interleukin 1 beta 
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(IL-1β), and IL-18] from dendritic cells and macrophages, suggesting that it may directly 
enhance tumoricidal activity of APCs [114-117].  
II.1.3 High Mobility Group Protein Box 1 
HMGB1 is nuclear protein, present in almost all eukaryotic cells, that functions to 
regulate transcription of several genes [118]. Interestingly, HMGB1 is upregulated in 
numerous tumor types including colorectal cancer, breast cancer, prostate cancer and 
pancreatic cancer [119-122]. In fact, intracellular HMGB1 is reported to play a role in 
cancer cell survival, functioning as an anti-apoptotic factor [123]. However, when it is 
secreted from cells experiencing ICD, HMGB1 functions as a DAMP signal by recruiting 
APCs into the tumor microenvironment [124-126]. Furthermore, the initially released 
HMGB1 from dying cells mediates signaling between the various recruited immune cells, 
causing activation of macrophages and maturation of DCs [127]. This can lead to the 
further secretion of HMGB1 and other cytokines such as tumor-necrosis factor (TNF) and 
interleukin-6 (IL-6) [128].  
II.1.4 Heat Shock Protein 70 & 90 
Heat shock proteins (HSPs) are the most abundant and universal intracellular 
protein in both prokaryotic and eukaryotic cells located in the cytosol, ER and 
mitochondria [102]. Mammalian HSPs are classified into five families based on molecular 
size: small HSPs, HSP60, HSP70, HSP90 and HSP100 [102]. They become highly 
expressed in response to physiological and environmental stress such as heat, oxidative 
stress and even anti-cancer drugs [129]. Under stress conditions, they perform multiple 
functions critical for cell survival, including catalyzing the proper folding of misfolded 
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proteins and inhibiting caspase activation and apoptotic cell death [130-133]. Certain HSPs 
are often overexpressed in a wide range of tumor cells and are associated with 
tumorigenesis and drug resistance [133-135]. However, following treatment with ICD-
inducers, HSP70 and HSP90 are released into the extracellular environment or become 
membrane bound to mediate immunological functions [136]. HSP70 and 90 in the 
extracellular space can initiate release of proinflammatory cytokines (e.g. TNF, IL-1β, IL-
12, etc.) from APCs, which have both tumoricidal and immunostimulatory effects [137]. 
Furthermore, HSP70 involvement in maturation of DCs and migration to draining lymph 
nodes have been documented [137, 138]. Externalization of HSP70 and 90 on the surface 
membrane of cancer cells can interact with multiple APC receptors to facilitate tumor cell 
uptake, tumor-associated antigen processing and presentation [139, 140]. 
II.2. GOLD STANDARD TEST FOR IMMUNOGENIC CELL DEATH 
While numerous ICD-associated markers have been identified, the most accepted 
approach to evaluate the capacity of a stimulus to cause ICD relies on a vaccination assay 
known as the ‘gold standard test’ [51]. Here, cancerous cells are exposed to the stimulus in 
vitro and then washed and resuspended in PBS. This is to thoroughly remove the stimulus 
from vaccination. Next, the treated cells are injected subcutaneously into the flank of 
immunocompetent, syngeneic mice. One week following immunization, mice are 
challenged with living cancer cells of the same type by subcutaneously introducing them 
into the contralateral flank. Mice are then monitored for the appearance of tumors. The 
degree of immunogenicity of cell death from the stimulus under evaluation is determined 
by the proportion of mice that are protected against tumor development upon cancer 
challenge. Established ICD-inducers, such as doxorubicin and mitoxantrone, effectively 
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protected 80% of vaccinated mice and may be used as a positive control [25, 60]. Not only 
is this assay the gold-standard indicator of induced ICD, several cancer vaccines have been 
developed through in vitro ICD induction and are currently being evaluated in clinical 
trials. 
II.3. PHYSICAL MODALITIES OF IMMUNOGENIC CELL DEATH 
A growing list of physical inducers of ICD have been identified which include 
various forms of radiation, photodynamic therapy with hypericin (PDT-Hyp) and high 
hydrostatic pressure (HHP).  
II.3.1 Radiation 
Radiation treatment is used in approximately 50% of cancer patients with the intent 
of curing cancer or alleviating associated pain [141]. In fact, when development of cancer 
therapies had primarily been focused on direct tumor-cell killing, radiotherapy provided 
early indications that the immune system contributed to positive therapeutic responses, 
known as ‘abscopal effects’ [142]. This was first reported in 1953 and described as a 
phenomenon where radiation therapy could reduce tumor growth at distal sites outside of 
primary treatment area, via anti-cancer immunity [143]. However, the immunological 
mechanisms remained largely unknown, and the irreproducibility of effect impeded its 
establishment as a therapeutic paradigm. This has changed over time with increasing 
knowledge of immunology and mounting evidence that anti-cancer immune responses play 
major roles in therapeutic success. 
In 2007, the group of Zitvogel and Kroemer reported that radiotherapy, including 
treatment with UV C light (280-200 nm), was capable of inducing ICD in tumor cells [24]. 
18 
 
 
 
Interestingly enough, ICD has not been observed following UV A (400-320 nm) or UV B 
(320-280 nm) treatment [60, 144]. Since UV A, B and C are all capable of stimulating 
intracellular ROS production and ER stress, the subtle differences that distinguish UV C 
as an ICD-inducer requires further investigation [145, 146]. Irradiation with X-rays, γ-rays 
and even α-rays (with bismuth-213) has been demonstrated to elicit ICD [24, 147-149]. In 
vitro, they have stimulated the emission of multiple DAMPs (ecto-CRT, ecto-HSP90 and 
HMGB1) from tumor cells and subsequent DC activation. Furthermore, vaccination with 
cancerous cells irradiated with these types of radiation induced long-lasting protective anti-
tumor response in mice upon tumor challenge. 
In humans, there are no clinical studies involving UV C treatment and evidence for 
ICD induction in cancer patients with other radiotherapies is scarce. Radiotherapy is often 
used in combination with chemotherapeutics to improve clinical outcomes of treatment 
[141]. Suzuki et al, demonstrated that chemoradiotherapy caused ICD in patients with 
esophageal squamous cell carcinoma leading to subsequent tumor-specific T cell responses 
[150]. Radiation therapy has also been shown to improve therapeutic response when used 
in combination with immunotherapeutic agents (e.g. monoclonal antibodies, cancer 
vaccines and checkpoint inhibitors) [151-154]. Presently, there are several ongoing clinical 
trials evaluating the use of radiation therapy with immunotherapy [141, 155]. 
II.3.2 Photodynamic Therapy with Hypericin 
Although PDT may not be considered a completely physical modality due to the 
use of chemical photosensitizer, it is discussed due to the critical involvement of its 
physical aspect [156]. PDT is a two-step process involving administration of a tumor 
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localizing photosensitizer followed by its activation with a specific wavelength of light 
[157]. This causes the photochemical production of ROS resulting in oxidative stress.  
A major advantage of PDT is the ability to incite oxidative stress in very specific 
locations, even subcellular organelles. Hypericin is a photosensitizer that mainly localizes 
in the ER membrane and thereby is able to cause ROS-based ER stress [158, 159]. It 
induces all the major molecular and immunological hallmarks of ICD in vitro and treatment 
in vivo has also produced anti-tumor effects [112, 158]. Although PDT has been used in 
over 200 clinical trials since the 1970s to treat numerous cancers, it has been focused on 
causing a mixture of apoptosis and necrosis [160]. Little is known on the immune effects 
of PDT, and there is no clinical data on the use of PDT-based cancer vaccines in 
immunotherapy. 
II.3.3 High Hydrostatic Pressure 
HHP, in biotechnology, is normally applied to sterilize food and pharmaceuticals, 
but in medicine, it can affect cell function (e.g. inhibition of enzyme functions and 
synthesis of stress proteins) [161, 162]. HHP between 1 and 100 megapascals (MPa) causes 
reversible morphological changes and induces cell stress responses [163, 164]. As HHP 
increases, 150-250 MPa, human cells undergo apoptosis, and when HHP increases above 
300 MPa, necrosis occurs [163, 164]. HHP induces ICD in human prostate and ovarian 
cancer cell lines, characterized by emission of the four major DAMP signals [165]. 
Furthermore, DCs loaded with tumor cells killed by HHP exhibited enhanced phagocytic 
capacity and stimulated high numbers of tumor-specific T cells [165]. In vivo evaluation 
of the ICD-inducing effects of HHP is still under investigation. 
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HHP treatment is mostly being used to create effective cancer vaccines [156]. There 
are presently multiple clinical trials evaluating the therapeutic potential of DC-based cancer 
vaccines stimulated with HHP-treatments for prostate and ovarian cancer [156].  
III. ICD INDUCTION REQUIRES ROS GENERATION AND ER-STRESS 
While it is not fully understood why some therapies can induce ICD while others 
cannot, the commonality between ICD-inducers is that they increase intracellular ROS and 
provoke ER-stress [41]. In fact, ICD has been shown to depend on the combined action of 
increased intracellular ROS and induction of ER stress. In the presence of antioxidants and 
other ROS attenuators, several ICD-inducers showed diminished immunogenicity cell 
death, highlighting the importance of ROS for ICD induction [40, 41]. However, increased 
intracellular ROS is not enough to prompt ICD, as cisplatin, a chemotherapeutic agent that 
alters cellular redox, was unable to evoke ICD because ER stress was not induced [166].  
ICD-inducers have been classified into two categories based on their action of 
inducing ER stress and apoptosis. A Type I ICD inducer is one that causes ER stress and 
apoptosis indirectly through ‘collateral’ effects [167]. These include most 
chemotherapeutic agents, such as doxorubicin and mitoxantrone, which mostly localize in 
the nucleus with a small portion found on extra-nuclear compartments, including the ER 
[168]. Type II inducers, on the other hand, selectively target the ER to trigger stress [167, 
169]. This includes photodynamic therapy with hypericin, described above, where the 
photosensitizer localizes in the ER membrane and produces ROS. While the exact 
connections between ER stress and ROS production for both Type I and Type II ICD 
inducers still need to be fully elucidated, it is clear that the parallel production of ROS and 
stress of the ER are essential events that dictate immunogenicity of cell death. 
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CHAPTER 3: PLASMA MEDINCE: PLASMA FOR CANCER TREATMENT 
I. PLASMA 
In medicine and biology, plasma is defined as the salt and protein solution of blood 
that keeps red and white blood cells in suspension. However, in the realm of physical 
sciences, plasma refers to the fourth state of matter, preceded by gases, liquids and solids. 
It is defined as an ionized medium, often gas, and is composed of a complex environment 
of physical (e.g. electric fields, UV light, shock waves, etc.) and chemical (e.g. electrons, 
ions, oxygen radicals, etc.) constituents [52, 170]. Plasmas occur widely in nature in many 
forms (e.g. lightning, aurora borealis, solar corona, etc.) but can also be man-made with 
applications in gas metal arch welding, fluorescent lighting and fabrication of 
semiconductor electronics [52, 171]. A distinguishing characteristic of plasma is its 
temperature, which can range from near room temperature (25oC) to over that of the surface 
of the sun (6,000oC) [172, 173]. Devices that generate high temperature, thermal plasmas, 
have been used for metallurgy and welding, and those that produce low temperature, non-
thermal plasmas, have been used for treatment of thermally sensitive surfaces, such as 
semiconductor electronics or fabrics [172-174]. In the process of plasma generation, the 
applied external energy is acquired much faster by electrons than ions, which are orders of 
magnitude heavier. Due to inefficient energy transfer between light electrons and heavy 
gas atoms and molecules, electron temperatures can reach 104 K while surrounding gas 
temperature remains relatively low and non-thermal, ~297K [175]. These non-thermal 
plasmas are also termed non-equilibrium plasma since electrons and gas molecules are at 
very different temperatures. On the other hand, given enough time for energy transfer 
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between electrons, heavy particles and the surrounding gas environment, temperature of 
heavy particles and electron reach equilibrium and thermal plasmas are generated [172]. 
II. PLASMA MEDICINE 
Historically, thermal plasmas for thermal ablation of tissue have been most widely 
used in clinical applications [176, 177]. Plasma devices and techniques, such as 
electrosurgery and argon plasma coagulation, have been used in the clinic as early as the 
1970’s. In recent years, non-thermal plasmas applications have been emerging for medical 
research, thus starting the field of plasma medicine. In contrast to using plasma for its 
thermal effects, non-thermal plasma relies on its chemical and physical products to induce 
cellular effects [32, 178, 179]. When non-thermal plasma is generated, a complex milieu 
of chemical and physical constituents is produced including: electric fields, ultraviolet 
(UV) light and charged and neutral reactive atoms and molecules [179]. In particular, a 
chemically rich mixture of reactive oxygen and nitrogen species (RONS) is produced, 
consisting of atomic oxygen (O), hydroxyl radical (OH), superoxide (O2
-), singlet-delta 
oxygen (1O2) hydrogen peroxide (H2O2), nitric oxide (NO), peroxynitrite (ONOO) and 
many others [180-184]. These species are known to affect the oxidative state of the cell, 
also known as the cellular oxidation and reduction (redox) environment, which is a balance 
of RONS production and removal by antioxidants [62, 63]. Changes to cellular redox can 
induce a wide array of cellular responses ranging from proliferation to senescence and 
death [185, 186]. Physiological levels of ROS influence cellular pathways related to cell 
survival and development such as growth and proliferation [185]. However, excessive 
intracellular ROS triggers oxidative stress pathways that may lead to metabolic alterations, 
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apoptosis and necrosis [187]. Therefore, using plasma to controllably administer RONS 
exogenously to influence cellular redox has potential therapeutic effects. 
As the focus of plasma medicine is to stimulate or stress living cells and tissue 
without thermal destruction, plasma devices must be able to produce non-thermal plasma 
stably and reproducibly under atmospheric pressure conditions and at relatively low 
temperatures (<40oC) at the point of contact with tissue to avoid thermal damage.  
II.1 PLASMA MEDICINE DEVICES 
Numerous plasma medicine devices have been developed and adapted since the 
beginning of this field, and most can be categorized into two families: Dielectric barrier 
discharges (DBD) and atmospheric pressure plasma jet (APPJ). 
DBDs generate plasma by applying high voltage, short duration pulses or sinusoidal 
waveforms between two electrodes, at least one of which is insulated by a dielectric 
material [29, 171]. The dielectric prevents build-up of current between the electrodes when 
the applied electric field breaks down the gas in the gap [175]. Thus, an electrically and 
thermally safe plasma is created. For medical applications, the target for treatment (e.g. 
cells and tissue) acts as the second electrode. Therefore, treatment with DBD plasmas are 
often considered the direct plasma approach as plasma is in direct contact with the treated 
tissue.   
Treatment with AAPJs, on the other hand, are considered an indirect plasma 
approach. Although there are numerous APPJ configurations, the underlying principle is 
same [173, 188]. In contrast to DBDs, here plasma is often generated remotely and 
transported to the target by a flow of working gas [188, 189]. Ionization waves also produce 
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some plasma at the treatment surface [189]. APPJs can differ by their gas and applied 
electrical properties, and therefore, the resulting chemical species produced in plasma can 
also vary. Not only is the proximity of plasma generation in relation to tissue different 
between the two systems, but the chemical species generated and deposited on the target, 
particularly short-living reactive species, are also altered [170, 175, 188].  
Both DBDs and APPJs have advantages and disadvantages in the medical setting. 
DBD electrodes can be fabricated to a variety of sizes for small, precise treatments or large 
field treatments [190]. APPJs are often limited to spot-like treatments as the plume of 
plasma exiting the aperture of the jet is only a couple millimeters in diameter [170]. One 
approach to treat larger areas involves moving the jet in a sweeping fashion, but this may 
result in uneven treatment and reproducibility of results is often difficult [191]. One 
advantage of APPJJs is that it can be more stable compared to DBDs, since the plasma is 
generated remotely and the discharge environment is controlled by the feed gas [54]. Since 
DBD plasmas are generated in atmospheric air, variations to environmental conditions, 
such as humidity, and treatment surface (e.g. skin conductivity or uneven surfaces) may 
affect the plasma discharge and subsequent biological outcomes [53, 192, 193]. 
II.2 PLASMA APPLICATIONS  
II.2.1 Blood Coagulation 
“Quasi-thermal” plasmas have long been used as cauterization devices for blood 
coagulation in wound treatment and surgery [176, 194]. Here, coagulation is a result of 
high plasma temperatures that denature tissue protein and desiccate blood [194]. In 2006, 
Fridman et al reported that non-thermal plasma could accelerate blood coagulation 
25 
 
 
 
independent of high temperature [195]. Kalghatgi et al went on to show that the mechanism 
of action is that plasma treatment induces the aggregation of coagulation protein fibrinogen 
into fibrin, which catalyzes blood coagulation factors [196]. These studies have been 
further validated in animal models where application of plasma on wounds stopped 
bleeding in mice as quickly as 10 seconds [197]. This application has great clinical 
potential for control of bleeding during surgery to decrease operative mortality [198].  
II.2.2. Wound Healing 
Wound healing is a multi-step process characterized by four phases: hemostasis, 
inflammation, proliferation and remodeling [199]. While non-thermal plasma has been 
shown to augment hemostasis, as described above, it has also been shown to affect the 
proliferation phase, where re-epithelialization and angiogenesis occurs [200-202]. Several 
studies have reported that plasma-produced ROS can induce angiogenesis, the growth of 
new blood vessels,  in vitro by stimulating the secretion of fibroblast growth factor-2 (FGF-
2) [202, 203]. Miller et al have reported that plasma treatment of mouse aortic rings in vitro 
stimulated increased microvessel outgrowth [204]. Furthermore, key angiogenetic genes, 
vascular endothelial growth factor (VEGF-A), matrix metalloproteinase-9 (MMP-9) and 
CXCL 1, were upregulated 7 days after plasma stimulation [204]. Plasma has also been 
reported to promote wound healing in mice, in part through inactivation of bacteria [205]. 
II.2.3. Inactivation of Microorganisms 
One of the earliest use of plasma for medicine was for inactivation of 
microorganisms. Plasma has been effective against various bacteria (e.g. Escherichia coli, 
Salmonella enterica, monocytogenes Staphylococci, Streptococci and Staphylococcus 
aureus) [206-209] and species of yeast (e.g. Aspergillus, Penicillum and Candida albicans) 
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[210-212] in vitro. In subsequent studies, it was demonstrated that the antimicrobial effects 
were not a result of heating or emitted UV light, but due to plasma-generated, short-lived 
chemical species [54, 55, 213]. Plasma has also been used to sterilize surfaces ranging from 
agricultural produce, wounds, burns and even diabetic ulcers to prevent infections [32, 214, 
215]. In Germany, Isbary and co-workers conducted a randomized Phase II clinical trial 
where 38 chronic infected wounds in 36 patients were safely and painlessly treated with 
plasma on top of standard wound care [216]. A highly significant reduction of bacterial 
load in treated wounds was reported without any adverse effects. In 2015, Metelmann, 
Weltmann and co-workers used an APPJ to treat 12 patients with advanced squamous cell 
carcinoma of the head and neck to decontaminate infected cancer ulcerations [217]. Not 
only was bacterial load of the ulcers reduced, but some patients reported reduced pain and 
reduction of fetid odor related to microbial load. While the anti-cancer effects of plasma 
were not thoroughly evaluated in this clinical trial, plasma for cancer treatment has also 
been rapidly emerging as a potential biomedical application.   
III. PLASMA TREATMENT OF CANCERS 
The first use of plasma to kill cancerous cells was done by the group of Eva Stoffels 
in 2006 [218]. Using a plasma needle device, they showed that treatment of human MR65 
cells derived from non-small cell lung carcinoma (NSCLC), induced apoptosis. Since then, 
numerous groups have shown that plasma treatment can induce apoptosis and necrosis, 
with multiple plasma devices and on a copious number of cancer cell lines (e.g. lung cancer, 
breast cancer, melanoma and pancreatic cancer) [35-37, 46, 219-221]. In addition to cell 
death, plasma has also been reported to induce other cellular responses in cancerous cells 
including, reduced proliferation, senescence and cell cycle arrest [35, 38, 219, 222]. 
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Furthermore, cancer cell motility has also been reported to decrease following plasma 
treatment, which may be crucial for cancer research since migration and infiltration are 
issues associated with tumor growth and metastasis [35, 219]. Despite these favorable 
outcomes, it has been difficult to understand the underlying mechanisms and predict the 
outcome of treatment due to two major factors: 1) most plasma devices are built in the lab 
and operated at different treatment parameters, thus making it difficult for comparison, and 
2) in addition to the different plasma sources used, multiple cell types have been treated 
and show varying degrees of sensitivity to plasma. However, elevated ROS has been 
continually cited as the main cause of cellular effect [38, 44, 45, 223].  
Increasing intracellular ROS with radiation therapy and certain chemotherapies, is 
a long-established anti-tumor strategy as ROS involvement in cancer initiation and growth 
is well documented [224, 225]. While low levels of ROS are well tolerated by cells, high 
levels of ROS lead to cell death. Cancerous cells have inherently higher metabolic activity 
compared to their normal counterparts and are essentially at the threshold of tolerable ROS 
levels [226-228]. Therefore, stimulation with plasma can cause cancerous cells to exceed 
tolerable ROS thresholds and lead to cell death while neighboring cells remain less affected 
[229]. This could also explain the observed selectivity of plasma; following identical 
plasma treatment parameters, cancer cells showed decreased cell viability compared to 
normal cells, suggesting that they are more sensitive to plasma treatment [220, 230, 231].  
The first in vivo experiments performed to determine anti-cancer effects of plasma 
were reported by Vandamme and co-workers [232]. They treated xerographs 
subcutaneously established with human U87 glioblastoma cells in mice. Glioblastoma is 
the most common and aggressive human brain tumor and is highly resistant to standard 
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radiation and chemotherapy. Using DBD plasma, they treated tumors for 5 consecutive 
days which resulted in significant tumor volume reduction and extended survival time. The 
authors reported that these effects were a result of tumor apoptosis induction with plasma-
generated ROS playing the major role in the observed therapeutic effects. Since then, 
multiple groups have reported on the killing effects of plasma on various cancer models in 
syngeneic mice (e.g. melanoma, neuroblastoma, pancreatic and cancer) using both DBDs 
and APPJs [36, 38, 48, 233]. In addition, Utsumi et al have shown that plasma activated 
media (PAM), also has therapeutic anti-cancer effects [234]. PAM is created by treating 
cell culture media with plasma to enrich it with dissolved RONS [235]. The authors then 
injected PAM locally to tumors subcutaneously established with NOS2 cells (derived from 
epithelial ovarian carcinoma cells) in mice [234]. PAM inhibited the growth of tumors in 
mice though the effect was reduced compared to treatment of tumors with plasma. 
However, this provides insight into another modality of treatment with plasma which may 
be useful when tumors are not easily accessible with plasma devices.  
III.1 CHALLENGES TO ADDRESS 
While promising therapeutic results have been demonstrated with plasma both in 
vitro and in vivo for different malignancies, several challenges must be addressed. A major 
issue is the treatment of “deep” cancers. In most mouse models and in current clinical trials, 
cancers have been superficial and easily accessible to plasma applicators. However, 
delivery of plasma into the body of patients, such as the colon or stomach, will broaden the 
application of plasma to treat different cancer types. One approach is through the use of 
the above mentioned, plasma activated media, which transfers plasma effects through local 
injection or perfusion of a liquid medium [234-236]. However, the effects are diluted 
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compared to direct treatment and the stability of plasma-diffused species are in question. 
Physicists and engineers have also been addressing the plasma delivery problem through 
their own approach, by designing plasma sources with varying geometries, including an 
endoscopic plasma source [237, 238]. Plasma has been demonstrated to propagate along 
tubes up to several meters in length and with diameters as small as 15 μm [237]. Following 
a minimally invasive surgery, this will allow for focused treatment of tumors in patient’s 
body cavities. Robert et al have evaluated the effectiveness of these endoscopic plasma 
devices in an in vivo pancreatic model [239]. Mice treated with plasma were reported to 
have smaller tumor volumes, both from bioluminescence imaging and tumor resection at 
the end of the study. This study opens up the possibility of plasma to be operated outside 
superficial limits. 
Another challenge in the plasma oncology community is the inability to eliminate 
all cancerous cells and cancer stem cells. The cells that survive treatment continue to divide 
when plasma is discontinued, resulting in tumor regrowth. [48]. This may be due to the 
ablative action and operation of plasma in these studies where the involvement of the 
immune system for resolution of cancer has been largely overlooked. Not only is this a 
challenge in the plasma medicine community, but it has also been a challenge in 
conventional cancer treatment for many years. However, treatment has begun to shift 
towards modalities that stimulate the patient’s natural immune response and plasma 
treatment of cancers should also move in this direction.  
III.2. IMMUNOSTIMULATORY EFFECTS OF PLASMA 
We have also previously demonstrated that plasma can directly augment 
macrophage function. In vitro, we reported that the migratory activity and secretion of anti-
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tumor cytokines, such as TNFα, from macrophages were enhanced following plasma 
stimulation [58, 98-100]. In vivo, mini pigs were exposed to plasma and myeloid cell 
recruitment was observed into the treated areas of the skin one week later [240]. We also 
showed that plasma treatment enhanced differentiation of hemocytes in the lymph organs 
of Drosophila melanogaster larvae [101]. Furthermore, larvae developed into adult flies 
and plasma treatment did not affect their viability, fertility or locomotion, which may 
provide insight into the safety of using plasma. 
Altogether, we suggest that plasma may synergistically boost anti-cancer immune 
responses through direct augmentation of immune cell functions and should be further 
explored. These results indicate that plasma could provide a significant advantage over 
other physical treatment modalities, such as radiation and PDT, as immune cells are among 
the most radiosensitive cells in the body and direct stimulatory effects with these treatment 
modalities remain undefined [157, 241, 242].   
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CHAPTER 4: UNIFORM NANOSECOND PULSED DIELECTRIC BARRIER 
DISCHARGE PLASMA ENHANCES ANTI-TUMOR EFFECTS BY INDUCTION 
OF IMMUNOGENIC CELL DEATH IN TUMORS AND STIMULATION OF 
MACROPHAGES 
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ABSTRACT 
Several studies have shown plasma to be efficacious against cancer cells in vitro 
and in vivo with minimal damage to non-cancerous cells and tissue. Most of the previous 
studies focused on direct influence of plasma on tumor cells. However, the body’s immune 
system also plays a crucial role in the control of cancer. A new concept of immunogenic 
cell death (ICD) has been emerging, where through this modality of cell death, an immune 
response may be stimulated. The goal of the presented study was to explore a regime of 
plasma treatment that induces ICD in tumor cells and stimulates anti-tumor effects in 
macrophages—a key immune cell type involved in the initiation of immunological 
responses. Here we show that treatment with uniform nanosecond pulsed dielectric barrier 
discharge (nspDBD) plasma directly activated anti-tumor effects in macrophages. We 
further show macrophage activation following the expression of plasma-induced damage 
associated molecular patterns (DAMPs) in tumor cells, characteristic of the ICD.  
 
 
 
 
 
 
Keywords: immunogenic cell death; damage-associated molecular patterns; nanosecond 
pulsed dielectric barrier discharge; plasma medicine; macrophage stimulation  
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Introduction 
Use of non-thermal plasmas is currently being explored for cancer therapy.[1-6] 
Local application of plasma on tumors in vivo has led to reduced tumor volume and 
increased animal survival, but complete remission of cancer through the use of plasma has 
not yet been attained.[2-4] Tumor cells harbor an arsenal of survival strategies that makes 
complete elimination of cancer difficult.[7] Included among these is resistance to cell death 
and the ability to evade immunological surveillance.[7, 8] Additionally, cancers are 
associated with immune suppression.[9] Therefore, an attractive form of therapy is one that 
increases cancer cell susceptibility to death, enhances recognition of poorly immunogenic 
cancer cells by the immune system, and subverts immunosuppression.[8-10] 
In recent years, a new concept of immunogenic cell death (ICD) has emerged.[11] 
This modality of cell death stimulates specific immune responses against antigens from 
stressed and dying cells.[12, 13] Although mechanisms that promote ICD are still unclear, a 
number of factors known to elicit immune responses have been identified.[14-17] These 
factors are known as damage-associated molecular patterns (DAMPs). DAMPs, such as 
adenosine triphosphate (ATP), are actively secreted by dying cells; alternatively, 
previously intracellular molecules like calreticulin (CRT) become exposed on the cell 
surface.[15] Secreted ATP acts as a prominent ‘find me’ signal for activating receptors on 
immune cells and may lead to proinflammatory cytokine release.[18, 19] CRT is a protein on 
the endoplasmic reticulum (ER), a eukaryotic organelle that is responsible for the synthesis, 
folding, and modification of proteins used by the cell.[15, 20] During ICD, the ER responds 
by upregulating stress genes such as activating transcription factors (ATF4, ATF6) and 
stanniocalcin (STC2), causing CRT to be translocated from the ER to the cell surface.[20-
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23] This ecto-CRT functions as an ‘eat me’ signal and mediates the engulfment of tumor 
cells by macrophages and dendritic cells, cells of the innate immune system.[11] These cells 
migrate to immune organs where tumor antigen presentation to cells of the specific immune 
system occurs resulting in the generation of a systemic, specific anti-tumor immune 
response.[13, 15] Therefore, in contrast to the current use of plasma for local treatment of 
tumors, plasma induced ICD could be a viable approach for systemic immunotherapy of 
cancer and requires investigation.  
We have previously shown that plasma can stimulate macrophage function in an in 
vitro migration assay.[24] Macrophages are key immune cells originating from the bone 
marrow progenitor cells. These cells are released into the bloodstream where they develop 
into monocytes. After circulating in the bloodstream, monocytes take residence in different 
tissue and differentiate into tissue-specific macrophages, displaying different phenotypes 
depending on the local environment.[25, 26] Classically activated macrophages, M1 
macrophages, are considered pro-inflammatory.[27] They secrete factors and cytotoxic 
substances such as tumor necrosis factor α (TNFα) and reactive oxygen and nitrogen 
species capable of killing cancerous cells.[28-30] We hypothesize that besides migration, 
plasma can also directly activate macrophages to exert anti-tumor effects.  
In the present study, we explored the potential for plasma to induce ICD in tumor 
cells and evaluated whether the DAMP signals associated with ICD enhance anti-tumor 
effects of macrophages. We also investigated whether plasma alone can stimulate 
macrophages to enhance killing of tumor cells. We utilized a uniform nanosecond pulsed 
dielectric barrier discharge (nspDBD) and exposed the CNE-1 nasophylangeal carcinoma 
cell line and the THP-1 macrophage cell line to a range of plasma doses in 24-well tissue 
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culture plates. To investigate anti-tumor effects of macrophages stimulated by either 
plasma or DAMP signals from tumor cells, a transwell insert system was used to co-culture 
macrophages and tumor cells together. Our results indicate that anti-cancer activity of 
macrophages is enhanced by plasma. Treatment of cancer cells in the same regime results 
in a dose-dependent increase in ATP secretion and ER stress. Furthermore, these DAMP 
signals enhanced CNE-1 cell killing following co-culture with non-plasma treated 
macrophages. This is the first report of non-thermal plasma enhanced anti-tumor effects 
through stimulation of macrophages both directly by plasma and indirectly via DAMP 
signaling from plasma induced ICD of tumor cells. 
Materials and Methods 
Cell Culture  
The radioresistant nasopharyngeal carcinoma (NPC) cell line, CNE-1, was 
originally derived from NPC patients in China. We obtained the CNE-1 cell line from Dr. 
Shaojun Lin's lab, Department of Radiation Oncology, Fujian Provincial Cancer Hospital, 
Fuzhou, Fujian, China. The CNE-1 cell line was cultured in RPMI-160 (RPMI) (Corning 
Life Sciences, USA) with 10% fetal bovine serum (FBS) (Corning Life Sciences, USA) 
and 1% penicillin/streptomycin (PS) (Life Technologies, USA). A human acute monocytic 
leukemia cell line (THP-1), was obtained as a kind gift from Dr. Kara Spiller (Drexel 
University, Philadelphia, PA, USA). These cells were cultured in RPMI supplemented with 
10% heat-inactivated FBS and 1% PS. All cells were grown at 37oC with 5% CO2 in a 
humidified atmosphere.  
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Differentiation of THP-1 Monocytes to M0 Macrophages  
THP-1 cells were differentiated into M0 macrophages one day prior to co-culture 
or plasma treatment. For co-culture with tumor cells, THP-1 cells were seeded in 6.5 mm 
transwell inserts with 0.4 μm pore size polyethylene terephthalate membrane (Corning Life 
Sciences, USA) at a concentration of 1.55×105 cells/insert. Cells were differentiated into 
M0 macrophages by the addition of 0.5 µL of 100 μL/mL phorbol 12-myristate 13-acetate 
(PMA) (Sigma-Aldrich, USA) to each well. The inserts were placed into a 24-well plate 
(Corning Life Sciences, USA) with 600 μL of THP-1 culture media, to prevent cells in the 
transwell inserts from drying. Cells were incubated overnight at 37oC with 5% CO2 in a 
humidified atmosphere and phosphate buffered saline (PBS) was used to wash the 
differentiated cells the next day. PBS was removed immediately before co-culture with 
CNE-1 cells. For plasma treatment, THP-1 cells were seeded into 24-well plates at a 
concentration of 7.0×105 cells/well. These cells were also differentiated into M0 
macrophages with 0.5 μL of PMA (100μL/mL). PBS was used to wash the differentiated 
cells following overnight incubation and removed immediately before plasma treatment. 
Nanosecond Pulsed Dielectric Barrier Discharge Plasma Parameters 
NspDBD plasma was produced by applying a positive voltage pulse to a high 
voltage electrode placed 1 mm above the cells in the wells. [31] Plasma pulse characteristics 
and methods of measuring energy per pulse of a single uniform nspDBD plasma discharge 
were defined in our previous work.[32] Briefly, the nanosecond pulser (FPB-20-05NM, FID 
GmbH, Germany) generated a 29 kV pulse with a 20 ns pulse width and with rise times of 
2 ns. Treatment duration was fixed at 10 seconds and the frequency of the pulses was 
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controlled with an external function generator (TTI, TG5011 LXT). The energy per pulse 
of a single uniform nspDBD plasma discharge in a 24-well plate was calculated by 
measuring voltage and current without displacement current and found to be 0.85 mJ/pulse. 
Table 1 reports the operating parameters for our nspDBD plasma treatments.  
Table 1 nspDBD Treatment Parameters 
Parameter Value 
Excitation Nanosecond Pulsed 
Voltage 29 kV 
Energy per Pulse 0.85 mJ/pulse 
Rise Time 2 ns 
Pulse Width 20 ns 
Treatment Time 10 s 
Application Distance 1 mm 
Set Frequency 5, 15, 30, 75 Hz 
Calculated Total Dose 47, 141, 282, 705 mJ 
 
Non-Thermal Plasma Treatment and Co-Culture with Macrophages 
For experimental assessment of CNE-1 cell viability and DAMP signals following 
plasma, cells were seeded at a concentration of 1.5×105 cells/well and grown to confluence 
in 24-well plates with 500 μL of complete cell culture media one day prior to treatment. 
Media were removed, cells were washed with PBS, and PBS was removed right before 
treatment. Immediately after treatment, 500 μL of fresh media were added to the wells and 
cells were incubated at 37oC with 5% CO2 for 1 h and 24 h. Subsequent viability, 
extracellular ATP, and ER stress analysis were performed after incubation. Mock plasma 
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treatment of cells, represented as 0 mJ, was performed in an identical manner but without 
the generation of plasma to serve as our negative control. A schematic drawing of our 
electrode and setup is shown in Figure 1. 
To determine whether DAMP signals released by tumor cells undergoing ICD can 
enhance anti-tumor effects in macrophages, CNE-1 cells were seeded into 24-well plates, 
treated with plasma as stated above, and co-cultured with THP-1 M0 macrophages. 
Following plasma treatment of the tumor cell line, 750 μL of CNE-1 complete media was 
added to each well. The transwell inserts with the M0 macrophages were then placed into 
the wells, and 750 μL of THP-1 cell culture media was added to the inserts. This system 
allowed for the exchange of DAMP signals and cytokines secreted into the media through 
the porous membrane (Figure 1). Media in the wells and inserts were replaced at 24 h and 
cells were cultured for a total of 48 h before subsequent assessment of CNE-1 cell viability.  
To evaluate whether plasma can stimulate THP-1 M0 macrophage cells to 
functionally increase the anti-tumor effects, M0 macrophages were treated with plasma and 
co-cultured with CNE-1 cells (Figure 1). CNE-1 cells were seeded into the inserts at a 
concentration of 2.0×104 cells/insert one day prior to co-culture. THP-1 cells were seeded 
and differentiated as described above. Immediately before plasma treatment of M0 
macrophages, PBS was removed from the wells. After treatment, 750 µL of THP-1 
complete media immediately added, and the transwell inserts with the CNE-1 cells were 
placed into the wells. Cells were cultured together for 48 h, and CNE-1 cell viability 
assessment was performed following 48 h incubation.  
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Figure 1. nspDBD treatment and co-culture system. (Left) Media were removed from each 
well and plasma was generated and applied directly onto the cells by a high voltage 
electrode. Immediately following treatment, fresh media were added into the well. 
(Middle) Tumor cells and macrophages were co-cultured in a transwell insert system. The 
bottom of the transwell insert was porous (0.4 μm pores) which kept two cell types 
separate, but allowed for the exchange of various factors in the media. (Right) To determine 
if plasma can stimulate M0 macrophages cells to increase anti-tumor effects, M0 
macrophages were treated with plasma and co-cultured with CNE-1 cells. 
Cell Counts and Viability Measurement and Analysis 
Cell viability was determined via fluorescence staining with 100 μg/mL of 
Propidium Iodide (PI) (Invitrogen, NY), a DNA-binding fluorescent reagent that permeates 
damaged cell membranes. Cells were stained at 1 and 24 h post plasma treatment for direct 
killing studies; cells were stained at 48 h post for co-culture experiments. Cell counts and 
viability data were collected with an image cytometer (Nexcelom Bioscience, USA) and 
further analysis, including size gating, was done on the FCS flow cytometry software 
(DeNovo Software, USA). 
Extracellular ATP Measurement 
An adenosine 5’-triphosphate (ATP) bioluminescent somatic cell assay kit (Sigma-
Aldrich, USA) was used to determine extracellular release of ATP from plasma treated 
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CNE-1 cells. ATP reacts with luciferin, which is catalyzed by the firefly luciferase found 
in the assay mix to form adenyl-luciferin. The adenyl-luciferin then reacts with oxygen to 
produce oxyluciferin, adenosine monophosphate, carbon dioxide and light. The light is 
measured in the PhotonMaster luminometer (LuminUltra, PM10146). By first calibrating 
the luminometer with the provided UltraClear calibration solution, the measured relative 
light units (RLU) is converted into pgATP/mL. This assay was performed on the cell 
culture media of the plasma treated CNE-1 cells 10 minutes after treatment.  
All reagents were prepared following the protocol provided in the kit. The ATP 
assay mix working solution was prepared by diluting the ATP assay mix stock solution 
1:25 fold with the dilution buffer. 100 μL of working solution were added into 12x55 mm 
test tubes (Hack, USA) and allowed to stand at room temperature for 3 minutes. 
Following plasma treatment, 50 μL of supernatant were collected from each well 
and placed into labeled Eppendorf tubes with 100 μL of ultrapure water (Sigma-Aldrich, 
USA). 50 μL of the cell solution in the Eppendorf tubes were then transferred into the 
12x55 mm test tubes containing 100 μL of ATP assay mix working solution. RLU were 
immediately measured with the PhotonMaster to determine extracellular ATP 
concentration.   
Western Blot Analysis for ER Stress 
Proteins from plasma treated CNE-1 cells were collected 24 h after treatment. Cells 
were washed three times with cold PBS and lysed with 100 μL urea buffer (8 M urea, 10 
mM Tris, 10% glycerol, 1% SDS, 5 mM dithiothreitol, 1 mM phenylmethylsulfonyl 
fluoride, 1× protease inhibitor mix, pH 6.8). Cells were then scraped with a mini cell 
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scraper and the suspension was collected in Eppendorf tubes. A 1 mL syringe was used to 
pipet the solution up and down 5-10 times to homogenize the cells. Tubes were then frozen 
at -80oC until Western blot analysis was to be performed. Western blotting was performed 
as previously described.[33] Protein concentrations were determined by Protein Assay Kit I 
(Bio-Rad, USA). The same amount of protein was loaded into Bio-Rad Mini-protein TGX 
precast gels or self-made 8% SDS-PAGE gels. The proteins were then transferred into Bio-
Rad PVDF membrane, blocked with 5% non-fat milk in TBST (50 mM Tris, 150 mM 
NaCl, 0.1% Tween 20, pH 7.5), and incubated with desired antibodies. Band signals were 
developed by using SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific, USA). 
Statistical Analysis 
All experimental data points were from triplicate samples and plotted as the mean 
± standard error of the mean (SEM). Data were analyzed by Student’s t-test to determine 
significance between data points. A value of p ≤ 0.05 was considered statistically 
significant and indicated with an asterisk (*) when comparing treated and untreated cells. 
A plus sign (+) was used to indicate a value of p ≤ 0.01. 
Results and Discussion 
Effect of Uniform nspDBD Plasma on CNE-1 Cell Viability 
The viability of CNE-1 cells following uniform nspDBD treatment was first 
established. Pulse frequencies for plasma treatment were 5, 15, 30, and 75 Hz 
corresponding to 47, 141, 282, and 705 mJ dose treatments. Cells were collected 1 h and 
24 h after treatment, stained with PI, counted in the Cellometer, and analyzed for viability. 
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Cell viability 1 h following treatment was normalized to the mock treated group (control) 
and represented as cell loss, shown in (Figure 2). A dose-dependent increase in cell loss 
following treatment was observed ranging from 32% cell loss for the lowest dose treatment 
to 66% cell loss following the highest dose treatment. Live cell counts increased in all 
plasma treated groups at 24 h (Figure 2) suggesting that surviving cells recovered and 
continued to proliferate.  
 
Figure 2. Effect of uniform nspDBD on viability of CNE-1 cells at 1 and 24 h. Viability 
was determined by trypsinizing the cells in each well, staining with Propidium Iodide and 
quantifying in the Cellometer. (Left) Viable cells 1 h post plasma treatment were 
normalized to mock treated cells (control) and represented as percent cell loss. Cell loss 
increased dose-dependently from 32% following 47 mJ treatment to 66% for 705 mJ 
treatment. (Right) All plasma treated cells continued to proliferate 24 h post treatment as 
determined by the increase in live cell counts. Data are represented as mean ± SEM. 
nspDBD Plasma Stimulates Extracellular ATP Secretion 
ATP is the most abundant intracellular molecule required for metabolism.[13] When 
cells experience physical or chemical stress, ATP can be released and acts as a messenger 
to stimulate diverse responses.[13, 19] As a DAMP signal, ATP is an important 
chemoattractant for monocytes and dendritic cells and also promotes secretion of key pro-
inflammatory cytokines such as IL-1β and IL-18 from immune cells.[15, 18] ATP has also 
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been associated with increased macrophage maturation and increased cytotoxicity of NK 
cells, other cell types of the innate immune system.[18, 19] 
CNE-1 cells were treated with plasma and incubated in RPMI 10% FBS and 1% 
PS for 10 minutes to allow time for ATP to be secreted into the media. ATP analysis was 
performed on the supernatant as described in the methods section. Extracellular ATP 
concentration in the supernatant of our mock treated cells, represented as 0 mJ dose 
treatment, was 9.0 nM. ATP concentration increased after plasma treatment from 45.4 nM 
for low dose treatments to 789.7 nM for our highest treatment (Figure 3). These results 
suggest that at this uniform plasma regime, plasma can stimulate CNE-1 cells to secrete 
ATP available for immune stimulation. 
 
Figure 3. Dose-dependent increase in extracellular ATP in the supernatant following 
plasma treatment. The media of CNE-1 cells were collected 10 minutes after plasma 
treatment, and an ATP bioluminescent kit was used to determine extracellular ATP 
concentration in the media. RLU measurements were taken in the PhotonMaster 
luminometer. While 9.0 nM ATP was measured in the media of mock treated cells (0 mJ), 
ATP concentration increased after plasma treatment: 45.4 and 789.7 nM for 47 and 705 mJ 
dose treatments, respectively. Data are shown as mean ± SEM. * p < 0.05, + p<0.01.  
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nspDBD Plasma Induces ER Stress 
In order to examine whether nspDBD plasma can trigger ER stress, we measured 
the protein levels of two cellular indicators of ER stress, activating transcription factor 4 
(ATF4) and stanniocalcin 2 (STC2), in response to our lowest and highest dose treatments. 
[21, 22] ATF4 is involved with the control of amino acid metabolism and redox chemistry 
following activation during ER stress.[21] STC2, a secretory glycoprotein, is overexpressed 
and secreted to the extracellular matrix upon a variety of cellular stresses including 
hypoxia, low glucose and low glutamine.[34] Irradiation usually activates the ER-stress 
related ATF4-STC2 pathway as part of cellular response to damage of cellular 
components.[35] Western Blot analysis of cellular proteins demonstrated that ATF4 and 
STC2 expression increased in a dose dependent manner 24 h post treatment with nspDBD 
plasma (Figure 4). These data indicate that nspDBD plasma treatment triggers ER stress. 
These stress proteins are upstream of another hallmark of ICD, ecto-CRT.[13, 21, 22] 
Following ER stress, intracellular CRT is translocated to the surface of the cell that 
increases immunogenicity of poorly immunogenic cells. This process is crucial for the 
engulfment of tumor cells by macrophages and dendritic cells, which is required for 
subsequent antigen processing and presentation.   
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Figure 4. Plasma treatment increased protein expression of ATF4 and STC2, two ER stress 
response proteins. CNE-1 cells were treated with plasma at 47 mJ and 705 mJ doses. Cells 
were then lysed at 24 h, protein samples were collected, and Western Blot analysis was 
performed. Protein levels of ATF4 and STC2 were examined as indicators of ER stress, 
and α-Tubulin was used as a loading control. The expression of both proteins increased 
when cells are exposed to higher energy. 
Enhanced CNE-1 Cell Death Following Plasma Treatment by ICD Mediated Macrophage 
Stimulation  
To examine whether plasma induced DAMP signals enhance macrophage anti-
tumor effects, CNE-1 cells were treated at 141 and 282 mJ and cultured for 48 h with non-
plasma treated THP-1 M0 macrophages in transwell inserts. These treatment doses were 
selected based on our previous results.[24] Cell viability assay was performed on the CNE-
1 cell line 48 h post treatment as previously described. Cell counts were normalized to 
CNE-1 cells cultured alone that had been plasma treated at the same energies (0, 141 or 
282 mJ) (plasma-treated control). Viability of CNE-1 cells untreated with plasma (0 mJ) 
and co-cultured with M0 macrophages reduced to 90% of untreated cells cultured alone 
(Figure 5). Following plasma treatment and co-culture, viability further reduced to 78% 
and 74% of corresponding controls for 141 and 282 mJ, respectively.  Since plasma-treated 
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CNE-1 cells produce more ATP (Figure 3), and ATP has been documented to increase 
secretion of cytokines such as IL-1β and IL-18,[15, 18] known anti-tumor effectors, this 
further decrease in could be a result of macrophage function stimulation.  
 
Figure 5. Viability of plasma-treated CNE-1 cells co-cultured with macrophages was 
reduced compared to cancer cells treated at the same energy and cultured alone. (Left) 
Following plasma treatment, CNE-1 cells were cultured for 48 h with M0 macrophages in 
0.4 µm pore transwell inserts. (Right) Cell viability following treatment and co-culture was 
normalized to CNE-1 cells that received plasma treatment at the same energies and cultured 
alone (plasma-treated control). Non-plasma treated CNE-1 cells cultured with M0 
macrophages (0 mJ) had 10% cell loss while 141 and 282 mJ dose treatments and co-
culture elicited 22% and 75% cell loss respectively compared to their controls. Data are 
represented as mean ± SEM. 
nspDBD Treatment of M0 Macrophages Enhances Anti-Tumor Effects 
In our past work, we have shown that nspDBD plasma can influence functional 
capabilities of macrophages in an in vitro wound-healing model.[24] Since macrophage 
migration was stimulated at certain regimes of plasma treatment, we hypothesized that 
other functions, particularly anti-tumor effects, could also be influenced. To test this, we 
treated THP-1 M0 macrophages with plasma and cultured them with CNE-1 cells in 
transwell inserts. While non-plasma treated M0 macrophages elicited 18% CNE-1 cell loss, 
141 and 282 mJ plasma stimulated macrophages elicited 33% and 38% cell loss 
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respectively (Figure 6). It is important to emphasize that in this experimental setup, the 
CNE-1 tumor cell line never came in direct contact with plasma.  
The conditioned media of classically activated monocyte-derived human 
macrophages and THP-1 macrophages has been shown to inhibit proliferation of colon 
cancer cell lines (HT-29 and CACO-2) in a dose-dependent manner.[36, 37] Classically 
activated macrophages or M1 macrophages respond to challenges by generating an 
inflammatory response that includes secretion of pro-inflammatory cytokines.[27, 30] On the 
other hand alternatively activated M2 macrophages are immunosuppressive and can release 
anti-inflammatory cytokines.[27] Engstrӧm et. al. cultured M1 macrophages in media for 48 
h. This media, which they referred to as conditioned media (CM), caused an inhibitory 
effect on cell proliferation when it was transferred and used to culture HT-29 and CACO-
2 colon cancer cell lines. However, CM from M2 macrophages did not elicit this response. 
The cytokine and chemokine expression profiles of both classes of macrophages were 
examined to identify the factors responsible for proliferation inhibition. Compared to M2 
macrophages, M1 macrophages released a variety of cytokines/chemokines, including 
tumor necrotic factor α (TNFα), interleukin 6 (IL6), CXCL1, RANTS, etc. to a much 
greater extent.[36] In addition to proinflammatory cytokines, macrophages also produce 
superoxide and hydrogen peroxide in a process called respiratory burst when they are 
activated.[29, 30] ROS from macrophages, particularly hydrogen peroxide, have also been 
reported to kill cancer cells.[38, 39]  Since it is well known that non-thermal plasma can affect 
the intracellular redox state of the cells,[40-42] the enhanced CNE-1 cell death we observed 
could be a result of higher proinflammatory cytokines secretion or ROS release from 
plasma stimulated M0 macrophages.  
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Figure 6. Plasma-treated macrophages increased cancer cell loss under co-culture 
conditions. (Left) THP-1 M0 macrophages were treated with plasma and co-cultured with 
the CNE-1 tumor cell line in the transwell insert system. (Right) CNE-1 cell viability was 
analyzed 48 h post co-culture and normalized to the control, cells that were cultured alone. 
Macrophages by themselves without plasma treatment (M0) induced 18% cell loss while 
those that were treated with 141 mJ plasma elicited 33% cell loss. 282 mJ plasma treatment 
caused 38% cell loss compared to the control. Data are represented as mean ± SEM, * p < 
0.05, + p<0.01. 
Conclusion 
This is the first report of enhanced tumor cell killing by uniform nspDBD plasma-
elicited immunogenic cell death of cancerous cells resulting in stimulation of macrophages 
indirectly. Following treatment, ATP secretion was augmented in the CNE-1 tumor cell 
line and ER stress proteins upstream of ecto-CRT, ATF4 and STC2, was upregulated. Co-
culture with unstimulated THP-1 M0 macrophages significantly reduced cell viability 
compared to tumor cells treated with plasma and cultured without macrophages (Figure 5). 
This indicates that stress signaling from tumor cells can stimulate macrophage function via 
factors secreted by tumor cells. Furthermore, the same regime of plasma treatment directly 
enhanced anti-tumor effects of M0 macrophages as seen by the reduced CNE-1 viability 
following co-culture in Figure 6. Taken together, these results suggest that the use of 
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plasma could enhance anti-tumor effects through both the induction of ICD in tumor cells 
and augmentation of macrophage function. Identification of the cytokines and ROS species 
secreted by macrophages following plasma treatment that are responsible for the anti-tumor 
activity is still required and ongoing. Future studies involve the application of plasma to in 
vivo tumor models where all the components of the immune system beyond macrophages, 
such as dendritic cells, T-cells and natural killer (NK) cells will be present. This will allow 
for establishment of specific systemic immune responses against tumors through the 
simultaneous treatment of cancerous cells and immune cells in the local tumor 
environment.  
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ABSTRACT 
Atmospheric pressure non-equilibrium plasmas are efficacious in killing both 
prokaryotic and eukaryotic cells. While the mechanism of plasma induced cell death has 
been thoroughly studied in prokaryotes, detailed investigation of plasma mediated 
eukaryotic cell death is still pending. When plasma is generated, four major components 
that interact with cells are produced: electric fields, radiation, charged particles, and neutral 
gas species. The goal of this study was to determine which of the plasma components are 
responsible for plasma-induced cell death by isolating and removing each from treatment. 
The C3H10T1/2 murine mesenchyme stem cell line was treated in six well plates, stained 
with Propidium Iodide to determine viability, and analyzed by image cytometry. Our 
results show that plasma-generated charges and reactive oxygen species are the primary 
contributors to cell death. 
 
 
 
 
 
 
 
Keywords: cell death; mesenchymal stem cell; nanosecond pulsed dielectric barrier 
discharge plasma medicine; reactive oxygen species  
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Introduction  
Non-equilibrium plasma technologies are recently growing as unique, therapeutic 
tools for medical applications.[1, 2] Studies have shown that plasma delivery can be tuned 
to induce cellular proliferation, differentiation, and apoptosis.[3-5] Plasma has been 
demonstrated to kill cancer cells in vitro and reduce tumor masses in vivo,[5, 6] suggesting 
possible applications in cancer therapy. However, the fundamental mechanism by which 
plasma triggers cell death and tumor reduction is still poorly understood. Plasma treatment 
delivers four major components: electric fields, radiation, charges, and neutral gas 
species.[7-9] These elements are known to independently influence cell death. For example, 
Beebe et al have shown that nanosecond pulsed electric fields alone can induce cellular 
apoptosis in vitro and reduce tumor size in vivo.[10] UV radiation has been known for a long 
time to induce DNA damage leading to cell death.[11, 12] Superoxide and hydrogen peroxide, 
examples of charged and neutral components of plasma generated species, are also well 
documented to induce apoptosis at certain concentrations.[13, 14] These constituents are all 
present in plasma, which raises the question: what is the relative contribution of each 
component on observed cell death following treatment? Determination of the key 
components in plasma responsible for cell death and controlling their delivery can lead to 
optimized treatment for future clinical use. Furthermore, they may lead to treatments that 
can be tuned to selectively kill cancerous cells and decrease toxicity in non-cancerous cells. 
In this study, we used a dielectric barrier discharge (DBD) plasma which operates at 
atmospheric pressure and ambient temperatures.[15] The electric fields and Columbic forces 
are known to dominate in electromagnetic interactions for DBDs.[16] Therefore, the 
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contribution of temperature and magnetic fields during plasma exposure is considered 
insignificant.  
DBDs create plasma in direct contact with living cells by applying fast, high voltage 
pulses between a copper electrode covered with a quartz dielectric and the biological 
target.[17] Previously, DBD plasma treatment studies were carried out with microsecond-
pulsed power supplies in atmospheric air, which resulted in the formation of streamers in 
the discharge.[4, 9, 18] The resulting plasma was in the non-uniform regime.[15] However, 
nanosecond pulsed dielectric barrier discharges (nspDBD) in air have been shown to 
generate a diffuse, uniform discharge without streamers at specific operating parameters: 
very high voltage (~30kV), fast rise times (~2ns) over small gap distances (~1mm). 
Uniformity is lost if any one of these conditions are not met.[19] Not only do streamers lead 
to uneven treatment of cells, but the head of the streamer also generates high local electric 
fields which result in higher electron energies compared to those in the uniform regime.[20] 
The electron energy influences the plasma-generated species, so changes in the plasma 
regime can also influence plasma chemistry. For this study, nspDBD plasma was operated 
primarily in the uniform regime because it was easier for plasma components to be 
separated. The authors have previously shown the effects of the different plasma 
components for microsecond-pulsed DBDs on biological systems while other labs have 
studied the components of plasma with non-thermal atmospheric jets and other plasmas.[9, 
21, 22] Although nanosecond and microsecond DBDs may seem similar, the energy of the 
two discharges is significantly different, and so a direct comparison is challenging.[9] 
However, to address the contribution of streamers and plasma filaments on cell viability, 
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the non-uniform regime of nspDBD was also explored. This would be reflective of 
microsecond DBDs.   
In the present study, we determined the relative contribution of major plasma 
components on the viability of C3H10T1/2 murine mesenchyme stem cells. We utilized a 
nanosecond pulsed dielectric barrier discharge (nspDBD) and exposed cells in 6-well tissue 
culture plates to various distinct plasma doses and treatment conditions that included or 
excluded specific plasma components. Our results indicate that the plasma generated 
charges and reactive oxygen species (ROS) are the major contributors for plasma induced 
cell death. Under these conditions, cell death seems to occur partially through direct cell 
lysis. 
Materials and Methods 
Cell Culture  
Murine mesenchymal stem cells (CH310T1/2, ATCC: CCL-226) were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) with 5% fetal bovine serum, 5% fetal calf 
serum, and 1% penicillin/streptomycin (Invitrogen, Life Science Technologies, USA) and 
incubated at 37oC with 5% CO2. Prior to seeding cells in 6-well plates, wells were coated 
with 0.15mg/mL Rat tail Collagen I (BD Biosciences, USA) in 0.02N acetic acid (Fischer 
Scientific, USA) for 1 hour and then washed 3 times with phosphate buffered saline (PBS) 
with calcium and magnesium. Type I collagen is a protein made up of three α-chains and 
is often used to coat surfaces to enhance cell adhesion.[23, 24] Cells were seeded in 2mL of 
media at concentrations of 2.0×105 or 1.0×105 cells/well and grown to confluence in one 
or two days respectively before plasma treatment. Before treatment, cell culture media was 
61 
 
 
 
removed, cells were washed with PBS, and 1mL of DMEM clear without serum added to 
each well. This media was removed right before plasma treatment and 1mL of fresh 
DMEM clear without any serum was replaced immediately after. 
Nanosecond Pulsed Dielectric Barrier Discharge Plasma Parameters 
NspDBD plasma was produced by applying a positive voltage pulse of 
approximately 29kV between the high voltage electrode and a grounded metal plate 
underneath the 6-well plate. Cells in the wells were are at floating potential. The power 
supply (FID technology, FPG-20-05NM) generated 20ns pulse widths with rise times of 
2ns. Frequency of the pulses was controlled with a function generation (TTi, TG5011 LXT) 
and treatment duration was fixed at 10 seconds. For uniform nspDBD plasma treatment, 
the gap distance was at 1mm. Mock plasma treatment of negative control cells was 
performed in an identical manner, but without plasma being generated. These are indicated 
as untreated in all our graphs. A schematic of our electrode and experimental setup is shown 
in Figure 1. 
 
Figure 1. nspDBD plasma treatment (left) schematic and (right) device setup 
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Accurate measurements of voltage at nanosecond times are possible when using 
techniques such as back current shunt. However, this method works when a relatively long 
transmission line, longer than the pulse duration, is used (in this case ~10 meters). In these 
experiments, we have used a short high voltage (HV) cable (~2 m long), and therefore 
could only use a HV probe (Tektronix, P6015A) in conjunction with a current probe (CM-
10-L, 2 ns usable rise time, Ion Physics Corporation) connected to a 1 GHz oscilloscope 
(DPO-4104B, Tektronix). Delay times from both voltage and current probes have been 
measured and accounted for using Tektronix AFG-3252 Arbitrary/Function Generator 
(signal rise/fall time of less than 2.5 ns and a typical jitter (RMS) less than 20 picoseconds 
with a delay time resolution of 10 picoseconds).  
The energy per pulse of a single uniform nspDBD plasma discharge in a 6-well 
plate was calculated after measuring voltage and current, using the method and instruments 
stated previously, and then subtracting displacement current. This was found to be 
0.9mJ/pulse. However, in some treatment conditions, a grounded metal mesh barrier was 
added between the cells and the high voltage electrode; the energy per pulse measured for 
this condition was 1.9mJ/pulse. The energy per pulse was also measured and calculated for 
the non-uniform nspDBD regime of plasma (0.6mJ/pulse) where gap distance was 
increased to 2mm. In order to keep the dose (total plasma energy delivered to the cells) the 
same during treatment, the frequency was adjusted based on the energy per pulse for each 
condition. Plasma treatment parameters are listed in Table 1.  
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Table 1. Operating parameters for nspDBD plasma treatment 
 
Isolation of Plasma Components 
Several treatment conditions, utilizing various barriers and gases, were designed to 
remove specific plasma components during exposure to cells. 
1. Direct Uniform nspDBD- Effect of All Components in Uniform Discharge 
Parameter Value 
Excitation Nanosecond Pulsed 
Voltage 29kV 
Rise Time 2ns 
Pulse Width 20ns 
Treatment Time 10s 
Total Doses 47, 141, 282, 705mJ 
Uniform 
Gap Distance 1mm 
Energy per Pulse (in wells) 0.9mJ/pulse 
Frequency 5, 15, 30, 75Hz 
Energy per Pulse (on copper 
mesh) 1.9mJ/pulse 
Frequency (for high 
doses) 15, 37Hz 
Non-Uniform 
Gap Distance 2mm 
Energy per Pulse (in wells) 0.6mJ/pulse 
Frequency (for high 
doses) 50, 128Hz 
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Direct uniform nspDBD in air, containing all the plasma effectors, served as our 
baseline for plasma induced cell death and as the control for all experiments. 
2. Electrode Dipped in Media- Effect of Global Electric Field 
To generate electric field without producing plasma, we did not remove the media 
prior to treatment. The electrode was dipped into the media and operated as before: 29kV 
at 30Hz and 75Hz (corresponding to the 282mJ and 705mJ doses respectively). Cells 
experienced electric fields of approximately 300kV/cm. 
3. Uniform nspDBD with Quartz Barrier- Effect of UV radiation 
To determine the contribution of plasma-generated UV radiation on cell viability, 
a grounded copper mesh with a 0.5mm-thick quartz barrier was positioned 1mm away from 
the high voltage electrode and placed directly on top of the cell surface. Thus, while plasma 
was generated between the high voltage electrode and the copper mesh, the quartz barrier 
is only transparent to UV >200nm; this consequently removes the gas species from 
treatment. 
4. Uniform nspDBD with Mesh Barrier- Effect of Charges and Short-Lived Neutral 
Species 
To study the contribution of charges and short-lived neutral species, we used a 
copper mesh without the quartz barrier.[8, 25] Only long-lived neutral gas species and UV 
were delivered to the cell layer during treatment. To keep the total energy delivered to the 
cells the same, pulse frequencies were adjusted to 15Hz and 37Hz as shown in Table 1. 
5. Uniform Discharge in Oxygen- Effect of Oxygen Species 
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In order to examine the effect of oxygen species, the electrode was inserted into a 
sealed well. 99.999% pure oxygen (Airgas, NJ, USA) was flown at a rate of 5 SCFM for 
10 seconds using 18 gauge inlet and outlet needles. The media was not degassed since it 
was removed immediately before treatment. Plasma treatment followed after oxygen was 
delivered and while gas was still flowing. Since the gas that plasma is created in can alter 
the energy per pulse, the discharge energy in both air and oxygen was measured and 
compared to ensure that total energy delivered to the cells during treatment was the same.  
6. Uniform Discharge in Nitrogen- Effect of Nitrogen Species 
To determine the effect of nitrogen species, the experimental setup was similar to 
the oxygen experiment, but oxygen gas was replaced with 99.999% pure nitrogen. 
Discharge energy was also measured in nitrogen and compared to that in air.  
Treatment in these two gas conditions helped delineate the contribution of plasma 
generated oxygen and nitrogen species on cell viability respectively. 
7. Non-Uniform nspDBD in Nitrogen- Effect of Streamers Part I 
NspDBD treatment was ignited in a pure nitrogen environment as previously stated. 
To operate in the non-uniform regime, voltage and treatment time was kept at 29kV and 
10 seconds respectively, but the electrode gap distance was increased to 2mm. To maintain 
the same doses delivered to the cells, pulse frequencies were adjusted to 50Hz and 128Hz 
based on our calculations tabulated in Table 1. 
8. Non-Uniform nspDBD in Air- Effect of Streamers Part II 
The non-uniform regime of plasma was produced in air by increasing gap distance 
to 2mm. 
66 
 
 
 
Taken together, these last two treatment conditions provided insight into the 
contribution of streamers on cell viability. 
Visualization of Plasma Uniformity 
Photographs of the plasma discharge were taken from underneath the well to 
determine the uniformity of plasma in air, oxygen, and nitrogen at 29kV and 1mm gap 
distances. The well rested on top of a clear plastic plate filled with water and sodium 
chloride (0.13g/mL) which acted as our second, grounding electrode. Gap distance was 
increased to 2mm under air and nitrogen gas environments to visualize the discharge in the 
non-uniform regime of plasma. Images were captured with a Nikon D700 at the following 
settings: 25600 ISO speed, f/4.5, 1/40 seconds exposure time, +5 step exposure bias, and 
105mm focal length. 
Cell Count and Viability Measurement and Analysis 
Cell viability following exposure to plasma was determined via fluorescence 
staining 1 hour post plasma treatment with a working concentration of 100ug/mL 
Propidium Iodide (Invitrogen, NY). Propidium Iodide (PI) is a DNA-binding fluorescent 
reagent that permeates damaged cell membranes. Data was collected with an image 
cytometer (Nexcelom Bioscience, USA) and further analysis including size gating was 
done on the FCS flow cytometry software (Nexcelom Bioscience, USA) as seen in Figure 
2. 
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Figure 2. Bright-field and fluorescent images of cells stained with Propidium Iodide and 
analysis. (Top left) A bright-field image and (top right) a fluorescent image of cells stained 
with PI was taken, within the same field on the Nexcelom Cellometer one hour post 
treatment. The number of cells in the bright-field and fluorescent images were counted. 
(Bottom) Further analysis and gating was done in the FCS Flow Cytometry Software. 
Untreated live cells and cells fixed with 4% paraformaldehyde (PFA) were also analyzed 
for each experiment to set the gates for positive and negative fluorescent signals. 
BCA Assay 
When cells are lysed, intracellular proteins are released into the supernatant. Hence, 
extracellular protein levels are a good indicator of damaged cells and can be quantified via 
a colorimetric assay. To determine if the observed cell loss was due to cell lysis, we 
performed the Bicinchoninic Acid (BCA) Assay (Thermo Scientific, USA). The released 
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proteins react with Cu2+ reducing it to cuprous cation (Cu1+). BCA then reacts with Cu1+ 
and the chelation of two molecules of BCA with Cu1+ results in a purple color change with 
strong absorbance at 562nm.[26] This assay was performed on the supernatant of plasma 
treated cells one hour post treatment and absorbance at 562nm was measured with a 
spectrophotometer (Beckman, USA). Protein concentrations were quantified based on a 
standard curve. 
Statistical Analysis 
All experimental data points were from triplicate samples and plotted as the mean 
± standard deviation. A Student’s t-test was used to determine significance between data 
points. A value of p≤ 0.05 was considered statistically significant and indicated with an 
asterisk (*) when comparing treated and untreated (mock treated) cells, and a pound sign 
(#) was used when comparing different treatment conditions within the same experiment. 
A plus sign (+) was used to indicate a value of p≤ 0.005. 
Results and Discussion 
Dose-Dependent Effects of Direct nspDBD Plasma on Cell Viability 
First, the dose-dependent effects of uniform nspDBD treatment in air directly in 
contact with the mesenchyme stem cell line CH310T1/2 were established. In this regime, 
cells were exposed to all components of plasma, i.e. electric field, radiation, charges, and 
neutral species. Pulse frequency for plasma treatment was 5, 15, 30, and 75Hz 
corresponding to total treatment doses of 47, 141, 282, and 705mJ. Cells were collected 
one hour after treatment, stained with PI, and analyzed for viability. The results were 
normalized to the untreated group. Low plasma doses had minimal effect on cell viability, 
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while higher doses decreased cell viability in a dose dependent manner (Figure 3). At 
282mJ the measured cell loss was 50% of the control and at 705mJ it was 80%. Since 
changes in cell viability would be more apparent at these two doses, we selected them to 
examine the effects of individual plasma components on cell death. BCA assay showed an 
increase in measured extracellular protein, which corresponds with a loss of viability that 
was dose-dependent. Taken together, these results suggest that in the uniform nanosecond 
regime, one mechanism of plasma induced cell death is cell lysis.  
 
Figure 3 Cell viability following plasma treatment is dose dependent. (Left) Live cell 
concentration following treatment was normalized to untreated. While low dose treatment 
did not result in cell death (47 and 141 mJ), high dose treatment (282 and 705 mJ) 
significantly reduced viable cells compared to cells untreated with plasma. (Right) This 
could be a result of cell lysis as total protein concentration in the cell culture medium 
increased after plasma treatment. Extracellular protein was measured with a BCA assay 
one hour post plasma. Results are normalized to the untreated cells. 
Images of the plasma were taken to confirm uniformity of the discharge (Figure 4). 
The difference in the intensity of the plasma discharge may be a result of the different 
emission wavelengths from the various gases. The camera may not be as sensitive in 
picking up the emissions from oxygen as opposed to nitrogen. However, the uniformity of 
the discharge can still be observed. 
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Figure 4 Uniform nspDBD in (left) air, (middle) pure oxygen, and (right) pure nitrogen. 
Images were captured with a Nikon D700 at the following settings: 25600 ISO speed, f/4.5, 
1/40 seconds exposure time, +5 step exposure bias, and 105mm focal length. Plasma was 
generated by applying a high voltage pulse of 29kV over a 1mm gap distance. Differences 
in light intensity may be due to the different emission wavelengths from the gases.  
Contribution of Plasma Components on Cell Death 
1. Direct Uniform nspDBD- Effect of All Components in Uniform Discharge 
As previously stated, direct uniform nspDBD induced 50% and 80% cell death 
following treatment. This condition served as the positive control for comparison in all 
other conditions. Untreated cells served as our negative control and are indicated as 
untreated on the graphs. 
2. Electrode Dipped in Media- Effect of Global Electric Field 
The dielectric strength for atmospheric air is approximately 30kV/cm whereas the 
dielectric strength of water exceeds 700kV/cm.[9] Since the electric field of nspDBD plasma 
(~300kV/cm) did not exceed the dielectric strength of water, plasma was not generated 
when the electrode was dipped in media. Therefore, to study the effect of global electric 
field in the absence of plasma, the electrode was operated submerged in media over cells. 
Under this treatment condition, no effect on cell viability was observed (Figure 5). This 
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indicates that the global electric field, generated from plasma, by itself does not play a role 
in cell killing. 
Pulsed electric fields applied on cells have been shown to trigger electroporation, 
the process of inducing temporary permeability of cellular membranes.[27] It was shown 
that at pulse durations on the order of microseconds, electroporation occurs and cell death 
can be induced in HeLa cells at low electric fields (2.25kV/cm).[28] Nanosecond 
electroporation, having pulse widths greater than 60ns, has also been shown to induce death 
in cancer cell in vitro and tumor regression in vivo.[29-31] Additionally, Beebe et al showed 
that by decreasing pulse widths to 10-60 nanoseconds, there is insignificant poration effect 
on Human Jurkat cells even at high electric fields (300kV/cm).[10, 32] In our study, plasma 
discharge was generated with pulse widths of 20ns and electric fields of ~300kV/cm. Hence 
cell killing from electroporation is unlikely to occur, and we can rule out the effect of 
plasma generated electric fields as a factor causing cell death in our system. 
3. Uniform nspDBD with Quartz Barrier- Effect of UV Radiation 
In the presence of the quartz barrier, only UV radiation generated from plasma was 
applied to cells, and all other plasma components were suppressed. Treatment with UV 
radiation at 282mJ and 705mJ reduced cell viability by 16% and 23% respectively (Figure 
5).  
DBDs have long been used as sources of ultraviolet (UV) radiation from vacuum 
UV (110-180nm) to UVA (320-400nm).[23] UV radiation greater than 200nm is known to 
be damaging to DNA,[12] and studies have shown that UV radiation can trigger and induce 
cell death through multiple independent pathways.[11, 33] Caricchio et al have shown that 
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high doses of irradiation (80mJ/cm2) can induce cellular necrosis.[33] Furthermore, UV 
radiation has also been known to generate intracellular reactive oxygen species (ROS) 
including hydrogen peroxides and hydroxyl radicals that have been known to initiate cell 
damage and death.[34, 35] Since we observed that UV treatment alone was not as effective 
in cell killing, it may play an ancillary role. 
Results from these three conditions, taken together, show that for effective killing, 
plasma generated charges and gas species are required (Figure 5). However, possible 
synergistic and minor effects with other components on cell processes cannot be ignored. 
 
Figure 5. Plasma generated global electric fields and UV radiation alone are not the major 
contributors of cell death. (Left) Live cells that remained one hour following nspDBD 
treatment in air were counted to determine cell viability and numbers. Data is expressed 
relative to the number of live cells in untreated wells and showed 50% and 80% cell death 
following 282mJ and 705mJ treatments respectively. This condition served as our positive 
control to the following treatments. (Middle) The electrode was dipped into the media and 
ran at 30Hz and 75Hz to produce pulsed electric fields without the generation of plasma. 
Results showed no cell death following treatment. (Right) Copper mesh and quartz barrier 
inserted 1mm from the high voltage electrode allowed for the penetration of UV radiation 
while removing charges and gas species generated from plasma. Cell death following this 
treatment was approximately 16% and 23% for the low and high doses respectively. 
4. Uniform nspDBD with Mesh Barrier- Effect of Long-Lived Neutral Species 
In order to determine the contribution of charged and short-lived neutral species, a 
copper mesh barrier without the quartz barrier was used. Cells under this condition were 
exposed only to long-lived neutral species and UV. Our results showed that treatment with 
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this barrier induced an average of 24% and 35% cell death at the 282mJ and 705mJ dose 
respectively (Figure 6). This is lower than our positive control, indicating that both charges 
and short-lived neutrals are very important for reduced cell viability. 
The effect of charges and short-lived species from plasma on prokaryotes was 
published by Fridman et al in their experiments with Staphylococci, Streptococci, and 
Candida species.[25] They demonstrated that the time required to inactivate bacteria in a 
lawn culture with DBD was more than one order of magnitude longer when charged species 
from plasma treatment were removed. Their results closely resemble our observations in 
mammalian cells.  
 
Figure 6. Contribution of charges and neutral gas species to cell killing. (Left) Treatment 
with a copper mesh barrier exposed cells only to long-lived neutral species in plasma and 
radiation. Live cell counts one hour post treatment showed 24% and 35% cell death at low 
and high doses respectively, suggesting that charges and short-lived species are important 
for cell killing. (Middle) Uniform discharge in oxygen showed significant cell death at both 
doses, indicating that the oxygen species produced are the major contributors in plasma 
induced cell death. (Right) Cells only exposed to plasma generated nitrogen species 
showed no cell death for both doses, further emphasizing that for effective cell killing, the 
presence of oxygen is required. 
5. Uniform Discharge in Oxygen- Effect of Oxygen Species 
To further delineate the chemical species affecting cell viability, the discharge was 
generated in pure oxygen so only oxygen species, such as OH, O2
-, H2O2, are produced 
during treatment. Our results showed that 282mJ and 705mJ dose treatments induced 58% 
and 85% cell death, only slightly higher than direct nspDBD treatment (Figure 6). 
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However, there was no statistically significant difference between uniform treatment in air 
and treatment in oxygen. This clearly demonstrated that the oxygen species produced by 
plasma are the major contributors to plasma induced cell death. 
Gas composition is known to affect discharge energy, which may in turn affect the 
total energy delivered to the cells during treatment. Therefore, it was crucial to verify 
whether the effect on cell viability was due to changes in treatment dose. Total discharge 
energy per pulse (including displacement current) in air and pure oxygen was measured 
and found to be 12.0±0.3mJ/pulse and 12.1±0.4mJ/pulse respectively. Since the discharge 
energies between air and oxygen were within error, the observed cell death was concluded 
to not be a result of changes in dose, but because of the species generated. 
Computational modeling and optical emission spectroscopy of atmospheric plasma 
discharges in air have shown the production of various oxygen species.[26, 36, 37] ROS, such 
as hydrogen peroxide, can function as a signaling molecule to regulate cell processes,[14, 34, 
38, 39] but at high concentrations, they can become agents that lead to cell death.[40] Laurent 
et al have shown that exogenous hydrogen peroxide at low concentrations (0.02-0.13µM) 
enhanced NIH 3T3 fibroblast proliferation while 0.25-2µM of hydrogen peroxide resulted 
in cell death.[14] Thirunavukkarasu et al have also shown that treatment of hepatic stellate 
cells with superoxide, another plasma generated ROS, caused cell death.[13] Our experiment 
in oxygen suggests that the cell death we observe following plasma treatment is likely a 
result of one or more of these oxygen species. 
NspDBD treatment of biological targets is usually carried out in air which is 
composed primarily of nitrogen and oxygen. Therefore, in addition to determining the 
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effect of plasma generated oxygen species, the contribution of nitrogen species on cell 
death is also important to study. To further isolate and remove the plasma generated 
chemical species in air, treatment of cells was performed in a pure nitrogen environment. 
6. Uniform Discharge in Nitrogen- Effect of Nitrogen Species 
Following discharge in ultra-high purity nitrogen gas, no cell death was observed 
for either of the doses (Figure 6). These results clearly show that nitrogen species alone, 
such as electronically excited N2 and N
+ ions,[9, 41] do not contribute to plasma induced cell 
death. 
The total discharge energy per pulse (including displacement current) pure nitrogen 
was also measured and found to be 10.4±0.3mJ/pulse. Although the discharge energy in 
nitrogen was slightly lower than that in air, we did not observe cell death in nitrogen, even 
for the high dose treatment. This re-emphasizes the importance of the presence of oxygen 
for plasma induced cell death. 
Our discharge environment may be in pure nitrogen gas, but it has been proposed 
that some oxygen species, such as hydroxyl radicals, can be generated from the humidity 
in the atmosphere or from residual liquid remaining on cells during treatment.[24] Therefore 
it is possible that there are some small concentrations of ROS in this condition. However, 
our results showed insignificant cell death in this condition, which suggests that even if 
ROS was being generated through the proposed mechanism, the levels are low enough that 
their contribution to cell death is trivial. 
This condition only considered the contribution of pure nitrogen species but did not 
take into account the effect of reactive nitrogen species (RNS) produced by plasma. The 
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production of RNS, such as nitric oxide (NO) or peroxynitrite (ONOO-), require the 
presence of oxygen, so their contribution cannot be ruled out. However, these results 
reaffirmed that the presence of oxygen is required for effective cell killing. 
It is important to note that electrons and ions are still present when cells are plasma 
treated in the presence of nitrogen. Since no effect on viability was observed, it strongly 
indicates that charges alone are not enough to induce cell death. However, a catalytic role 
in facilitating cell death with the oxygen species cannot be ruled out. 
7. Non-Uniform nspDBD in Nitrogen and Air-Effect of Streamers 
Since treatment in the pure nitrogen condition did not affect cell viability, this 
condition was used to assess the contribution of streamers in non-uniform plasma 
discharges. Any effect on cell viability following non-uniform plasma treatment in nitrogen 
would then be a direct result of the streamers generated in this regime. As stated in Table 
1 the frequency of pulses was adjusted to 50Hz and 128Hz for 282mJ and 705mJ dose 
treatments respectively. To confirm the presence of streamers, images of the non-uniform 
plasma were taken. Comparing the images of uniform discharge in Figure 4 and non-
uniform discharge in Figure 7, streamers are only observed in the non-uniform regime. 
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Figure 7. Non-Uniform nspDBD in (left) nitrogen and (right) air. In the non-uniform 
regime of plasma, streamer structures are clearly observed. Images were captured at the 
same settings as those of the uniform discharge. In order to generate plasma in the non-
uniform regime, the voltage was set at 29kV, and the gap distance was increased from 1mm 
to 2mm. 
Following both uniform and non-uniform plasma treatment in pure nitrogen, no 
significant effect on cell viability was observed. This suggests that the streamers and 
corresponding local electric fields do not play a role in cell killing. However, when both 
regimes of nspDBD were performed in air, non-uniform treatment resulted in 62% and 
89% cell death for 282mJ and 705mJ dose treatments respectively (Figure 8). While only 
the effect at 282mJ is statistically significant, cell death in both cases is higher than uniform 
nspDBD treatment at the same doses. There are two possible explanations for this effect: 
 streamers may play a synergistic role with charges and oxygen species in affecting 
cell killing 
 the high local electric fields from the streamer heads altered the concentration of 
chemical species generated  
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Further investigation and comparison of the species generated in the uniform and 
non-uniform regime of plasma is therefore required.  
 
Figure 8. Comparison of uniform and non-uniform regimes of nspDBD treatment. (Left) 
Following non-uniform treatment under pure nitrogen conditions, results showed that the 
streamers and corresponding local electric fields from the streamer head did not 
significantly induce cell death. (Right) However when the discharges were done in air, 
analysis showed non-uniform treatment resulted in 62% and 89% cell death; this is greater 
than uniform nspDBD for both doses. The difference between uniform and non-uniform 
treatment was statistically significant for the 282mJ dose treatment but not for the higher 
705mJ dose treatment. 
In summary, cell death following plasma treatment is a result of plasma generated 
oxygen species with contribution from charges. Our results from the various treatment 
conditions are compiled in Table 2.  
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Table 2. Summary of conditions used to isolate and remove plasma components. 
The percent cell death following exposure at 282mJ and 705mJ are shown in the two 
columns on the right 
 Effectors Present Effectors Absent 
2
82mJ 
7
05mJ 
1. Direct 
Uniform nspDBD in 
Air 
Global E-Field, 
Radiation, Charges, Neutrals 
Streamers 
5
0% 
8
0% 
2. Electrode 
Dipped in Media 
Global E-Field 
Radiation, Charges, 
Neutrals, Streamers 
0
% 
0
% 
3. Uniform 
nspDBD w/Quartz 
Barrier 
UV Radiation 
Global E-Field, 
Charges, Neutrals, Streamers 
1
6% 
2
3% 
4. Uniform 
nspDBD w/Mesh 
Barrier 
Long-Lived Neutrals, 
Radiation 
Global E-Field, 
Charges, Short-Lived Neutrals, 
Streamers 
2
4% 
3
5% 
5. Uniform 
nspDBD in Oxygen 
ROS, Charges, Global 
E-Field, Radiation 
Other Neutral Species, 
Streamers 
5
8% 
8
5% 
6. Uniform 
nspDBD in Nitrogen 
Nitrogen Species, 
Charges, Global E-Field, 
Radiation 
Other Neutral Species, 
Streamers 
0
% 
0
% 
7. Non-
Uniform nspDBD in 
Nitrogen 
Streamers, Nitrogen 
Species, Charges, Global E-
Field, Radiation 
Other Neutral Species 
2
% 
1
6% 
8. Non-
Uniform nspDBD in 
Air 
Streamers, Neutrals, 
Charges, Global E-Field, 
Radiation 
None 
6
2% 
8
9% 
 
Conclusion 
It was shown that the cell viability of C3H10T1/2 murine mesenchyme stem cells 
is reduced in a dose dependent manner with nspDBD plasma treatment. Cell lysis was 
identified as one mechanism of cell death following nspDBD treatment. Oxygen species 
and charged particles are the major plasma components contributing to cell death. UV 
radiation was shown to play a minor role, and the roles of global electric field and nitrogen 
species have been ruled out. Additionally, in the non-uniform regime of plasma treatment, 
the streamers and the corresponding high local electric fields at the streamer heads alone 
were not important for cell killing.  
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As the field of plasma medicine continues to progress with great promise in the area 
of cancer treatment, it is crucial to understand the components of plasma that induce cell 
death. Future studies include comparing effects of plasma components on various 
cancerous and non-cancerous cell types. Intracellular biochemistry and cell cycle analysis 
following treatment will be studied. Additionally, while we observed cell death through 
direct cell lysis, cell death from apoptosis must also be investigated. Understanding these 
fundamental plasma-cell interactions will enhance the tunability of plasma devices and 
lead to further optimization of plasma for cancer treatment while reducing toxicity to 
surrounding, non-cancerous cell types. 
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CHAPTER 6: NANOSECOND-PULSED DBD PLASMA-GENERATED 
REACTIVE OXYGEN SPECIES TRIGGER IMMUNOGENIC CELL DEATH IN 
A549 LUNG CARCINOMA CELLS THROUGH INTRACELLULAR 
OXIDATIVE STRESS   
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ABSTRACT 
A novel application for non-thermal plasma is the induction of immunogenic cancer 
cell death for cancer immunotherapy. Cells undergoing immunogenic death emit danger 
signals which facilitate anti-tumor immune responses. Although pathways leading to 
immunogenic cell death are not fully understood, oxidative stress is considered to be part 
of the underlying mechanism. Here, we studied the interaction between dielectric barrier 
discharge plasma and cancer cells for oxidative stress-mediated immunogenic cell death. 
We assessed changes to the intracellular oxidative environment after plasma treatment and 
correlated it to emission of two danger signals: surface-exposed calreticulin and secreted 
adenosine triphosphate. Plasma-generated reactive oxygen and charged species were 
recognized as the major effectors of immunogenic cell death. Chemical attenuators of 
intracellular reactive oxygen species successfully abrogated oxidative stress following 
plasma treatment and modulated emission of surface-exposed calreticulin. Secreted 
adenosine trisphosphate from cells undergoing immunogenic death enhanced the anti-
tumor activity of macrophages. This study demonstrated that plasma triggers immunogenic 
cell death through oxidative stress pathways and highlights its potential development for 
cancer immunotherapy. 
 
 
Keywords: Non-thermal plasma; cancer immunotherapy; immunogenic cell death; 
oxidative stress; calreticulin; adenosine triphosphate; plasma immunotherapy; 
nanosecond-pulsed dielectric barrier discharge 
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1. Introduction 
Methods to induce immunogenic cell death (ICD), where dying cells emit 
immunostimulatory signals, are being actively explored for cancer immunotherapy [1-5]. 
Cancerous cells undergoing ICD recruit and stimulate antigen presenting cells (APCs), key 
immune cells required for initiation of an adaptive immune response [4-6]. This leads to 
the subsequent development and activation of tumor-specific effector T cells and memory 
T cells [7-11]. Thus, cancer is suppressed systemically and long-term protection against 
cancer recurrence is possible [9, 10]. 
While mechanisms that promote ICD are under investigation, molecules 
characteristic of ICD known as damage-associated molecular patterns (DAMPs), have 
been identified [12, 13]. These molecules are exposed on the cell surface or secreted by 
cells undergoing autophagy, endoplasmic reticulum (ER) stress or oxidative stress from 
reactive oxygen species (ROS) [6, 12-15]. DAMPs that are characteristically associated 
with ICD are: surface-exposed calreticulin (ecto-CRT), secreted adenosine triphosphate 
(ATP), released high mobility group protein B1 (HMGB1), and surface-exposed heat shock 
protein 90 (HSP90) and HSP70 [15-18]. Of these, CRT and ATP are identified as the major 
predictors of the immunostimulatory capacity of anti-cancer therapeutics [17-20]. 
Retrospective evaluation of experimental and clinical data has led to the identification of 
several ICD inducers, including some chemotherapeutics (anthracyclines and oxaliplatin), 
ionizing radiation, and photodynamic therapy with hypericin [1-3]. At the same time, new 
ICD inducers, such as non-thermal plasma, are also being investigated.  
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Plasma, known as the fourth state of matter, is an ionized gas composed of 
electrons, various ions, electronically excited atoms and neutral atoms and molecules [21]. 
Two major family of devices for generating non-thermal plasma at atmospheric pressure 
for biological and medical applications are (Figure 1): 1) plasma jets and 2) direct 
dielectric barrier discharges (DBDs) (employed in this study) [22, 23]. In jets, most of 
plasma is generated remotely, and plasma products are often delivered to the biological 
target via a carrier gas [23]. Ionization waves also produce some plasma at the treatment 
surface [24]. DBDs generate plasma directly at the surface being treated [22]. Owing to the 
electrode design, DBDs are typically able to a cover much larger surface area compared to 
jets [25]. Furthermore, chemical species deposited on target surfaces, in particular, charged 
energetic particles and short-lived reactive species, are different between the two systems 
[22, 23, 26].  
Besides applied electric field and plasma temperature, a major determinant of the 
exact composition of plasma is the gas environment in which plasma is generated [27]. In 
the presence of oxygen, reactive oxygen species (ROS) such as atomic oxygen (O), 
hydroxyl radicals (∙OH), superoxide (O2∙-), singlet oxygen (1O2) and hydrogen peroxide 
(H2O2) are produced [28-31]. When reactive nitrogen species (RNS) are desired for wound 
healing or other specific applications, nitrogen may be introduced into the discharge 
environment [32]. Major measured species include atomic nitrogen (N), peroxynitrite 
(ONOO-) and nitric oxide (NO) [33]. Therefore, it is plausible to optimize plasma treatment 
parameters to produce various chemical effectors for desired biological outcomes. 
The highly reactive species are known to influence biological processes and their 
role in cancer cell killing has been extensively researched [34, 35]. In fact, chemotherapies 
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and radiation therapy often rely on the formation of ROS to induce oxidative stress in 
cancerous cells [36-38]. PDT with hypericin (a photosensitizing agent), another treatment 
for cancers, causes massive production of ROS including 1O2
 in the ER, leading to ICD 
[39-42]. Typically, DBDs are richer in short-lived reactive species including 1O2
 and ∙OH, 
both of which are influencers of biochemical processes [27, 43, 44]. However, in specific 
operating modes, certain jets are also able to produce these radicals and other metastables 
[45, 46]. Consequently, it is important to understand the contribution of short-lived plasma 
species for ICD induction.  
 
Figure 1. Two major families of non-thermal, atmospheric pressure plasma devices for 
biomedical applications are jets and DBDs. A) Jets remotely generate bulk plasma and 
plasma species are often transported to the target via a carrier gas. B) DBDs plasma use 
the target as a grounding electrode to generate plasma directly onto cells and tissue. 
Although mounting evidence in literature suggests that it is the plasma-generated 
reactive species that are responsible for provoking cellular responses, electric fields and 
ultraviolet (UV) light are also produced in plasma, and their interaction with cells and tissue 
should not be overlooked [26, 47]. Plasma-associated pulsed-electric fields may affect cell 
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processes, as electric fields have often been used for electroporation, a process that makes 
cellular membranes permeable temporarily [48]. Since intracellular changes leading to 
apoptosis and necrosis can be induced by changing pulsed-electric fields characteristics 
(e.g. pulse duration, electric field intensity, etc.) [48-50], we investigated the contribution 
of electric fields, in our system, on ICD induction. 
UV light emitted from plasma may also be crucial for induction of biological 
responses, as UV with wavelengths up to 400 nm are known to induce DNA damage and 
cell death through multiple pathways [51-53]. Furthermore, Obeid, et al., have also 
reported that UV C is able to induce emission of ecto-CRT and increase immunogenicity 
of cancerous cells [54]. Since DBDs have long been used as sources of UV radiation 
ranging from vacuum UV (110-180 nm) to UV A (320-400 nm) [55], the role of plasma-
generated UV for ICD merits investigation. 
Altogether, it is clear that plasma is composed of multiple effectors that have been 
reported to individually induce ICD for cancer immunotherapy. Understanding the role of 
these plasma components is critical for development and optimization of plasma 
technology and deeper mechanistic understanding. Additionally, synergistic effects 
between plasma components may also provide significant advantages over contemporary 
therapies.  
Numerous studies have reported that plasma changes the oxidative status of cells 
through stimulation of intracellular ROS production [26, 56, 57]. The overall redox status 
of the cell induces a wide array of cellular responses ranging from proliferation to 
senescence and death [58, 59]. Physiological levels of ROS influence cellular pathways 
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related to growth and proliferation [58]. However, excessive intracellular ROS triggers the 
oxidative stress pathways that may lead to metabolic alterations and even death [60]. On 
this spectrum is ER stress, which has been observed in cells undergoing ICD [14, 61]. We 
have reported the upregulation of two ER stress proteins, activating transcription factor 4 
(ATF4) and stanniocalcin (STC2), in response to non-thermal plasma exposure of cells 
[62]. These two genes are upstream of ecto-CRT, a critical DAMP signal for ICD [63, 64]. 
Increased secretion of ATP, another DAMP signal and hallmark of ICD, was also observed 
from cells treated with plasma [62]. Therefore, plasma seems to induce ICD through the 
canonical cellular oxidative stress pathways.  
In this study, we investigated the role of both, the plasma-delivered, extracellular 
ROS and the triggered intracellular ROS for the induction of ICD. Using a nanosecond-
pulsed dielectric barrier discharge (nspDBD) plasma, we treated the A549 lung carcinoma 
cell line and measured one cell-surface DAMP, ecto-CRT, and one released mediator, 
ATP, as indicators of ICD. To further test the immunogenicity of these cells, we measured 
the tumor killing capacity of co-cultured macrophages. We assessed the influence of 
intracellular ROS on ICD by using two chemical ROS attenuators: N-acetyl cysteine 
(NAC) and diphenyleneiodonium (DPI). Since each component of plasma has individually 
been demonstrated to affect cellular redox, the role of plasma effectors on ICD was 
evaluated by isolating and removing each sequentially during treatment of cells. 
Our results show that plasma-delivered ROS and charged species increased 
intracellular ROS and induced DAMP emission. Inhibition of intracellular ROS partially 
reversed this effect, indicating that plasma triggers cellular oxidative stress pathways. 
Additionally, ICD induction was accompanied by enhanced anti-tumor activity of 
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macrophages, which was also modulated when ICD was attenuated. This study describes 
a new biomedical application of non-thermal plasma which merits further in vivo 
validation, as plasma could be a safe ICD inducer for cancer immunotherapy.  
2. Results 
2.1. NspDBD Plasma Elicits Apoptosis in an Energy-Dependent Manner 
Under certain conditions, not fully defined yet, apoptotic cells have been shown to 
emit DAMPs [18, 65]. Therefore, we first examined the effect of different plasma energies 
on cell viability of the A549 lung carcinoma cell line by exposing them to a range of plasma 
energies, 50 mJ to 700 mJ as calculated from treatment time, frequency of pulses, and 
energy per pulse (described in materials and methods). We have previously shown, with 
increasing energy, plasma may cause direct cell lysis [47]. Therefore, to assess early 
damaging effects of plasma, viable cells were quantified with a Propidium Iodide (PI) 
exclusion assay, one hour post treatment. Cell viability decreased and the percent of 
apoptotic cells increased in an energy-dependent manner. At 300 mJ treatment, cell 
viability was 50% of the untreated cells (Figure 2A). 24 hours post plasma treatment, a 
statistically significant increase in the number of early apoptotic cells (Annexin V+/PI) was 
observed at all energies, 100 mJ and above (Figure 2B, C). Therefore, more cells are likely 
to express ligands for phagocytic cell receptors for uptake by APCs [66, 67].  
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Figure 2. Plasma induced cell death in an energy dependent manner. A) 1 hour after plasma 
exposure, A549 viability decreased as quantified with a PI exclusion assay, indicating early 
damaging effects of plasma (One Way ANOVA, Dunnett’s multiple comparison test). B) 
Representative dot plots of Annexin V/PI double stained cells 24 hours post plasma 
treatment. Results are summarized in C). Early apoptotic cells (Annexin V+/PI-) were 
increased significantly compared to untreated controls for all energies above 50 mJ (Two 
Way ANOVA, Sidak’s multiple comparison test). Data are represented as mean±SEM. 
*p<0.05, **p<0.005, ***p<0.001 
2.2. NspDBD Plasma Induces Oxidative Stress 
The oxidative and reductive (redox) state of the cell is a dynamic balance of 
oxidants and anti-oxidants [68]. However, when oxidants, either endogenously produced 
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or derived externally, exceed the cell’s anti-oxidant capacity, the result is oxidative stress 
[59]. Several studies have linked oxidative stress from increased intracellular ROS to 
induction of ICD [61, 69]. Since most plasma-associated effects are reported to be a result 
of changing cellular redox [57, 70], we explored the role of intracellular ROS in plasma-
induced ICD.  
A time-course study was carried out to quantify fluctuations in cellular redox 
following plasma exposure. A549 cells were treated with nspDBD plasma and stained with 
an intracellular ROS probe, 2’,7’-dichlorofluorescein diacetate (DCFDA), immediately, 1 
hour, 4 hours, and 24-hours post exposure. Image cytometry and analysis showed an 
increase in ROS positive cells with the highest change at 4 hours (Figure 3A). By 24 hours, 
intracellular ROS decreased, but did not return to basal level. To abrogate changes to 
cellular redox, we incubated cells with 10 mM NAC supplemented media , a scavenger of 
both plasma delivered and cell generated ROS, 1 hour prior to 300 mJ plasma treatment 
[71, 72]. Incubation with 5 μM DPI supplemented media, an inhibitor of NADPH oxidase, 
1 hour prior to 300 mJ plasma treatment, prevented generation of intracellular ROS [73]. 
This energy corresponded to the highest measured ROS. NAC completely reversed the 
intracellular ROS levels but DPI was only partially effective, indicating that the increase 
in intracellular ROS after plasma exposure is because of plasma-delivered and plasma-
triggered events. Since both agents were efficacious in modulating intracellular ROS 
(Figure 3B), they were used for subsequent experiments to elucidate the involvement of 
oxidative stress on plasma-induced ICD. 
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Figure 3. NspDBD increased intracellular ROS. A) A time course of intracellular ROS 
induction following plasma treatment showed the greatest increase of ROS positive cells 
at 4 hours. Cell were collected at the indicated times after plasma exposure, stained with 
DCFDA, and quantified using image cytometry. This experiment was performed once 
(n=2) to determine the ideal time point to observe changes in intracellular ROS for 
subsequent experiments. B) NAC (10 mM) and DPI (5 μM) reduced intracellular ROS (4 
hours post plasma) when cells were pre-incubated with these agents for 1 hour, prior to 300 
mJ treatment (One Way ANOVA, Dunnett’s multiple comparison test). Data are 
represented as mean±SEM. *p<0.05, **p<0.005, ***p<0.001  
2.3. NspDBD Plasma Elicits Surface Exposure of CRT 
Ecto-CRT is a prominent ‘eat me’ DAMP signal that facilitates the engulfment of 
cells by APCs, such as macrophages and dendritic cells (DCs) [14, 18, 19, 67]. This is 
followed by their migration to immune organs and processing and presentation of 
antigens—critical steps for the development of a specific, anti-cancer immune response [7, 
10, 74]. Since both apoptosis and increased intracellular ROS was measured at energies 
100 mJ and 300 mJ, we tested the externalization of CRT at these energies. A statistically 
significant increase in ecto-CRT was measured at 300 mJ, 24 hours post treatment (Figure 
4A, B). To determine if ROS is involved in plasma-induced ICD at this energy, we 
compared the emission of ecto-CRT in the presence and absence of NAC and DPI 
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following plasma exposure. Both NAC and DPI modulated ecto-CRT expression (Figure 
4C, D), indicating that plasma-induced CRT emission follows defined oxidative stress 
pathways.  
                                                  
Figure 4. Plasma-elicited emission of surface CRT is associated with increased 
intracellular ROS. A) Representative histograms of ecto-CRT showed an energy dependent 
rightward shift in peak fluorescence 24 hours following plasma treatment, and B) 
percentage of ecto-CRT positive cells increased from 8.6% to 31.2% at 300 mJ (One Way 
ANOVA, Dunnett’s multiple comparison test). Pre-incubation with NAC and DPI C) 
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inhibited the peak shift and D) reduced the percentage of surface-exposed CRT cells (One 
Way ANOVA, Dunnett’s multiple comparison test). Data are shown as mean±SEM. 
*p<0.05, **p<0.005, ***p<0.001 
2.4. NspDBD Plasma Elicits Secretion of ATP 
Extracellular ATP acts as an important ‘find me’ DAMP signal to recruit and 
activate APCs in the vicinity [15, 17, 75]. Therefore, secreted ATP was also measured in 
response to plasma treatment in the presence and absence of NAC and DPI to further 
establish the integration of oxidative stress pathways in plasma-induced ICD. ATP secreted 
into the cell culture media was analyzed with a firefly luciferase and luciferin 
chemiluminescence kit 10 minutes after plasma exposure. Extracellular ATP increased 
significantly, from 12.3 nM in the untreated cells to 831.2 nM following 300 mJ treatment 
(Figure 5A). While reduction of secreted ATP by DPI was statistically significant, NAC 
had no inhibitory effect on ATP secretion (Figure 5B). This is potentially because ROS-
triggered ATP secretion may occur more rapidly than the scavenging effects of NAC. 
 
Figure 5. DPI inhibited plasma-elicited ATP secretion. A) Secreted ATP measured in the 
supernatant 10 minutes following plasma treatment increased from 12.3 nM up to 831.2 
nM at 300 mJ treatment (One Way ANOVA, Dunnett’s multiple comparison test). B) DPI 
was able to temper ATP secretion, while NAC did not (Two Way ANOVA, Sidak’s 
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multiple comparison test). Data are shown as mean±SEM. *p<0.05, **p<0.005, 
***p<0.001 
2.5. NspDBD-Elicited ICD Enhances Anti-Tumor Activity of Macrophages  
Cells undergoing ICD become immunogenic and should therefore interact with 
macrophages to increase their phagocytic activity [76]. Extracellular ATP stimulates DCs 
and macrophages to release proinflammatory cytokines, such as tumor necrosis factor 
alpha (TNF-α), interleukin 1 beta (IL-1β), and IL-18, causing tumoricidal activity [77-81]. 
Therefore, we evaluated the capacity of plasma-stimulated ICD to enhance anti-tumor 
activity of macrophages. A549 cells were treated at 100 mJ and 300 mJ and cultured with 
phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 macrophages (M0 
macrophages) in transwell inserts. These inserts separated the two cell types from direct 
contact but allowed for the exchange of secreted DAMPs from tumor cells and cytokines 
from macrophages in the media. Quantification of viable A549 cells was performed with 
the PI exclusion assay 48 hours post plasma treatment and co-culture and normalized to 
untreated A549 cells cultured alone. Since surviving cells continued to proliferate, counts 
were normalized to the untreated group. In response to plasma alone, 68% and 58% cells 
remained viable at 100 mJ and 300 mJ treatment, respectively. Under co-culture conditions 
with M0 macrophages, viability of untreated A549 cells was 65%. This served as the 
baseline anti-tumor activity of M0 macrophages. Following plasma treatment and co-
culture with macrophages, viability reduced significantly (34% and 32% for 100 mJ and 
300 mJ treatments, respectively), compared to cells treated at the same energy and cultured 
alone (Figure 6A). In the presence of DPI, where secreted ATP levels are lower (Figure 
5B), plasma-treated A549 cells in co-culture showed significantly higher viability 
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compared to those treated and co-cultured in regular media (77% vs 34%, p<0.001) (Figure 
6B). Furthermore, in DPI supplemented media, the difference in viability between plasma-
treated A549 cells cultured alone or in the presence of M0 macrophages is insignificant, 
indicating that the observed cell death is a result of direct plasma treatment. As expected, 
in the presence of NAC where ATP secretion was not modulated, tumor cell killing by co-
cultured macrophages was comparable to that in media (Figure 6B). Based on these results, 
the observed enhanced anti-tumor activity of macrophages is presumed to be due to 
secreted ATP and other DAMPs from cancerous cells undergoing ICD.  
 
Figure 6. Plasma treatment of tumor cells in ICD-inducing regimes enhanced anti-tumor 
activity of macrophages. A) 48 hours post plasma treatment and co-culture with M0 
macrophages, A549 cells showed reduced viability compared to those treated with plasma 
and cultured alone. B) Enhanced anti-tumor effects were abrogated when ATP secretion 
was inhibited with DPI (Two Way ANOVA, Tukey’s multiple comparison test). Data are 
shown as mean±SEM. *p<0.05, **p<0.005, ***p<0.001  
2.6. NspDBD Plasma-Generated ROS and Charges are the Major Effectors of ICD 
When plasma is generated, a complex milieu consisting of electric fields, ultraviolet 
light (such as UV A, B, C and vacuum UV), charged species and neutral gas species is 
produced [26, 43, 82, 83]. To identify which of these is the major contributor of plasma-
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induced ICD, we dissected the plasma using barriers and treatment conditions engineered 
to remove components from treatment (summarized in Table 2 of Materials and Methods). 
Parameters that generated a plasma discharge at 300 mJ were used for all treatment 
conditions (29kV, 30 Hz, 10 second treatment time, and 1 mm application distance) and 
ecto-CRT and secreted ATP were measured as indicators of ICD. Results are expressed as 
percent (CRT) or fold (ATP) change with respect to mock-treated cells, which served as 
our negative control. Cells exposed to complete plasma served as the positive controls and 
correspond to 50% cell death, 27% increase in ecto-CRT positive cells and 87-fold increase 
in secreted ATP (Figure 7). 
To examine the contribution of global electric fields and UV light, a liquid barrier 
and a quartz barrier, were employed, respectively. When the electrode is submerged in a 
liquid, the applied electric field is less than the dielectric strength of the medium. Therefore, 
while electric fields are present, plasma is not generated (Appendix A). Quartz prevents 
penetration of all plasma components except UV A, B and C. Our results show that in both 
cases, cell viability and DAMP emission remained similar to untreated controls. Lack of 
effect of local electric fields within the plasma was also observed when plasma was 
operated in different modes of DBD (Figure A1). This implies that plasma-associated 
electric fields and UVs have negligible effects on ICD induction.  
When a mesh barrier is used, plasma is generated between the electrode and the 
mesh and only the long-lived species may be delivered to the cells. In general, secondary 
plasma generation may also occur between the mesh and the cells but it was not visibly 
observed in this case. When we used the mesh barrier, cell viability recovered marginally 
(64% viable cells from 50%) as compared to those treated with all plasma components. 
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However, DAMP emission decreased significantly. CRT decreased from 27% to 4% and 
ATP went down from 87-fold to 17-fold. This strongly suggests that while long-lived 
species (e.g. H2O2, NO, O3, etc.) are crucial factors causing cell death, two components 
vital to direct cells toward the ICD pathway are charged and short-lived reactive species 
(e.g. 1O2, ∙OH, O2∙-, etc.). 
Both, RNS and ROS affect biological processes and cellular functions [84]. Since 
our plasma treatment is performed in air composed mostly of nitrogen and oxygen, we 
studied the individual effects of plasma-generated nitrogen and oxygen species. Cells were 
treated in a pure nitrogen or pure oxygen environment following evacuation of air from the 
well. Because species produced by plasma are highly sensitive to the gas in their 
environment [55, 85], in each case, plasma would produce either nitrogen or oxygen 
species only, respectively. Our results showed that cell viability remained high when 
plasma was generated in nitrogen and no change in DAMP signal expression was observed, 
signifying no role of nitrogen species in this process. However, when plasma was generated 
in oxygen, the effects on cells were similar to those in air. Viability increased marginally 
from 50% to 58% under the oxygen environment and ecto-CRT remained similar (27% 
and 28%). The change in ATP emission was more noticeable, though not statistically 
significant (87-fold and 68-fold, complete plasma vs oxygen species, respectively). 
Nitrogen plasma retains certain charged species, e.g. electrons, electronically excited N2, 
N+ ions, etc. [26]. The insignificant changes observed above, suggest that charges by 
themselves are not sufficient to elicit ICD but require the presence of oxygen species. 
Taken together, the major effectors of plasma-induced ICD are identified to be: 1) plasma-
generated ROS and 2) charged species. 
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Figure 7. Plasma-generated charges and oxygen species are the major effectors for ICD 
induction. Components of the complete nspDBD plasma were removed from treatment 
with physical and gas barriers. Secreted ATP, viability, and ecto-CRT were analyzed at 10 
minutes, 1 hour and 24 hours respectively (One Way ANOVA, Dunnett’s multiple 
comparison test). Data are shown as mean±SEM. *p<0.05, **p<0.005, ***p<0.001 
3. Discussion 
In this study, we investigated the interaction of two intricate systems, plasma and 
cancer cells, for the initiation of ICD through oxidative stress (Figure 8). Induction of 
immunogenic death in cancer cells has great potential for amplifying anti-cancer immune 
processes and improving clinical efficacy with the added benefit of fewer adverse effects 
[1]. ICD involves changes to the surface composition of the cell and secretion of soluble 
factors [5]. Use of non-thermal plasma is a novel approach to elicit the emission of danger 
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signals, known as DAMPs, characteristic of ICD [62]. The contribution of each plasma 
component to ICD induction was investigated and the cellular responses to plasma 
manipulation were measured. This lays the foundation for future development of plasma 
technology for ICD-mediated cancer immunotherapy.  
 
Figure 8. Plasma and cancer cell interaction for the induction of immunogenic cell death. 
When plasma comes in contact with a biological target, four major effectors are delivered: 
electric fields, UV light, and charged and neutral species. Plasma-generated ROS and 
charged species are the major contributors for eliciting ICD. Following plasma exposure, 
DAMP signals (ecto-CRT and secreted ATP) are emitted. Extracellular ATP acts as a ‘find 
me’ DAMP signal to recruit immune cells to the vicinity and activate them.[75] Surface-
exposed CRT serves as an “eat me” signal and mediates engulfment of tumor cells by 
antigen presenting cells (APC).[18] Plasma-induced DAMP emission is associated with 
increased intracellular ROS and may result from diffusion of plasma-generated species, or 
from stimulation of the cell’s own ROS-generating mechanisms. DPI was used to inhibit 
cellular ROS production, while NAC was used to scavenge both extracellularly diffused 
and intracellular generated ROS. Both ROS attenuators abrogated intracellular ROS and 
surface CRT expression. (Abbreviations: ATP, adenosine triphosphate; CRT, calreticulin; 
DPI, diphenyleneiodonium; NAC, N-acetyl-L-cysteine; nspDBD, nanosecond-pulsed 
dielectric barrier discharge; ROS, reactive oxygen species) 
Plasma is a complex milieu of electric fields, ultraviolet radiation, and charged and 
neutral species. For the induction of ICD, we showed that the key plasma effectors are 
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short-lived, charged and neutral ROS (Figure 7). In our system, applied electric fields do 
not contribute to plasma-induced ICD; this can be attributed to the pulse parameters of our 
nspDBD system. Although pulsed-electric fields have been shown to cause cell death, it is 
highly dependent on pulse amplitude and duration [50, 86-88]. Beebe et al have shown that 
applied electric fields at 300 kV/cm with pulse widths between 10- 60 ns did not affect cell 
membrane integrity [49]. The pulse width of our plasma regime (20 ns at 300 kV/cm) are 
within this range and are therefore insufficient to alter cell functions by themselves. 
However, plasma with different voltage pulse characteristics will have different applied 
electric fields resulting in other biological outcomes (e.g. reversible 
electropermeabilization, cell death and inactivation of bacteria) [88-90]. The role of 
plasma-generated UV A, B, and C also appear to be insignificant for the induction of ICD. 
Obeid et al reported that UV C is a robust ICD inducer: cancer cells irradiated at 100 J/cm2 
expressed ecto-CRT as early as 1 hour post treatment and persisted for 24 hours [54]. In 
our plasma system, UV power is approximately 15 μW/cm2 as measured with a vacuum 
photodiode and radiometer (InternationalLight Technologies, USA). Over the 10 second 
treatment time, cells experienced approximately 150 μJ/cm2 of UV radiation from plasma, 
which is orders of magnitude less than the reported amount required for UV C-induced 
ICD. Therefore, we conclude that in our nspDBD regime, plasma-induced ICD is a result 
of plasma-produced chemical species. Comparing cell response to plasma discharges in 
nitrogen, oxygen, and air, we conclude that the charges and short-lived oxygen species are 
required for induction of ICD with nspDBD plasma. Some of these species include 1O2, 
∙OH and O2∙- as identified through computational modeling, optical emission spectroscopy 
of plasma, and liquid analysis with plasma-treated solutions [26, 33, 44, 91]. Delineation 
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of the exact species responsible is required for understanding of the underlying 
mechanisms of plasma and cell interactions and for additional optimization and 
development of plasma systems for medical applications. Furthermore, the effect of RNS 
(e.g. NO, ONOO-, etc.) which require both oxygen and nitrogen should also be studied as 
their contribution cannot be elucidated through the physical barriers or gas conditions used 
here. The use of specific scavengers may be employed for a detailed examination of those 
individual species.   
The oxidative stress from plasma treatment may result from diffusion of plasma-
generated species, or from stimulation of the cell’s own ROS generating mechanisms. In 
order to analyze the biochemical response of cancer cells to plasma and its correlation to 
DAMP emission, we used two chemical agents, DPI and NAC to abrogate intracellular 
ROS. Since plasma treatments were done in the absence of liquid, cells were incubated in 
the presence of DPI or NAC, both before and after treatment. This was done to avoid any 
modifications by plasma to the two inhibitors. DPI is an inhibitor of NADPH oxidase, an 
enzyme whose primary function is to generate intracellular ROS for cellular metabolism 
[73, 92]. Pre-treatment of cells with DPI prevented the rise of intracellular ROS associated 
with plasma exposure (Figure 3B), and also reduced externalization of CRT and secretion 
of ATP (Figure 4C, D, Figure 5B). However, neither intracellular ROS nor measured 
DAMP signals returned to baseline with the use of DPI. This may be explained by the fact 
that in addition to NADPH oxidase, mitochondria are an important source of intracellular 
ROS. They are also a key effector of apoptosis and the site of cellular ATP synthesis [93, 
94]. Plasma increases ROS production by mitochondria but DPI is not known to inhibit 
mitochondrial enzymes [56]. Some of the measured intracellular ROS may also be from 
107 
 
 
 
the diffusion of plasma-generated species. Furthermore, exogenously generated ROS may 
be able to elicit ICD to some degree, though the effects are more pronounced when the 
cell’s metabolic ROS mechanisms have been stimulated.  
NAC is a precursor of glutathione that decreases oxidative stress by directly 
neutralizing ROS [71, 72]. It scavenges both plasma-produced and cell-generated 
intracellular ROS, whether from NAPDH oxidase or the mitochondria [56]. We observed 
that intracellular ROS levels of plasma-treated cells were similar to those of untreated cells, 
when cells were pre-incubated with NAC (Figure 3B). This further supports our 
assumption that plasma can modulate cellular redox by both exogenously delivered and 
endogenously stimulated ROS. NAC was also able to abrogate the emission of ecto-CRT 
(Figure 4C, D), which is translocated to the cell surface when cells undergo ER stress with 
concomitant intracellular ROS generation [4, 5]. Previously, we have shown that non-
thermal plasma operated in the ICD-inducing regime, can upregulate ER stress genes 
associated with CRT translocation [62]. Our results here with the use of scavengers, 
provide strong evidence that plasma-induced emission of ecto-CRT requires the 
participation of oxidative and ER stress pathways.  
NAC did not reduce plasma-induced secretion of ATP while DPI did (Figure 5B). 
This could be attributed to the different mechanisms by which NAC and DPI attenuate 
intracellular ROS and the temporal progression of ATP secretion pathways. Sun et al 
studied the effects of Clostridium difficile toxin B for the induction of intracellular ROS 
and ICD and report similar observations [69].  
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Altogether, we observed that treatment conditions involving physical barriers, 
controlled atmosphere, and chemical attenuators, did not revert emission of DAMP signals 
back to physiological levels. This suggests that plasma effects are not a result of any 
individual component, but rather, cancer cell interactions with plasma must involve 
multiple, complex pathways in addition to modification of ROS. Thus, a combination of 
plasma effectors is required for ICD induction in cancer cells. 
We also demonstrated that emitted ATP from plasma-treated cells undergoing 
immunogenic death was immunostimulatory through our co-culture experiments with 
macrophages. Macrophages were inhibitory to tumor cells in our system (Figure 6A). 
However, ICD induction in tumor cells further increased this anti-tumor effect of 
macrophages. Plasma-treated A549 cells secrete ATP, but other DAMPs secreted in 
response to oxidative stress include HMGB1, HSP70, and HSP90 [95]. We measured 
fluctuations in ATP levels as a representative secreted DAMP. Extracellular ATP 
stimulates macrophage secretion of TNF-α, IL-1β and other cytokines that are cytotoxic to 
cancerous cells [17, 77, 80, 96]. As a result, plasma-treated A549 cell viability was 
decreased when cultured in the presence of macrophages compared to that of cells cultured 
alone (Figure 6A). This effect was also observed in two other cancer cell lines: a CNE-1 
radiation resistant nasopharyngeal cancer cell line co-cultured with THP-1 M0 
macrophages and a CT26 colorectal cancer cell line co-cultured with RAW 264.7 
macrophages (Figure 9). To establish the contribution of macrophages to cancer cell 
killing, viability of co-cultured cancer cells was normalized to that of cells treated with 
plasma at the same energies and cultured alone. To determine the contribution of DAMPs 
for stimulating macrophage function, plasma-treated groups were compared to the 
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untreated group (0 mJ). Plasma-treated A549 and CT26 cells under co-culture conditions 
showed statistically significant enhancement of macrophage anti-cancer activity. Co-
cultured CNE-1 cells also showed the same effect, though results were not statistically 
significant. Macrophages exert their tumoricidal function through different mechanisms 
(e.g. cytokine secretion, phagocytosis). The limited enhancement of this activity in our 
system may be because the cells are co-cultured but never make direct contact.  
 
Figure 9. Viability of plasma-treated cancer cells co-cultured with macrophages was 
reduced compared to cancer cells treated at the same plasma energy and cultured alone 
(plasma-treated control). Using the transwell insert system, this effect was observed in 
three cancer cell lines: CNE-1 radiation resistant nasopharyngeal cancer cell line, A549 
lung carcinoma cell line and CT26 colorectal cancer cell line. THP-1 M0 macrophages 
were used for co-culture with CNE-1 and A549 cells and RAW 256.7 macrophages were 
used for co-culture with CT26. (One-Way ANOVA, Dunnett’s multiple comparison test). 
Data are shown as mean±SEM. *p<0.05, **p<0.05, ***p<0.001. 
When ATP was inhibited by DPI, the enhanced tumoricidal activity of 
macrophages under co-culture conditions were also reduced (Figure 6B). Our results 
provide evidence that plasma can be a potential immunostimulator for cancer therapy. 
Bundscherer et al have previously shown the effect of plasma on mitogen-activated protein 
kinase (MAPK) signaling pathways that are involved in all aspects of immune response 
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[97]. A recent study using an animal model of melanoma also highlights plasma’s ability 
to modulate immune function for control of tumors [98].  
Plasma for cancer treatment has focused mainly on its ablative properties, utilizing 
energies where damage to tumor cells exceeds harmful effects to surrounding normal tissue 
[99-104]. While results seem promising, in animal studies, tumors recurred when treatment 
was discontinued and there was visible and histological damage in the treatment area [99, 
105]. In this study, we used stress-inducing regimes of plasma on cells in contrast to those 
previously reported [62, 106]. We show that plasma can act as an adjuvant by eliciting 
immunogenic cancer cell death for the engagement of the patient’s immune system to 
eradicate cancer. We have also previously demonstrated that plasma can directly augment 
macrophage function. In vitro, we demonstrated that the migratory activity and secretion 
of anti-tumor cytokines from macrophages were enhanced following plasma stimulation 
[62, 107-109]. In vivo, we showed that plasma treatment enhanced differentiation of 
hemocytes in the lymph organs of Drosophila melanogaster larvae [110]. Augmented 
recruitment of myeloid APCs one week after a single treatment was also demonstrated by 
us in the treated skin of live mini-pigs [111]. Therefore, plasma not only stimulates APCs 
directly, but also indirectly through induction of ICD on tumors. We suggest that plasma 
may synergistically boost anti-cancer immune responses through more efficient uptake of 
cancerous cells, leading to exposure of neoantigens from the tumors and allowing for the 
development of a robust new T-cell response.   
These initial in vitro results are being expanded and validated in an in vivo study of 
murine colorectal cancer (manuscript in preparation). Included is a vaccination assay, the 
‘gold-standard’ test that shows that plasma is a bone fide ICD-inducer [2, 13, 112]. Our 
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results support the feasibility and clinical potential of plasma-induced ICD for cancer 
immunotherapy. 
4. Materials and Methods 
4.1. Cell Culture and Plating 
Human lung carcinoma cells (A549, ATCC: CCL-185) were a gift from Dr. Bela 
Peethambaran (University of the Sciences, Philadelphia, PA, USA) and were cultured in 
RPMI 1640 with 10% fetal bovine serum and 1% penicillin/streptomycin (Corning Life 
Sciences, USA). The human monocyte cell line (THP-1, ATCC:TIB-202) was a gift from 
Dr. Kara Spiller (Drexel University, Philadelphia, PA, US). THP-1 cells were cultured in 
complete media: RPMI 1640 with 10% heat inactivated fetal bovine serum and 1% 
penicillin/streptomycin (Corning Life Sciences, USA). All cells were grown at 37OC with 
5% CO2 in a humidified atmosphere (Panasonic, MCO-19AICUVH-PA, USA). 
A549 cells were plated into 24-well plates at 3.0×105 cells/mL (0.5 mL/well) or 
into 6-well plates at 4.0×105 cells/mL (2 mL/well) one day prior to plasma treatment. 
Before plasma treatment, media was removed and cells were washed twice with phosphate 
buffered saline (PBS). PBS from the second wash was removed right before plasma 
treatment and 500 μL or 2 mL of complete cell culture media was added immediately after 
cells were exposed to plasma in 24- or 6-well plates, respectively.  
For co-culture experiments, THP-1 monocytes were seeded into transwell inserts 
(0.4 µm pore size) (Corning Life Sciences, USA) at 1.6 x 105 cells/mL and differentiated 
into M0 macrophages with 0.5 µL of 100 µL/mL phorbol 12-myristate 13-acetate (Sigma-
Aldrich, USA). Inserts were placed into a 24-well plate with 600 μL of THP-1 complete 
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media, and cultured separately in a humidified environment at 37OC with 5% CO2 
overnight. Following incubation, cells were washed with PBS before co-culture. 
Immediately following plasma treatment of A549 cells, 750 μL of complete media was 
added to each well and M0 macrophages in transwell inserts were transferred to each well. 
An additional 750 μL of THP-1 complete media was added to the inserts. Media was 
changed at 24 hours with fresh complete media, and cells were cultured for an additional 
24 hours before viability analysis. 
4.2. NspDBD Plasma Treatment Parameters 
All plasma treatments of cells were performed in the absence of liquid. Media was 
removed and cells were washed with PBS immediately prior to plasma exposure and media 
was added back straightaway. Cells were treated in a humidity controlled environment 
(~60% relative humidity). Non-thermal plasma was produced by applying a high voltage 
pulse to a DBD electrode 1 mm above the cells in the wells. The DBD electrode used for 
all experiments without physical barriers, was 1.3 cm in diameter and fit into the wells on 
a 24-well plate. The wells rested on a grounding plate that acted as our second electrode, 
and plasma was generated in the gap between the electrode and the plate, in direct contact 
with the cells (Figure 10). When the mesh and quartz barriers were used, more space 
between the electrode and the walls of the well was required. For those studies, cells were 
treated in 6-well plates (3.5 cm diameter wells) with a 2.5 cm diameter electrode, to 
accommodate space required for the barrier. Plasma energies were measured with the 6-
well plate and treatment parameters re-calculated to account for this changed configuration. 
In this set up, the plasma was generated between the electrode and the mesh, right above 
the cells.  
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The characteristics of our plasma pulse and the methods of measuring energy of a 
single discharge have been defined in our previous work [47]. In this study, we used a 
nanosecond pulser (FPB-20-05NM, FID GmbH, Germany) that generated 29 kV pulses 
with 2 ns rise times and 20 ns total pulse duration. The duration of all our treatments was 
fixed at 10 seconds, and the pulse frequency was controlled with an external function 
generator (TTi, TG5011 LXT, USA). Total plasma energy delivered to the cells was 
calculated from treatment time, frequency of pulses, and energy per pulse. Since energy 
per pulse is dependent on the discharge surface (polystyrene plate vs grounded copper 
mesh), for some experiments the frequency was recalculated to achieve comparable plasma 
treatment energies. Table 1 depicts the operating parameters for our plasma treatments. 
 
Figure 10. NspDBD plasma treatment system. A) Plasma is generated between the high 
voltage (HV) electrode and the cells in a well. A z-positioner was used to standardize 
plasma application distance. B) A 1 mm gap was maintained between the electrode and the 
cells on the bottom of the plate.  
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Table 1 NspDBD Plasma Parameters 
Parameter Value 
Excitation Nanosecond-pulsed 
Voltage 29 kV 
Rise Time 2 ns 
Pulse Width 20 ns 
Treatment Time 10 s 
Plasma Discharge in 24-Well Plate 
(Energy per pulse: 0.9 mJ/pulse) 
Gap Distance 1 mm 
Frequency 5, 15, 30, 75 Hz 
Total Plasma Energies 50, 100, 300, 700 mJ 
Plasma Discharge on Copper Mesh Barrier 
(Energy per pulse: 1.9 mJ/pulse) 
Gap Distance 1 mm 
Frequency 15 Hz 
Total Plasma Energy 300 mJ 
 
4.3. Removal of Plasma Effectors to Determine Major Contributors of Plasma-Induced 
ICD 
We operated our nspDBD at 300 mJ to determine the relative contribution of 
plasma effectors on ICD. The barriers and conditions designed to remove specific plasma 
effectors delivered to cells during treatment have been detailed in our previous study and 
summarized in Table 2 [47]. Briefly, the direct nspDBD in air contained all plasma 
effectors (complete plasma) and was used as our positive control for all experiments. To 
determine the contribution of electric fields, we did not remove PBS prior to treatment; the 
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electrode was dipped into PBS, positioned 1 mm above the cells, and operated at 30 Hz 
pulse frequency, corresponding to 300 mJ of plasma treatment. Therefore, with the same 
applied voltage, plasma was eliminated while applied electric field remained [113]. The 
contribution of plasma-generated UV A, B, and C was determined by containing the plasma 
between a grounded copper mesh and quartz barrier. Since quartz is only transparent to 
wavelengths greater than 200 nm (Technical Glass Products, Inc., Fused Silica), this barrier 
allows only UV light to be delivered to the cells. The grounded mesh barrier, without the 
quartz, allowed for the long-lived neutral species to be delivered to cells during treatment, 
while removing charged species and short-lived species [27]. Since the energy per pulse of 
plasma generated on the copper mesh was 1.9 mJ/pulse, frequency was adjusted to 15 Hz 
to keep plasma treatment energy the same (300 mJ) for those two conditions (Table 1). 
Most DBD treatments are done in atmospheric air, composed mainly of oxygen and 
nitrogen, so we examined the effect of oxygen species by inserting the electrode into the 
well and sealing it. We flowed 99.999% pure oxygen (Airgas, NJ, USA) into the well 
through a 22-gauge inlet needle at a rate of 2 SCFM for 5 seconds; an outlet needle was 
placed on the other side to allow existing air to be displaced. Plasma discharged in this 
oxygen environment eliminated nitrogen and other non-oxygen chemical species. To 
determine the effect of nitrogen species, 99.999% pure nitrogen (Airgas, NJ, USA) was 
passed into the well similar to oxygen in the previous setup, thus removing plasma-
generated oxygen species. Plasma exposure under these two conditions helped elucidate 
the contribution of plasma-generated oxygen and nitrogen species for ICD induction.  
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Table 2. Summary of treatment conditions and delivered plasma effectors 
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4.4. UV Power Measurements 
UV light emitted from our plasma discharge was measured with a vacuum 
photodiode (InternationalLight Technologies, SED220, USA) and radiometer 
(InternationalLight Technologies, IL1700, USA). The photodiode has a fused silica 
window and active area of 50 mm2. The detector was placed parallel to the grounded copper 
mesh barrier with the electrode discharging 1 mm above it at the 300 mJ treatment 
parameters. The radiometer was operated in the DC signal mode with 0.5 second sampling 
times and zeroed to ambient room conditions before every run. Ten readings were taken 
and data were reported as μW/cm2. The addition of quartz to the mesh barrier did not 
attenuate UV power density.  
4.5. Pre-Treatment with NAC and DPI to Attenuate Intracellular ROS 
Media supplemented with 10 mM NAC (Sigma-Aldrich, USA) or 5 μM DPI 
(Sigma-Aldrich, USA) was used to culture cells 1 hour before plasma exposure. A dose 
response was performed for both ROS attenuators to select the concentration required to 
modulate oxidative stress based on previous studies [69, 114]. Cells were then washed 
twice with PBS (with calcium and magnesium) supplemented with NAC and DPI at the 
same concentrations. Immediately after plasma exposure, fresh media with the ROS 
attenuators were added back into the well for up to 24 hours. For co-culture experiments 
only, media was changed at 24 hours, and cells were cultured for an additional 24 hours in 
the absence of ROS attenuators. 
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4.6. Quantification of Cell Viability 
A Propidium Iodide (PI) (Thermo Fisher Scientific Inc., USA) exclusion assay was 
used to assess cell viability. PI is a DNA-binding fluorescent agent that penetrates damaged 
cell membranes. Cells were trypsinized 1 hour post plasma treatment and stained with 100 
μL/mL of PI (Invitrogen, USA) to assess early damaging effects of plasma. Live cells were 
quantified with an image cytometer (Nexcelom CBA Vision, Nexcelom Bioscience, USA) 
and additional analysis, including size gating was performed using the FCS flow cytometry 
software (FCS 4.0, DeNovo Software, USA). Viability was determined by normalizing live 
cell counts of plasma treated samples with mean live cell counts of untreated controls. Data 
represent viable cells as a percentage of controls.  
4.7. Quantification of Apoptotic and Necrotic Cells 
Apoptosis at 24 hours post treatment was determined by measuring surface 
exposure of phosphatidylserine (PS) with an Annexin V-PI apoptosis assay. Cells were 
collected, washed with PBS, pelleted and resuspended in 100 μL of 1 x Annexin V binding 
buffer (Thermo Fisher Scientific Inc., USA). 5 μL of Annexin V, Alexa Fluor 488 
conjugate (Thermo Fisher Scientific Inc., USA) and 2 μL of PI (1 mg/mL) was added to 
the cell suspension and incubated at room temperature in the dark for 15 minutes. 
Following incubation, cells were washed twice with 1 x Annexin V binding buffer and 
image cytometer was used to measure fluorescence. Annexin V+/PI- cells indicate early 
apoptosis, Annexin V+/PI+ cells indicate late apoptosis and Annexin V-/PI+ cells indicate 
necrosis. Dot plots were made with the FCS software and percentage of Annexin V positive 
and PI positive cells were graphed. 
119 
 
 
 
4.8. Quantification of Extracellular ATP 
10 minutes following plasma treatment, 50 μL of media was collected and 
extracellular ATP was quantified using an adenosine 5’-triphosphate chemiluminescent 
somatic cell assay kit (Sigma-Aldrich, USA). All reagents were prepared following 
manufacturer instructions. ATP assay mix stock solution was diluted at a ratio of 1:25 with 
dilution buffer to prepare the working solution. 100 µL of working solution was added to 
12 x 55 mm test tubes (Hach, USA) and allowed to stand at room temperature for 3 minutes 
before use. 50 μL of the collected cell supernatant was diluted with 100 μL of ultrapure 
water (Sigma-Aldrich, USA) and 50 μL of the diluted supernatant was transferred into the 
12 x 55 mm test tubes containing ATP assay mix working solution. The assay mix, 
containing firefly luciferase and luciferin, catalyzes the reaction between ATP and luciferin 
to form adenyl-luciferin. Adenly-luciferin goes on to react with oxygen to produce 
oxyluciferin, adenosine monophosphate, carbon dioxide, and light, which is measured in a 
luminometer (Photon-Master, LuminUltra, USA). The luminometer was calibrated with 
the provided UltraClear calibration solution and the measured relative light units (RLU) 
are converted into pgATP/mL. RLU from the samples were measured with the Photon-
Master immediately following mixing with the ATP assay mix in the test tubes and 
extracellular ATP concentration was determined. Data were represented as either ATP 
concentration (nM) or fold change of untreated controls. 
4.9. Fluorescence Detection of Ecto-CRT 
24 hours after plasma treatment, A549 cells were collected and washed with 
blocking buffer (2% FBS in PBS) and incubated with rabbit anti-human calreticulin 
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antibody (ThermoFisher Scientific, USA) in blocking buffer (1:200 dilution) at room 
temperature, in the dark, for 30 minutes. Cells were then washed twice with blocking buffer 
and incubated with Alexa Fluor 488 conjugated goat anti-rabbit IgG (ThermoFisher 
Scientific, USA) secondary antibody (1:500 dilution in blocking buffer) in the dark, at 
room temperature, for 40 minutes. At the end of the incubation, cells were washed twice 
and analyzed by image cytometry and FCS software. Representative histograms were 
plotted and normalized to the number of cells detected. Data are represented as percentage 
of cells positive for surface CRT staining or the difference in percent from untreated. 
4.10. Statistical Analysis 
Each experiment was performed with a minimum of three replicates and repeated 
at least twice unless otherwise stated. Data are presented as mean±SEM. Statistical analysis 
was performed in GraphPad Prism 6 using one-way ANOVA with post hoc Dunnett’s or 
Tukey’s multiple comparisons test. A two-way ANOVA test was also used with post hoc 
Sidak’s or Tukey’s multiple comparisons test. p<0.05 was considered significant. Only 
statistically significant comparisons are indicated in figures.  
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Appendix A 
DBD plasma exposure to cells in vitro often involves treatment of relatively smooth 
surfaces such as plates or petri dishes. However, when surfaces become topographically 
uneven, plasma can concentrate on ‘ridges’ (where gap distance is minimal), resulting in a 
non-uniform discharge [115]. This becomes particularly problematic in subnanosecond-
pulsed DBDs as plasma in this non-uniform regime produce filamentary structures that 
may cause highly localized heating and damage [116]. However, by applying high electric 
fields (~85 kV/cm) over nanosecond rise times, a more uniform discharge is achieved, even 
over uneven surfaces, thus reducing injurious effects of filaments [115, 117]. Using fast 
intensified charge-coupled device (ICCD) imaging, Liu et al observed the transition from 
non-uniform to uniform discharge and quantified uniformity with a chi-square test [117]. 
Furthermore, using spectroscopic measurements of electric field in the discharge, they 
report that filamentary structures create strong electric fields locally within plasma, 
resulting in distinctly higher electric fields in the non-uniform regime compared to that of 
the uniform regime [117]. This has been reported both, experimentally and in simulations, 
for plasma jets and DBDs [118-120]. Due to the close relationship between electric fields 
and plasma chemistry, changing the mode of plasma could also influence biological effects 
[44, 120]. Therefore, the uniformity of plasma for induction of ICD requires investigation. 
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To determine the effect of plasma uniformity on induction of ICD, we compared 
the outcomes of the nspDBD system operated in the uniform and non-uniform regime 
(Figure A.1A). NspDBD plasma transitions into a filamentary, non-uniform regime when 
the applied electric field in the discharge gap is reduced [117]. In our system, this occurs 
when the gap distance is increased from 1 mm to 2 mm [117]. Since the energy per pulse 
of plasma in the non-uniform regime was 0.4 mJ/pulse, as measured in our previous 
publications, frequency was adjusted to 75 Hz to ensure that the total plasma energy 
delivered to cells during treatment was kept at 300 mJ [47]. Plasma, in both regimes, was 
discharged in air and nitrogen. When plasma is discharged in nitrogen gas, the influence of 
local electric fields from filaments can be delineated [47]. We observed no significant 
difference between the two regimes of plasma in air on cell death and DAMP response 
(Figure A.1B). However, non-uniform discharge in nitrogen did not affect viability or 
cause ICD, meaning that higher electric fields from filamentary structures in the non-
uniform regime are inconsequential. 
For in vivo treatment with DBD plasma, surfaces are never completely smooth so 
transition to non-uniform regime may be inevitable. Our results indicate that induction of 
ICD may be achieved at multiple DBD plasma regimes and is crucial for translation of 
plasma technology for clinical applications.  
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Figure A.1 A) Filamentary structures of non-uniform plasma can be observed as bright 
pixels in the presented photographs of plasma discharges (taken from our previous 
publication; methods and photograph parameters detailed there [47]). B) Non-uniform 
plasma treatment was performed in air (labeled ‘Non-Uniform Plasma’) and nitrogen 
(labeled ‘Filamentary Structures’) and compared to uniform treatment to compare the two 
regimes (One Way ANOVA, Tukey’s multiple comparison test). Data are shown as 
mean±SEM. *p<0.05, **p<0.005, ***p<0.001 
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ABSTRACT 
Immunogenic cell death is a form of cell death characterized by the emission of 
danger signals that can facilitate activation of an adaptive immune response against dead-
cell antigens. In the case of cancer therapy, tumor cells undergoing immunogenic death 
will promote anti-cancer immune effects in the body. Identification and optimization of 
stimuli that induce immunogenic cancer cell death has tremendous potential to improve the 
outcomes of cancer therapy. In this study, we show that non-thermal, atmospheric pressure 
plasma can be operated to induce immunogenic cell death in a colorectal cancer cell line. 
Danger signals were measured following treatment of cells with plasma in vitro. 
Furthermore, co-culturing cancerous cells undergoing plasma-induced immunogenic death 
with macrophages showed that tumoricidal activity of macrophages was enhanced, 
providing initial evidence that secreted danger signals can stimulate immune cell functions. 
A vaccination assay with a plasma-created whole-cell vaccine showed that plasma elicits 
protective immune effects against challenge in Balb/c mice. Plasma treatment of 
subcutaneous tumors elicited emission of danger signals and recruitment of antigen 
presenting cells into the tumor which was followed by an enhanced immune responses 
against the colorectal cancer antigen guanylyl cyclase C (GUCY2C). Altogether, this study 
provides evidence that non-thermal plasma is a bone fide inducer of immunogenic cell 
death and highlights its potential for clinical translation for cancer immunotherapy.  
 
Key Words: Non-thermal plasma, immunogenic cell death, colorectal cancer, plasma 
cancer immunotherapy  
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Introduction 
Cancer is the second leading cause of death with 8.2 million deaths worldwide, and 
in the US alone, it was anticipated that there would be 1.7 million new cases and 0.6 million 
deaths in 2016 [1]. Improved diagnostics and new therapeutic approaches to cancer therapy 
have been major topics of research, leading to improved rates of cancer survival. However, 
the short and long term side effects of therapy are often unavoidable, and many patients 
experience disease recurrence and develop resistance to treatment, ultimately leading to 
unacceptable failure rates [2-5]. Furthermore, due to higher life expectancy following 
treatment, the associated economic burden of long term care has also increased, with the 
total projected cost estimated at $120 billion in 2020 [6, 7]. It is altogether clear that new 
treatment methodology and novel therapeutic modalities are required to address the 
ongoing healthcare and economic burden.  
Immunogenic cell death (ICD), initially described by Zitvogel, Kroemer and co-
workers, is a modality of death where dying cells stimulate immune responses against 
dead-cell antigens [8-10]. In cancer therapy, this is advantageous as tumor cells undergoing 
ICD activate an adaptive anti-tumor immune response. While the circumstances that trigger 
ICD are not fully understood, “danger signals” associated with ICD involve changes to the 
surface composition of the cell and secretion of soluble factors. These signals, referred to 
as damage-associated molecular patterns (DAMPs) include: surface exposure of 
calreticulin (CRT), heat shock protein 70 (HSP70) and HSP90 and secretion of adenosine 
triphosphate (ATP) and high mobility group box 1 (HMGB1) [11-14]. These signals recruit 
and activate antigen presenting cells (APCs) which lead to subsequent presentation of 
tumor-antigens to T cells and development of specific effector and memory T cells [15-
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19]. Anti-cancer drugs in the past have been developed to cause apoptotic tumor cell death, 
a process that is often tolerogenic rather than immunogenic, resulting in the absence of 
specific immune responses [10]. Cells that escape treatment often continue to grow, leading 
to tumor recurrence and even development of resistance to therapy [4, 10]. Therefore, 
changing treatment approaches from those inducing tolerogenic cell death to those eliciting 
immunogenic cell death offers additional options with potential to improve outcomes of 
cancer therapy. 
Plasma, the fourth state of matter, is ionized gas composed of charged particles, 
active neutral gas species, electric fields, and very low amounts of ultraviolet (UV) light 
[20-24]. It is a well-established tool for industrial use, especially for fabricating electronics, 
but now, development of plasmas that can be sustained in atmospheric pressure and at room 
temperature has opened doors for biomedical applications [25, 26]. Mounting evidence 
demonstrates that these ‘non-thermal plasmas’ (NTP) can rapidly change the oxidative 
status of cells through stimulation of ROS production [27-29]. Since ROS production 
influences multiple signaling pathways that regulate cell processes (e.g. proliferation, 
differentiation, death, etc.) [30-32], over the last decade, NTP has emerged as a novel 
technology for treatment of many diseases, including cancers [33-38]. Several reports have 
documented that NTP preferentially kills cancerous cells in vitro as compared to their 
normal counterparts [39-44]. In vivo, plasma systems have been optimized to destroy 
tumors while minimizing damage to neighboring healthy tissue [42-45]. That plasma is a 
viable therapy for cancers is deomonstrated by studies that observed decreased tumor 
burden and prolonged animal survival [46]. In addition, we recently demonstrated that NTP 
treatment of multiple cancer cell lines induced secretion of two surrogate markers of ICD 
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recognized as the major predictors of immunostimulatory capability: surface-exposed CRT 
(ecto-CRT) and secreted ATP [47, 48]. This is partially due to intracellular ROS-mediated 
endoplasmic reticulum (ER) stress pathways: NTP increased intracellular ROS and the ER 
stress proteins, activating transcription factor 4 (ATF4) and stanniocalcin (STC2) [47]. 
Moreover, abrogation of oxidative stress reversed NTP-induced DAMP emission.  
While previous studies revealed increased DAMP emission following in vitro NTP 
exposure, the ability of NTP to induce ICD is unknown [47]. In this study, the capacity of 
NTP to elicit ICD was demonstrated in an in vivo metastatic colorectal cancer model. Using 
a nanosecond-pulsed dielectric barrier discharge (nspDBD) plasma system, NTP induced 
the expression of two key surrogate markers of ICD in murine CT26 colorectal cancer cells: 
ecto-CRT and secreted ATP. Importantly, a vaccination assay employing syngeneic Balb/c 
mice demonstrated that plasma is a bone fide ICD-inducer, inducing protective immunity 
in mice immunized with NTP-treated CT26 cells. Moreover, in vivo treatment of colorectal 
tumors expressing the colorectal cancer antigen guanylyl cyclase C (GUCY2C) enhanced 
expression of ICD markers in tumors, APC recruitment and GUCY2C-specific immune 
responses following GUCY2C vaccination. Together, our findings establish the application 
of plasma for cancer immunotherapy via ICD and highlight its potential for clinical 
development.  
Results 
Plasma induces emission of surrogate markers of ICD 
To measure cell death in response to nspDBD plasma, the CT26 colorectal 
carcinoma cell line was treated at several plasma energies. Cell viability, quantified with a 
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Muse Cell Analyzer 24 hours after plasma exposure, decreased in an energy dependent 
manner (Figure 1A). As previously described, not all modalities of cell death are 
immunogenic and capable of initiating anti-tumor effects. The identification of ICD in vitro 
mainly relies on detection of associated DAMPs. Therefore, we examined the effect of 
plasma on cell viability and two DAMP signals, hallmarks of ICD in CT26 cells: 
externalization of CRT and secretion of ATP [49]. For all in vitro evaluations, cells were 
treated once, in the absence of liquid, for 10 seconds and incubated until assessment.  
Obeid et al, have reported that surface calreticulin dictates the immunogenicity of 
cancer cell death [13]. CRT is a protein located on the ER membrane where it acts as a 
molecular chaperone and regulates calcium homeostasis and signaling [50-52]. It is 
translocated to the plasma membrane when cells undergo ER stress with concomitant 
oxidative stress [50, 53]. On the cell surface, exposed CRT acts as an ‘eat me’ DAMP 
signal that facilitates recognition, engulfment and processing of tumor cells by APCs [54-
56], a critical step for the initiation of an adaptive anti-cancer response [16, 18, 57]. 
Surface-exposure of CRT in response to plasma treatment was measured 24 hours after 
plasma treatment. Intact cells were labeled with anti-CRT antibodies, stained with 
fluorescent secondary antibodies and analyzed using flow cytometry. The emission of ecto-
CRT on CT26 cells increased at all treatment energies, suggesting the potential for plasma 
to increase the immunogenicity of tumor cells (Figure 1B, C).  
ATP, the most abundant intracellular molecule required for metabolism, is secreted 
from cells undergoing ICD [53]. Although the precise mechanism by which ICD inducers 
stimulate ATP secretion is not fully understood, it is considered pre-apoptotic and known 
to be facilitated by autophagy [58-60]. It has even been suggested that secretion of ATP 
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follows overlapping pathways with externalization of CRT [60]. Once ATP reaches the 
extracellular space, it becomes another hallmark of ICD and can increase the 
immunogenicity of dying cells, by functioning as a ‘find me’ DAMP signal for recruitment 
and activation of APCs [59-61]. To detect this secreted DAMP by cells exposed to plasma, 
the cell culture media was collected 10 minutes after treatment and extracellular ATP was 
quantified. ATP levels were low at baseline (8.2 nM) and increased 70-fold (582.1 nM) 
following 300 mJ plasma treatment (Figure 1D). 
 
Figure 1. Plasma-induced ecto-CRT and secretion of ATP in CT26 cells. A) Cell viability 
is indicated by the percentage of live CT26 cells normalized to untreated (0 mJ), 24 hours 
after plasma treatment. B, C) 24 hours after plasma exposure, CRT was detected on the 
surface of intact CT26 cells. B) Representative histograms and C) mean fluorescence 
intensity showed increased surface CRT following plasma treatment. C) ATP content was 
detected in the media 10 minutes after plasma treatment using a chemiluminescent kit. 
CRT, ATP and viability data are presented as means ± S.E.M. *p<0.05, **p<0.01, 
***p<0.001 (One-Way ANOVA, Dunnett’s multiple comparison test). 
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Plasma-induced DAMP emission enhances tumoricidal activity of macrophages 
Because not all emitted DAMPs can trigger an immune response [62-64], we first 
determined whether plasma-induced DAMP emission can enhance existing immune 
responses using a co-culture system with macrophages (RAW 264.7) and plasma–treated 
CT26 cells. Extracellular ATP is known to stimulate the release of anti-tumor factors [e.g. 
tumor necrosis factor alpha (TNFα), interleukin 1 beta (IL-1β), and IL-18] from dendritic 
cells and macrophages [65-68]. Therefore, secretion of ATP by plasma-treated CT26 cells 
was predicted to enhance the tumoricidal activity of co-cultured macrophages. Following 
exposure to plasma at 100 mJ and 300 mJ, CT26 cells were co-cultured with macrophages 
in transwell inserts with a semi-permeable membrane (0.4 µm pore diameter). This system 
hindered direct contact between the two cell types, but allowed the exchange of soluble 
factors (ATP from treated CT26 cells and tumoricidal factors from macrophages) through 
the media. Cells were cultured together for 48 hours and a PI exclusion assay was 
performed to determine CT26 cell viability.  
The baseline anti-tumor activity of macrophages was established by co-culturing 
untreated CT26 cells (represented in the graph as 0 mJ) with macrophages (Figure 2). CT26 
viability was modestly reduced compared to that of untreated cells cultured alone 
(86.6±3.0% vs 100±2.4%; p<0.05). Following plasma treatment at 300 mJ, CT26 viability 
decreased further when co-cultured with macrophages as compared to those treated with 
plasma but cultured alone (49.7±3.4% vs 69.3±3.3%; p<0.001). This suggests that the anti-
tumor activity of macrophages was enhanced because of interaction with secreted DAMPs 
such as ATP, HMGB1, HSP90 and HSP70 from cells undergoing plasma-induced ICD.  
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Figure 2. Plasma-induced DAMP emission enhanced macrophage anti-tumor activity. 
Plasma-treated CT26 cells co-cultured with untreated RAW 264.7 macrophages in a 
semipermeable transwell insert showed that cells undergoing immunogenic death 
enhanced the tumoricidal effects of macrophages. Data are presented as means ± S.E.M. 
*p<0.05, ***p<0.001 (Two-Way ANOVA, Tukey’s multiple comparison test) 
Plasma-treated cells are immunogenic: Vaccination with plasma-induced ICD cells 
provides protection against tumor challenge in mice 
Our in vitro results provided evidence that plasma induces ICD and that emitted 
DAMPs enhance the anti-tumor activity of cultured macrophages. To test if plasma is a 
bona fide inducer of ICD, we performed the vaccination assay known as the ‘gold standard 
approach’ [49]. Balb/c mice were immunized with CT26 cells treated in vitro with 1) 
plasma at the ICD-inducing regime (29 kV, 30 Hz, 1 mm gap distance, 10 seconds), 2) 
media only, or 3) Cisplatin (50 μM for 24 hours), a non-ICD inducer [49, 69]. Cells were 
prepared for inoculation and injected into the left flank as a whole-cell vaccine to allow an 
immune response to develop. One week after immunization, mice were challenged with 
live CT26 cancer cells on the opposite flank and tumor growth was monitored twice a week 
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until day 26 when the study was terminated because a subset of the animals had tumor 
volumes greater than the IACUC approved limit (Figure 3A). Challenge tumors in the 
media and Cisplatin groups grew rapidly while tumors in the plasma group developed 
relatively slowly (Figure 3B-D). The mean tumor volume for the plasma immunized group 
was significantly smaller compared to that of the media group (414.7±104.3 mm3 vs 
847.4±141.5 mm3; p<0.001) or the Cisplatin group (1041.8±208.3 mm3) at day 26 (Figure 
3E). Indeed, 90% of the mice in the plasma immunized group had tumor volumes smaller 
than the mean tumor volume of the media group (850 mm3), suggesting that these mice 
were partially protected by vaccination. Moreover, 3 out of the 10 mice in the plasma group 
did not develop subcutaneous tumors on the challenge site (Figure 3F), supporting the 
hypothesis that plasma is an authentic ICD inducer.  
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Figure 3. Immunization of mice with cancer cells plasma-treated at ICD-inducing regimes 
slowed the growth rate in challenge tumors. A) Balb/c mice were injected with media-, 
Cisplatin-, or plasma-treated CT26 cells subcutaneously into the left flank (n=10 per 
group). One week later, mice were challenged with live CT26 cells on the opposite flank 
and monitored for 26 days. Challenge tumors grew more rapidly in mice immunized with 
cells treated with media (B) or Cisplatin (C) compared to mice immunized with plasma-
treated cells. Data in A-C indicate tumor growth of each mouse. A dotted line is plotted to 
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indicate the mean tumor volume of the control group (mock media treatment). E) Mean 
tumor volumes in the mice vaccinated with plasma-treated cells were significantly smaller 
compared to those immunized with untreated cells. Data are presented in E as mean value 
± S.E.M. ***p<0.001 (Two-way ANOVA, Dunnett’s multiple comparisons test). F) The 
percentage of mice with tumor volumes less than the mean volume of the media group and 
the percentage of mice that did not develop subcutaneous tumors at the challenge site. 
Plasma induces ICD in vivo and stimulates immune cell recruitment 
To directly validate whether plasma could induce ICD in vivo, CT26 colorectal 
tumors were established subcutaneously in Balb/c mice and exposed to plasma when they 
became palpable (Figure 4). A safe operating plasma regimen was first identified by 
exposing subcutaneous CT26 tumors in Balb/c mice to plasma for various treatment times 
(10, 25, 50 sec) at set plasma parameters (29 kV and 750 Hz) once daily for five 
consecutive days. One day and 3 days after the final treatment, tumors were resected along 
with overlaying skin, fixed and stained with hematoxylin and eosin (H&E) to assess the 
structural changes in the dermal and epidermal layers of the skin resulting from plasma. 
 
Figure 4. In vivo plasma treatment system. A) A nanosecond-pulsed power supply 
generated 29 kV pulses and a function generator was used to control the frequency of pulses 
and the plasma exposure time. A z-positioner was used to hold the high voltage electrode 
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in place during treatment, approximately 1 to 2 mm above the target. B) Plasma was 
generated directly above of the subcutaneous tumor. 
Ten seconds of plasma treatment resulted in minimal epidermal damage but no 
changes to the tumor were observed with H&E staining (Figure 5B, F). When plasma 
treatment duration was increased to 25 seconds, thermal and necrotic damage in the 
epidermis was observed one day after plasma (Figure 5C) but none in the underlying tumor. 
By the third day after treatment, the epidermis appears improved but not fully healed, 
suggesting that the damage was reversible (Figure 5G). The 50-second treatment resulted 
in significant damage through all the layers of the skin, and, in fact, tumors just below the 
skin showed thermal and necrotic damage (Figure 5D). By the third day thermal damage 
was still apparent and changes in collagen had begun to appear. There were also more 
neutrophils in the skin signifying an inflammatory response (Figure 5H).  
 
Figure 5. H & E staining of plasma-treated subcutaneous tumors. Tumors with overlaying 
skin were resected 1 day (A-D) or 3 days (E-H) following the final plasma treatment. 
Tumors received  no treatment (A, E), 10-second treatment (B, F), 25-second treatment (C, 
G) or 50-second treatment (D, H) daily over the course of 5 days. Images were taken at 
20x. 
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Based on the above observations, we investigated if the 10-second plasma treatment 
induced ICD. We treated subcutaneous tumors at the parameters defined above, for five 
consecutive days. Three days after the last plasma treatment, tumors were resected, fixed, 
and sectioned. To identify induction of ICD, immunofluorescence microscopy was 
performed on tumor sections to detect the DAMP signals CRT and HMGB1 (Figure 6A,B). 
HMGB1, much like ATP, is a chemoattractant signal that recruits inflammatory immune 
cells and mediates signals between APCs [70-72]. The emission of both DAMP signals 
increased (CRT = 1.4±0.2 fold and HMGB1 = 1.6±0.3 fold) (Figure 6C,D). 
To further optimize treatment procedures, tumors were treated for five consecutive 
days at: 1) the same area each day (Plasma 1 Spot), 2) two areas of the tumor each day 
(Plasma 2 Spots) or 3) different areas each day (Plasma Multiple Spots). CRT and HMGB1 
were increased in plasma-treated tumors and maximal following the “Multiple Spot” 
regimen (CRT = 1.6±0.2 fold, p<0.05 and HMGB1 = 1.9±0.3 fold, p<0.05).  
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Figure 6. Plasma treatment of subcutaneous tumors in Balb/c mice induced DAMP 
emission. A-D) Tumor sections were stained with CRT (A) and HMGB1 (B) antibodies 
and imaged by fluorescence microscopy (10x). Fluorescence intensity of representative 
sections of the tumor were quantified with ImageJ and normalized to untreated controls. 
The emission of CRT (A, C) and HMGB1 (B, D) increased in all plasma treatment groups 
by ~1.5-fold. Data are presented from individual resected tumors. *p<0.05, (One-way 
ANOVA, Dunnett’s multiple comparisons test). 
To determine if emitted DAMPs stimulated the recruitment of immune cells into 
the tumor environment, we also stained for CD45+ (leukocytes) and CD11c+ (APCs) 
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immune cells (Figure 7A, B). Indeed, increased CRT and HMGB1 were associated with 
increased CD45+ (2.0±0.4 fold, p<0.05) and CD11c+ cells (1.8±0.2 fold, p<0.05) 
following the Multiple Spot regimen (Figure 7C, D). Because CD45 is expressed by all 
leukocytes, including T cells, B cells, neutrophils, NK cells and others [73, 74], it is 
possible that other immune cell subsets are also being recruited as a downstream 
consequence of ICD induction. Altogether, Multiple Spot treatments enhanced both 
emission of DAMPs and recruitment of immune cells compared to the other application 
methods, suggesting that treatment of different spots is more beneficial compared to 
repeated treatment of the same area. This treatment condition was further investigated for 
downstream T cell response. 
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Figure 7. Leukocytes and APCs increased in the tumor following plasma treatment at 
DAMP emitting regimes. A-D) Tumor sections were stained with CD45 (A) and CD11c 
(B) antibodies and imaged by fluorescence microscopy (10x). The presence of leukocytes 
(C, CD45+ cells) and APCs (D, CD11c+ cells) increased 3 days following plasma 
treatment compared to untreated tumors. Data are presented from individual resected 
tumors. *p<0.05, **p<0.05 (One-way ANOVA, Dunnett’s multiple comparisons test). 
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Plasma amplifies specific T-cell responses against CT26-GUCY2C tumors 
To analyze whether plasma-induced ICD could stimulate an adaptive anti-tumor 
response, we treated established subcutaneous tumors expressing the colorectal cancer 
antigen GUCY2C (CT26-GUCY2C) in Balb/c mice with plasma alone or in combination 
with the Ad5-GUCY2C-S1 vaccine [75, 76]. Mice were treated with plasma for five 
consecutive days and one group was vaccinated with the Ad5-GUCY2C-S1 vaccine, one 
week after the last plasma treatment (Figure 8A). An untreated group and the vaccine only 
group (Ad5-GUCY2C-S1 vaccination) served as our negative and vaccine controls, 
respectively. Splenic GUCY2C-specific T-cell responses were analyzed by IFNγ ELISpot 
assay 28 days after the initial tumor inoculation. Plasma treatment alone had a marginal 
effect on GUCY2C-specific responses (22.1±11.9 spots vs 3.0±1.8 spots in Untreated; 
p=ns). However, plasma treatment prior to vaccination amplified GUCY2C-specific T-cell 
responses (167.8±41.5 spots vs 109.7±22.3 spots with vaccine alone, p<0.05) (Figure 8B). 
This ascertains that the emitted DAMP signals stimulate the canonical pathways required 
for tumor control. Therefore, plasma is an effective ICD inducer and should be further 
studied. 
Epitope spreading, an immunological phenomenon where tumor cell death elicits 
cross-presentation of tumor-antigens [77, 78]. We tested whether plasma and vaccination 
treatment exposes neoantigens unrelated to the original vaccination target, in our case, 
GUCY2C [79]. We measured T-cell responses against AH1, an endogenous 
immunodominant MHC class I-associated epitope from gp70 expressed by CT26 tumor 
cells (Figure 8C) [79-81]. Mice receiving both plasma and vaccination exhibited a modest 
increase in the AH1-specific T-cell response (24.2±8.3 vs 11.0±4.3 spots; p=ns). While the 
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study was not powered to detect a statistically-significant change, epitope spreading was 
observed. It may be possible to augment this with further optimization of plasma treatment. 
Altogether, we provide strong evidence that plasma acts as an adjuvant for cancer therapy 
as shown by the amplification of GUCY2C-specific and AH1-specific T-cell responses in 
mice. Increased efficacy with the addition of vaccine suggests that plasma may prime the 
host’s immune system and may allow for its use in other combination therapies. 
 
Figure 8. Plasma enhanced cancer-specific T-cell responses when combined with 
vaccination. A) Mice were challenged with CT26-GUCY2C cells (Day 0) and treated with 
plasma on day 7. A subgroup of the plasma-treated mice were vaccinated on day 14 with 
Ad5-GUCY2C-S1. B) GUCY2C-specific and C) AH1-specific T-cell responses were 
quantified by IFNγ ELISpot in the spleen on day 28.  
Discussion 
Although significant advancement in conventional tumor-targeted cancer therapies 
(e.g. surgery, chemotherapy, radiation therapy, etc.) has reduced cancer related morbidity 
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and mortality, this comes at the cost of significant toxicity. Another major challenge is 
relapse from cells that escape treatment and eventually develop resistance to therapy [91-
93]. In contrast, immunotherapy aims to activate the patient’s natural defenses to 
selectively target tumors for resolution of cancer [93-96] with reduced non-specific damage 
to normal tissue. While current strategies (e.g. adoptive T-cell transfer, checkpoint 
inhibitors, etc.) are clinically efficacious, with increased use, several instances of serious 
adverse effects, including pneumonitis and enterocolitis, are being reported [97, 98]. To 
address these, a novel approach being explored is ICD-mediated immunotherapy, where 
cancer cells undergoing ICD release DAMP signals that engage APCs to expose 
neoantigens and facilitate the initiation of a new adaptive immune response [15, 49, 99]. 
The methods to induce ICD include certain chemotherapeutic agents, irradiation, 
photodynamic therapy with hypericin (PDT-hypericin), and high hydrostatic pressure 
[100].  
Here, we provide evidence that non-thermal plasma is another viable candidate. In 
vitro, we demonstrated that nspDBD plasma elicited CRT emission and secretion of ATP 
from CT26 colon carcinoma cells. Furthermore, macrophages co-cultured with plasma-
treated CT26 cells undergoing ICD, exhibited enhanced anti-tumor activity, demonstrating 
the capacity of emitted DAMPs to stimulate immune function. Several in vitro studies have 
established the direct immunostimulatory effect of plasma on macrophages including 
migration and increased tumoricidal activity through the secretion of TNF-α [47, 101-103]. 
This activity is specific against tumor cells as plasma-treated macrophages did affect the 
viability of co-cultured normal cells [101]. Therefore, plasma can stimulate immune 
function both directly and through ICD-mediated pathways.  
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Our vaccination study validated the protective effects of plasma-induced ICD and 
provides evidence that a plasma-created whole-cell vaccine could be developed for T cell 
priming. Optimization of plasma treatment parameters (pulse frequency, application time, 
etc.) are needed to improve efficacy. Uptake of this vaccine would be enhanced if APCs 
were already present at the vaccination site. In fact, plasma has been demonstrated to recruit 
myeloid cells into the treated areas of the skin in mini pigs one week after plasma exposure 
[104]. This is an advantage over radiation or PDT, known ICD inducers, as they are 
reported to be detrimental to immune cells [105-107]. While our results suggest that 
immunostimulation is occurring in mice, long-term survival studies along with 
optimization of plasma systems must be done. Ogawa et al have shown dendritic cell 
maturation following ICD induction using near-infrared photoimmunotherapy [108]. 
Therefore, characterization of cell populations involved in this protective response is also 
required.  
We have demonstrated that NTP can facilitate the initial step of modulating 
recognition and phagocytosis of tumor cells by APCs via induction of immunogenic cancer 
cell death. We also showed that mice immunized with cancer cells treated with ICD-
inducing plasma showed partial protection against cancer cell challenge.  
In agreement with in vitro studies, in vivo plasma treatment of subcutaneous tumors 
also induced immunogenic cancer cell death. Plasma treatment at different areas of the 
tumor each day (Multiple Spots) elicited the greatest emission of DAMPs and recruitment 
of APCs into the tumor area and led to a tumor-antigen-specific T-cell response. Further in 
depth studies to evaluate plasma effects on other key players in the ICD pathway must be 
performed to help optimize plasma treatment parameters for better efficacy. Combination 
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with other immunotherapeutic agents may provide additional clinical value. Adopted 
strategies should be considered based on their effect on the different steps of adaptive 
immune response development [109]. For example, plasma-induced ICD primes the host 
immune response against tumor antigens, and this immunity can be boosted by a vaccine. 
A major challenge for the use of plasma in cancer treatment is clinical 
administration. For superficial cancers such as melanomas, administration of plasma is 
relatively straight-forward, as cancerous tumors/lesions are easily accessible for direct 
treatment and deposition of plasma-generated reactive species. However, treatment of non-
superficial cancers is a challenge for the plasma medicine field. One approach to deliver 
plasma species to deep tumors is through the use of plasma activated media (PAM) [110, 
111], in which media is treated with NTP to enrich dissolved reactive oxygen and nitrogen 
species (RONS) and injected locally in the tumor or perfused through body cavities [112, 
113]. Utsumi and co-workers demonstrated that injection of PAM locally into 
subcutaneous tumors can inhibit growth of malignant tumors in mice though the anti-tumor 
effects are not as prominent as direct plasma treatment [113]. This is likely due to the 
instability of plasma-dissolved species in the media and the animals’ antioxidant capacity 
[114]. Optimization of PAM generation and storage is required before it finds a role in 
clinical cancer treatment. A more direct, but invasive approach may involve intraoperative 
plasma treatment following surgical tumor excision to eliminate cancer cells remaining in 
the surgical margins. Physicists and engineers are designing different plasma sources and 
geometries for a less invasive and more focused approach to deliver plasma inside the body 
[115-117]. Plasma has been shown to propagate along tubes up to several meters in length 
and with diameters as small as 15 μm [115, 116]. The effectiveness of some of these 
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endoscopic plasma devices is being tested in an in vivo pancreatic cancer model [117]. For 
effective clinical application with this approach, a detailed understanding of the RONS 
delivered to the target from the plasma aperture is critical. Finally, as we show here, 
immunization with a plasma-created whole-cell vaccine provided protective anti-tumor 
effects. With optimization of vaccine development and delivery this could be a feasible 
strategy for plasma-mediated cancer control where plasma acts as an adjuvant. 
Conclusion 
We recently proposed a new paradigm of plasma treatment for cancer: ‘plasma 
onco-immunotherapy’ [118]. This approach not only debulks tumors, but also engages the 
innate immune system via ICD to initiate adaptive immune responses [118, 119]. In this 
study, we demonstrated that plasma is a bona fide ICD inducer and can be used alone or in 
combination with other immunotherapies to generate tumor-specific T-cell responses. With 
further optimization of plasma systems and administration protocols, it has potential for 
clinical translation as a standalone treatment modality or an adjuvant for cancer 
immunotherapy. 
Materials and Methods 
NspDBD plasma system and treatment parameters 
NTP was generated in vitro by applying high voltage pulses to a dielectric barrier 
discharge (DBD) electrode. DBD electrodes used in this study were fabricated in our lab 
and have a quartz dielectric covering a copper electrode. This prevents current build-up 
and creates an electrically safe plasma without heating surrounding gas and tissue. A 
nanosecond pulser (FPB-20-05NM, FID GmbH, Germany) was used to generate high 
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voltage pulses, characterized in our previous work [21]. Briefly, our system produced: 29 
kV pulses, 2 ns rise times, 20 ns total pulse duration and 0.9 mJ/pulse.  
Cell culture and in vitro plasma treatment 
Colorectal cancer cell line CT26.WT obtained from ATCC (CRL-2638). 
Generation of CT26-GUCY2C cells was described previously [75]. Cells were cultured in 
complete media: DMEM with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin (Corning Life Sciences, USA). All cells were grown in a 
humidified environment at 37oC with 5% CO2 (Panasonic, MCO-19AICUVH-PA, USA). 
Cells were plated one day prior to plasma treatment in 24-well plates at 3.0x105 cells/mL 
(0.5 mL/well). Before treatment with plasma, media was removed from each well and cells 
were washed twice with phosphate buffered saline (PBS). PBS from the second wash was 
removed from the well right before cells were exposed to plasma in the absence of any 
liquid. Fresh, complete media (0.5 mL) was immediately added back into the well 
following exposure to plasma.  
For treatment with plasma, a DBD electrode (1.3 cm diameter) was placed 1 mm 
above cells in the 24-well plate on top of a grounded metal plate with a z-positioner. Since 
all liquid was removed, plasma was generated in the gap between the electrode and the 
plate, directly on the cells by applying high voltage pulses from the nanosecond pulser. 
Treatment time was fixed to 10 seconds, and pulse frequency was controlled by an external 
function generator (TTi, TG5011LXT, USA). A range of pulse frequencies were used (50, 
15, 30 and 75 Hz), and the combination of plasma treatment parameters produced in the 
following plasma treatment energies: 50, 100, 300 and 700 mJ, respectively [21].  
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Mice and in vivo plasma treatment 
Balb/c mice were obtained from Jackson Laboratory (USA), and animal protocols 
were approved by The Thomas Jefferson University Institutional Animal Care and Use 
Committee. Subcutaneous tumors were established by injecting 1x105 CT26-GUCY2C 
cells in the flanks of mice, and monitored for growth. Prior to plasma treatment, hair over 
the tumor area was removed using a chemical depilatory agent to avoid obstruction with 
plasma generation and treatment. Tumors were treated once daily with plasma beginning 
on day 7 (for effector T cell development studies) or day 18 (for ICD and recruitment 
studies) and continued for 5 consecutive days. A smaller DBD electrode (3 mm diameter) 
was fabricated and used for treatment of mouse tumors. The nanosecond pulser and 
function generator used for in vitro treatment were also used here. Pulse frequency was 
adjusted to 750 Hz and treatment time was 10, 25 or 50 seconds. Mice were anesthetized 
with 5% isoflurane and treated on the grounding plate with the electrode positioned 
approximately 1 mm above the tumor with the z-positioner. Tumor volumes were 
monitored by measuring 3 orthogonal diameters and calculated using:  
4
3
𝜋 ×  𝑟1 ×  𝑟2  ×
 𝑟3. 
Cell viability assay 
Cell viability was determined 24 hours after plasma treatment using a Muse Cell 
Analyzer (Millipore, USA). Cell suspensions were collected, diluted 1:20 with Muse Count 
& Viability Reagent (Millipore, USA) and analyzed according to the manufacturer’s 
instructions. The percent viability was determined for each sample. 
ATP release assay 
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Cell supernatant was collected 10 minutes after plasma treatment and extracellular 
ATP was measured using a luciferin and luciferase-based chemiluminescent kit (Sigma-
Aldrich, USA). All procedures were performed and reagents were prepared following 
manufacturer instructions. Luminescence value was measured by a Photon-Master 
luminometer (LuminUltra, USA) which was calibrated with the provided UltraClear 
calibration solution. The measured relative light units were converted into ATP 
concentration (pgATP/mL). Data were represented at ATP concentration (nM). 
Fluorescence detection of surface-exposed calreticulin 
CT26 cells were collected 24 hours after plasma treatment and washed twice with 
blocking buffer (PBS+ 1% heat-inactivated FBS). Cells were then incubated with rabbit 
anti-human calreticulin antibody (ThermoFisher Scientific, USA) in blocking buffer 
(1:200) for 30 minutes in the dark at room temperature. Following incubation, cells were 
washed twice with blocking buffer and stained with Alexa Fluor 488 conjugated goat anti-
rabbit IgG secondary antibody (ThermoFisher Scientific, USA) at 1:500 in blocking buffer. 
Cells were incubated at room temperature, in the dark, for 40 minutes. Following staining, 
cells were washed and fixed with 4% PFA and analyzed by FACS.  
Co-culture of plasma treated CT26 cells with RAW macrophages and viability analysis 
RAW macrophages were cultured in the same complete media as CT26 cells and 
seeded into transwell inserts (0.4 μm pore size) at 2.4x105 cells/mL (0.5 mL/insert) one day 
prior to co-culture. Before co-culture, RAW cells were washed twice with PBS. 
Immediately following plasma treatment of CT26 cells, PBS was removed from RAW cells 
and transwell inserts were placed into the plasma treated plate of CT26 cells. Complete 
160 
 
 
 
media (750 μL) was added back into the inserts following transfer, and cells were cultured 
together for 48 hours at 37oC with 5% CO2. At 24 hours, media was replaced with fresh, 
complete media and cells were cultured for an additional 24 hours before viability analysis. 
Viability analysis was performed on CT26 cells with a Propidium Iodide (PI) 
exclusion assay. Cells were detached and stained with 100 μL/mL of PI (Invitrogen, US), 
a fluorescent agent that penetrates damaged cell membranes and binds to DNA. Live cells 
were quantified with the Nexcelom CBA Vision (Nexcelom Bioscience, USA) and 
viability was determined by normalizing data to mean live cell counts of untreated controls 
cultured alone. Viability data are represented as a percentage of controls. 
Anti-tumor vaccination assay 
To prepare the whole-cell vaccine, CT26 cells were treated with either: 1) 300 mJ 
of plasma, 2) Cisplatin (50 μM) or 3) complete media. Plasma-created vaccine was 
prepared from cells treated in 24-plates with plasma and cultured in regular media for 24 
hours. Cisplatin-vaccine was prepared from cells incubated for 24 hours in Cisplatin media. 
Media-Vaccine was prepared from cells cultured in regular, complete media for 24 hours. 
Cisplatin- and media- vaccines were used as controls.  
After a 24-hour incubation 3x106 cells in 100 μL of PBS were inoculated 
subcutaneously into the left flank of Balb/c mice. Seven days later, mice were challenged 
with 3x105 live CT26 cells subcutaneously injected into the right flank. Tumors were 
measured twice weekly with calipers and all mice were euthanized on day 28. 
H & E staining of tissue sections and damage assessment 
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Tumors, with overlaying skin, were resected 1 or 3 days after the final plasma 
treatment and fixed in 10% formalin for at least 48 hours. Tissue was then paraffin-
embedded, sectioned with a microtome, deparaffinized and stained with hematoxylin and 
eosin. Images of stained sections were captured using the EVOS FL Auto Cell imaging 
system. Sections were evaluated for damaged by a blinded pathologist (J. S.) 
Immunofluorescence staining of tumor tissue 
Tumor sections from day 3 after final plasma treatment were used for fluorescence 
detection of DAMP signals and immune cell recruitment. For antigen retrieval, slides were 
transferred to a Dako Target Retrieval buffer pH9 (1:10 dilution in H2O) and boiled for 15 
min in a pressure cooker. Slides were then cooled and blocked with blocking solution (10% 
milk in PBS + 0.3% v/v TritonX + 15 μL Fab donkey anti-mouse IgG (H+L) fragments) 
for 1 hour at room temperature in a humidified chamber. Following blocking, tumor 
sections were stained the following antibodies (1:100 in blocking solution) overnight at 
4oC in a humidified environment: anti-mouse CRT (PA3-900, ThermoFisher Scientific, 
USA) and anti-mouse HMGB1 (MA5-16264, ThermoFisher Scientific, USA) or anti-
mouse CD45 (103101, Biolegend, USA) and anti-mouse CD11c (33483, Abcam, USA). 
Tissue samples were then washed four times with PBS + 0.1% v/v Tween (PBST). 
Secondary antibodies (1:1000 in blocking bluffer) were added: donkey anti-rabbit IgG 
Alexa Fluor 594 for CRT (A21207, Life Technologies, USA), goat anti-mouse IgG Alexa 
Fluor 488 for HMGB1 (115-545-205, Jackson Immuno, USA), donkey anti-rat IgG (H+L) 
Alexa Fluor 594 for CD45 (A21209, Life Technologies, USA) and goat anti-armenian 
hamster IgG (H+L) Alexa Fluor 488 for CD11c (127-545-160, Jackson Immuno, USA). 
Tissue sections were stained for 1.5 hours at room temperature in a humidified 
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environment, protected from light. Following secondary staining, tissue sections were 
washed four times with PBST and mounted with DAPI (P36935, Molecular Probes, USA). 
A glass cover slip was placed on top of each tissue section and cured overnight. Sections 
were viewed under an EVOS FL Auto Imaging System (Life Technologies, USA). Using 
ImageJ software, mean fluorescence intensity of DAMPs and CD45+/CD11c+ signals 
were determined by measuring the intensity of three representative areas on the tissue. Data 
are presented as normalized mean fluorescence intensity of individual resected tumors. 
ELISpot analysis 
IFNγ ELISpot assays were previously described [75]. Briefly, multiscreen filtration 
plates (Millipore, MSIPS4W10) were coated with 10 μg/mL anti-mouse IFNγ-capture 
antibody (BD Biosciences, USA) overnight. Splenocytes were collected and 1x106 per well 
were stimulated with DMSO, 10 µg/mL GUCY2C254-262 peptide (JPT, Germany) or 10 
µg/mL AH-1 peptide (AnaSpec, USA) for 24 hours. Spots were developed with 2 μg/mL 
biotinylated anti-IFNγ detection antibody (BD Biosciences, USA) and 2 μg/mL alkaline 
phosphatase-conjugated streptavidin (ThermoFisher Scientific, USA), followed by 
NBT/BCIP substrate (ThermoFisher Scientific, USA). Spot forming cells were enumerated 
using computer-assisted video imaging analysis (ImmunoSpot v5, Cellular Technology 
Limited, USA) and normalized by subtracting baseline negative control values (DMSO).  
References  
1. Cancer Statistics. 2016 January 24, 2017. 
2. Peeters, K., et al., Late side effects of short-course preoperative radiotherapy 
combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in 
irradiated patients—a Dutch colorectal cancer group study. Journal of Clinical Oncology, 
2005. 23(25): p. 6199-6206. 
163 
 
 
 
3. Sun, C.C., et al., Rankings and symptom assessments of side effects from 
chemotherapy: insights from experienced patients with ovarian cancer. Support Care 
Cancer, 2005. 13(4): p. 219-27. 
4. Agarwal, R. and S.B. Kaye, Ovarian cancer: strategies for overcoming resistance 
to chemotherapy. Nature Reviews Cancer, 2003. 3(7): p. 502-516. 
5. Yasuda, H., Solid tumor physiology and hypoxia-induced chemo/radio-resistance: 
novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric 
Oxide, 2008. 19(2): p. 205-16. 
6. Yabroff, K.R., et al., Economic Burden of Cancer in the US: Estimates, Projections, 
and Future Research. Cancer Epidemiol Biomarkers Prev, 2011. 20(10): p. 2006-14. 
7. Yabroff, K.R., et al., Economic burden of cancer in the United States: estimates, 
projections, and future research. Cancer Epidemiology and Prevention Biomarkers, 2011. 
20(10): p. 2006-2014. 
8. Casares, N., et al., Caspase-dependent immunogenicity of doxorubicin-induced 
tumor cell death. The Journal of experimental medicine, 2005. 202(12): p. 1691-1701. 
9. Obeid, M., et al., Leveraging the immune system during chemotherapy: moving 
calreticulin to the cell surface converts apoptotic death from “silent” to immunogenic. 
Cancer Research, 2007. 67(17): p. 7941-7944. 
10. Green, D.R., et al., Immunogenic and tolerogenic cell death. Nature Reviews 
Immunology, 2009. 9(5): p. 353-363. 
11. Srivastava, P., Roles of heat-shock proteins in innate and adaptive immunity. 
Nature Reviews Immunology, 2002. 2(3): p. 185-194. 
12. Aymeric, L., et al., Tumor cell death and ATP release prime dendritic cells and 
efficient anticancer immunity. Cancer Research, 2010. 70(3): p. 855-858. 
13. Obeid, M., et al., Calreticulin exposure dictates the immunogenicity of cancer cell 
death. Nature medicine, 2007. 13(1): p. 54-61. 
14. Jia, L., et al., Extracellular HMGB1 promotes differentiation of nurse-like cells in 
chronic lymphocytic leukemia. Blood, 2014. 123(11): p. 1709-1719. 
15. Krysko, O., et al., Many faces of DAMPs in cancer therapy. Cell death & disease, 
2013. 4(5): p. e631. 
16. Guermonprez, P., et al., Antigen presentation and T cell stimulation by dendritic 
cells. Annu Rev Immunol, 2002. 20(1): p. 621-667. 
17. Jung, S., et al., In vivo depletion of CD11c+ dendritic cells abrogates priming of 
CD8+ T cells by exogenous cell-associated antigens. Immunity, 2002. 17(2): p. 211-220. 
18. Klebanoff, C.A., et al., Central memory self/tumor-reactive CD8+ T cells confer 
superior antitumor immunity compared with effector memory T cells. Proceedings of the 
164 
 
 
 
National Academy of Sciences of the United States of America, 2005. 102(27): p. 9571-
9576. 
19. Savina, A. and S. Amigorena, Phagocytosis and antigen presentation in dendritic 
cells. Immunological reviews, 2007. 219(1): p. 143-156. 
20. Dobrynin, D., et al., Physical and biological mechanisms of direct plasma 
interaction with living tissue. New Journal of Physics, 2009. 11(11): p. 115020. 
21. Lin, A., et al., Non‐Equilibrium Dielectric Barrier Discharge Treatment of 
Mesenchymal Stem Cells: Charges and Reactive Oxygen Species Play the Major Role in 
Cell Death. Plasma Processes and Polymers, 2015. 
22. Bruggeman, P. and C. Leys, Non-thermal plasmas in and in contact with liquids. 
Journal of Physics D: Applied Physics, 2009. 42(5): p. 053001. 
23. Babaeva, N.Y. and M.J. Kushner, Intracellular electric fields produced by 
dielectric barrier discharge treatment of skin. Journal of Physics D: Applied Physics, 2010. 
43(18): p. 185206. 
24. Babaeva, N.Y. and M.J. Kushner, Reactive fluxes delivered by dielectric barrier 
discharge filaments to slightly wounded skin. Journal of Physics D: Applied Physics, 2013. 
46(2): p. 025401. 
25. Fridman, G., et al., Applied plasma medicine. Plasma Processes and Polymers, 
2008. 5(6): p. 503-533. 
26. Kogelschatz, U., Dielectric-barrier discharges: their history, discharge physics, 
and industrial applications. Plasma Chemistry and Plasma Processing, 2003. 23(1): p. 1-
46. 
27. Steinbeck, M.J., et al., Skeletal Cell Differentiation Is Enhanced by Atmospheric 
Dielectric Barrier Discharge Plasma Treatment. PLoS One, 2013. 8(12): p. e82143. 
28. Ahn, H.J., et al., Targeting cancer cells with reactive oxygen and nitrogen species 
generated by atmospheric-pressure air plasma. PLoS One, 2014. 9(1): p. e86173. 
29. Lu, X., et al., Reactive species in non-equilibrium atmospheric-pressure plasmas: 
Generation, transport, and biological effects. Physics Reports, 2016. 630: p. 1-84. 
30. Thannickal, V.J. and B.L. Fanburg, Reactive oxygen species in cell signaling. 
American Journal of Physiology-Lung Cellular and Molecular Physiology, 2000. 279(6): 
p. L1005-L1028. 
31. Martindale, J.L. and N.J. Holbrook, Cellular response to oxidative stress: Signaling 
for suicide and survival*. Journal of cellular physiology, 2002. 192(1): p. 1-15. 
32. Sarsour, E.H., et al., Redox control of the cell cycle in health and disease. 
Antioxidants & redox signaling, 2009. 11(12): p. 2985-3011. 
33. Vandamme, M., et al., Antitumor effect of plasma treatment on U87 glioma 
xenografts: preliminary results. Plasma Processes and Polymers, 2010. 7(3‐4): p. 264-273. 
165 
 
 
 
34. Miller, V., et al., Microsecond-pulsed dielectric barrier discharge plasma 
stimulation of tissue macrophages for treatment of peripheral vascular disease. Physics of 
Plasmas (1994-present), 2015. 22(12): p. 122005. 
35. Chernets, N., et al., Nonthermal atmospheric pressure plasma enhances mouse limb 
bud survival, growth, and elongation. Tissue Engineering Part A, 2014. 21(1-2): p. 300-
309. 
36. Heinlin, J., et al., Plasma medicine: possible applications in dermatology. JDDG: 
Journal der Deutschen Dermatologischen Gesellschaft, 2010. 8(12): p. 968-976. 
37. Isbary, G., et al., A first prospective randomized controlled trial to decrease 
bacterial load using cold atmospheric argon plasma on chronic wounds in patients. British 
Journal of Dermatology, 2010. 163(1): p. 78-82. 
38. Yan, D., J.H. Sherman, and M. Keidar, Cold atmospheric plasma, a novel 
promising anti-cancer treatment modality. Oncotarget, 2016. 5. 
39. Zucker, S.N., et al., Preferential induction of apoptotic cell death in melanoma cells 
as compared with normal keratinocytes using a non-thermal plasma torch. Cancer Biol 
Ther, 2012. 13(13): p. 1299-1306. 
40. Keidar, M., et al., Cold atmospheric plasma in cancer therapya). Physics of 
Plasmas (1994-present), 2013. 20(5): p. 057101. 
41. Partecke, L.I., et al., Tissue tolerable plasma (TTP) induces apoptosis in pancreatic 
cancer cells in vitro and in vivo. BMC cancer, 2012. 12(1): p. 473. 
42. Keidar, M., et al., Cold plasma selectivity and the possibility of a paradigm shift in 
cancer therapy. Br J Cancer, 2011. 105(9): p. 1295-1301. 
43. Walk, R.M., et al., Cold atmospheric plasma for the ablative treatment of 
neuroblastoma. J Pediatr Surg, 2013. 48(1): p. 67-73. 
44. Brullé, L., et al., Effects of a non thermal plasma treatment alone or in combination 
with gemcitabine in a MIA PaCa2-luc orthotopic pancreatic carcinoma model. PLoS One, 
2012. 7(12): p. e52653. 
45. Chernets, N., et al., Reaction Chemistry Generated by Nanosecond Pulsed 
Dielectric Barrier Discharge Treatment is Responsible for the Tumor Eradication in the 
B16 Melanoma Mouse Model. Plasma Processes and Polymers, 2015. 
46. Hirst, A.M., et al., Low temperature plasmas as emerging cancer therapeutics: the 
state of play and thoughts for the future. Tumor Biology, 2016: p. 1-11. 
47. Lin, A., et al., Uniform Nanosecond Pulsed Dielectric Barrier Discharge Plasma 
Enhances Anti‐Tumor Effects by Induction of Immunogenic Cell Death in Tumors and 
Stimulation of Macrophages. Plasma Processes and Polymers, 2015. 12(12): p. 1392-1399. 
48. Lin, A., et al., Nanosecond-Pulsed DBD Plasma-Generated Reactive Oxygen 
Species Trigger Immunogenic Cell Death in A549 Lung Carcinoma Cells through 
166 
 
 
 
Intracellular Oxidative Stress. International Journal of Molecular Sciences, 2017. 18(5): p. 
966. 
49. Kepp, O., et al., Consensus guidelines for the detection of immunogenic cell death. 
Oncoimmunology, 2014. 3(9): p. e955691. 
50. Krysko, D.V., et al., Immunogenic cell death and DAMPs in cancer therapy. Nature 
Reviews Cancer, 2012. 12(12): p. 860-875. 
51. Santos, C.X., et al., Mechanisms and implications of reactive oxygen species 
generation during the unfolded protein response: roles of endoplasmic reticulum 
oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxidants & 
redox signaling, 2009. 11(10): p. 2409-2427. 
52. Johnson, S., et al., The ins and outs of calreticulin: from the ER lumen to the 
extracellular space. Trends in cell biology, 2001. 11(3): p. 122-129. 
53. Kroemer, G., et al., Immunogenic cell death in cancer therapy. Annu Rev Immunol, 
2013. 31: p. 51-72. 
54. Gardai, S.J., et al., Cell-surface calreticulin initiates clearance of viable or 
apoptotic cells through trans-activation of LRP on the phagocyte. Cell, 2005. 123(2): p. 
321-334. 
55. Panaretakis, T., et al., Mechanisms of pre‐apoptotic calreticulin exposure in 
immunogenic cell death. The EMBO journal, 2009. 28(5): p. 578-590. 
56. Chao, M.P., et al., Calreticulin is the dominant pro-phagocytic signal on multiple 
human cancers and is counterbalanced by CD47. Science Translational Medicine, 2010. 
2(63): p. 63ra94-63ra94. 
57. Fernandez, N.C., et al., Dendritic cells directly trigger NK cell functions: cross-talk 
relevant in innate anti-tumor immune responses in vivo. Nature medicine, 1999. 5(4): p. 
405-411. 
58. Michaud, M., et al., Autophagy-dependent anticancer immune responses induced 
by chemotherapeutic agents in mice. Science, 2011. 334(6062): p. 1573-1577. 
59. Martins, I., et al., Molecular mechanisms of ATP secretion during immunogenic 
cell death. Cell Death & Differentiation, 2014. 21(1): p. 79-91. 
60. Garg, A.D., et al., A novel pathway combining calreticulin exposure and ATP 
secretion in immunogenic cancer cell death. The EMBO journal, 2012. 31(5): p. 1062-
1079. 
61. la Sala, A., et al., Alerting and tuning the immune response by extracellular 
nucleotides. Journal of leukocyte biology, 2003. 73(3): p. 339-343. 
62. Kazama, H., et al., Induction of immunological tolerance by apoptotic cells 
requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity, 
2008. 29(1): p. 21-32. 
167 
 
 
 
63. Picher, M., L.H. Burch, and R.C. Boucher, Metabolism of P2 Receptor Agonists in 
Human Airways IMPLICATIONS FOR MUCOCILIARY CLEARANCE AND CYSTIC 
FIBROSIS. Journal of Biological Chemistry, 2004. 279(19): p. 20234-20241. 
64. Zhao, X., et al., Inducing enhanced immunogenic cell death with nanocarrier-
based drug delivery systems for pancreatic cancer therapy. Biomaterials, 2016. 102: p. 
187-197. 
65. Hide, I., et al., Extracellular ATP Triggers Tumor Necrosis Factor‐α Release from 
Rat Microglia. Journal of neurochemistry, 2000. 75(3): p. 965-972. 
66. Kusner, D.J. and J.A. Barton, ATP stimulates human macrophages to kill 
intracellular virulent Mycobacterium tuberculosis via calcium-dependent phagosome-
lysosome fusion. The Journal of Immunology, 2001. 167(6): p. 3308-3315. 
67. Mariathasan, S., et al., Cryopyrin activates the inflammasome in response to toxins 
and ATP. Nature, 2006. 440(7081): p. 228-232. 
68. Cruz, C.M., et al., ATP activates a reactive oxygen species-dependent oxidative 
stress response and secretion of proinflammatory cytokines in macrophages. Journal of 
Biological Chemistry, 2007. 282(5): p. 2871-2879. 
69. Tesniere, A., et al., Immunogenic death of colon cancer cells treated with 
oxaliplatin. Oncogene, 2010. 29(4): p. 482-491. 
70. Bell, C.W., et al., The extracellular release of HMGB1 during apoptotic cell death. 
American Journal of Physiology-Cell Physiology, 2006. 291(6): p. C1318-C1325. 
71. Bianchi, M.E. and A.A. Manfredi, High‐mobility group box 1 (HMGB1) protein at 
the crossroads between innate and adaptive immunity. Immunological reviews, 2007. 
220(1): p. 35-46. 
72. Orlova, V.V., et al., A novel pathway of HMGB1‐mediated inflammatory cell 
recruitment that requires Mac‐1‐integrin. The EMBO journal, 2007. 26(4): p. 1129-1139. 
73. Altin, J.G. and E.K. Sloan, The role of CD45 and CD45-associated molecules in T 
cell activation. Immunology and Cell Biology, 1997. 75(5). 
74. Ledbetter, J.A., et al., CD45 regulates signal transduction and lymphocyte 
activation by specific association with receptor molecules on T or B cells. Proceedings of 
the National Academy of Sciences, 1988. 85(22): p. 8628-8632. 
75. Snook, A.E., et al., Guanylyl Cyclase C–Induced Immunotherapeutic Responses 
Opposing Tumor Metastases Without Autoimmunity. J Natl Cancer Inst, 2008. 100(13): p. 
950-961. 
76. Witek, M., et al., Tumor radiation therapy creates therapeutic vaccine responses 
to the colorectal cancer antigen GUCY2C. International Journal of Radiation Oncology* 
Biology* Physics, 2014. 88(5): p. 1188-1195. 
77. Ribas, A., et al., Determinant spreading and tumor responses after peptide-based 
cancer immunotherapy. Trends in immunology, 2003. 24(2): p. 58-61. 
168 
 
 
 
78. van der Most, R.G., et al., Cranking the immunologic engine with chemotherapy: 
using context to drive tumor antigen cross-presentation towards useful antitumor 
immunity. Cancer Research, 2006. 66(2): p. 601-604. 
79. Facciponte, J.G., et al., Tumor endothelial marker 1–specific DNA vaccination 
targets tumor vasculature. The Journal of clinical investigation, 2014. 124(4). 
80. Huang, A.Y., et al., The immunodominant major histocompatibility complex class 
I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene 
product. Proceedings of the National Academy of Sciences, 1996. 93(18): p. 9730-9735. 
81. Rice, J., S. Buchan, and F.K. Stevenson, Critical components of a DNA fusion 
vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor 
antigen. The Journal of Immunology, 2002. 169(7): p. 3908-3913. 
82. Yu, Z., et al., Treatment of osteosarcoma with microwave thermal ablation to 
induce immunogenic cell death. Oncotarget, 2014. 5(15): p. 6526. 
83. Zitvogel, L., et al., Immunological aspects of cancer chemotherapy. Nature 
Reviews Immunology, 2008. 8(1): p. 59-73. 
84. Palumbo, M.O., et al., Systemic cancer therapy: achievements and challenges that 
lie ahead. Frontiers in pharmacology, 2013. 4. 
85. Bentzen, S.M., Preventing or reducing late side effects of radiation therapy: 
radiobiology meets molecular pathology. Nat Rev Cancer, 2006. 6(9): p. 702-13. 
86. Burstein, H.J., Side effects of chemotherapy. Journal of Clinical Oncology, 2000. 
18(3): p. 693-693. 
87. Mellman, I., G. Coukos, and G. Dranoff, Cancer immunotherapy comes of age. 
Nature, 2011. 480(7378): p. 480-489. 
88. Naidoo, J., et al., Pneumonitis in Patients Treated With Anti–Programmed Death-
1/Programmed Death Ligand 1 Therapy. Journal of Clinical Oncology, 2016: p. 
JCO682005. 
89. Gameiro, S.R., et al., Radiation-induced immunogenic modulation of tumor 
enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell 
killing. Oncotarget, 2014. 5(2): p. 403-416. 
90. Galluzzi, L., et al., Immunogenic cell death in cancer and infectious disease. Nature 
Reviews Immunology, 2016. 
91. Vanneman, M. and G. Dranoff, Combining immunotherapy and targeted therapies 
in cancer treatment. Nature Reviews Cancer, 2012. 12(4): p. 237-251. 
92. Miller, V., et al., Plasma Stimulation of Migration of Macrophages. Plasma 
Processes and Polymers, 2014. 11(12): p. 1193-1197. 
169 
 
 
 
93. Ranieri, P., et al., Nanosecond pulsed Dielectric Barrier Discharge induced Anti-
Tumor Effects Propagate Through the depth of Tissue via Intracellular Signaling. Plasma 
Medicine, 2017. in Press. 
94. Lin, A., et al., Immune cells enhance selectivity of nanosecond-pulsed plasma 
against tumor cells. Plasma Medicine, 2017. In Press. 
95. Kaushik, N.K., et al., Cytotoxic macrophage-released tumour necrosis factor-alpha 
(TNF-α) as a killing mechanism for cancer cell death after cold plasma activation. Journal 
of Physics D: Applied Physics, 2016. 49(8): p. 084001. 
96. Manda, K., et al., Effects of ionizing radiation on the immune system with special 
emphasis on the interaction of dendritic and T cells. Frontiers in oncology, 2012. 2: p. 102. 
97. Castano, A.P., P. Mroz, and M.R. Hamblin, Photodynamic therapy and anti-tumour 
immunity. Nature Reviews Cancer, 2006. 6(7): p. 535-545. 
98. Kohoutova, D., et al., Esophageal neoplasia arising from subsquamous buried 
glands after an apparently successful photodynamic therapy or radiofrequency ablation 
for Barrett’s associated neoplasia. Scandinavian journal of gastroenterology, 2015(ahead-
of-print): p. 1-7. 
99. Mohades, S., et al., Evaluation of the effects of a plasma activated medium on 
cancer cells. Physics of Plasmas, 2015. 22(12): p. 122001. 
100. Traylor, M.J., et al., Long-term antibacterial efficacy of air plasma-activated water. 
Journal of Physics D: Applied Physics, 2011. 44(47): p. 472001. 
101. Yan, D., et al., Principles of using cold atmospheric plasma stimulated media for 
cancer treatment. Scientific reports, 2015. 5: p. 18339. 
102. Utsumi, F., et al., Effect of indirect nonequilibrium atmospheric pressure plasma 
on anti-proliferative activity against chronic chemo-resistant ovarian cancer cells in vitro 
and in vivo. PLoS One, 2013. 8(12): p. e81576. 
103. Judée, F., et al., Short and long time effects of low temperature Plasma Activated 
Media on 3D multicellular tumor spheroids. Scientific reports, 2016. 6. 
104. Weiss, M., et al., Cold atmospheric plasma treatment induces anti-proliferative 
effects in prostate cancer cells by redox and apoptotic signaling pathways. PloS one, 2015. 
10(7): p. e0130350. 
105. Polak, M., et al., Innovative Plasma Generation in Flexible Biopsy Channels for 
Inner‐Tube Decontamination and Medical Applications. Plasma Processes and Polymers, 
2012. 9(1): p. 67-76. 
106. Kim, J.Y., et al., Apoptosis of lung carcinoma cells induced by a flexible optical 
fiber-based cold microplasma. Biosensors and Bioelectronics, 2011. 28(1): p. 333-338. 
107. Robert, E., et al., Perspectives of endoscopic plasma applications. Clinical Plasma 
Medicine, 2013. 1(2): p. 8-16. 
170 
 
 
 
108. Miller, V., A. Lin, and A. Fridman, Why Target Immune Cells for Plasma 
Treatment of Cancer. Plasma Chemistry and Plasma Processing, 2015: p. 1-10. 
109. Kepp, O., et al., Molecular determinants of immunogenic cell death elicited by 
anticancer chemotherapy. Cancer and Metastasis Reviews, 2011. 30(1): p. 61-69.  
171 
 
 
 
CHAPTER 8: IMMUNE CELLS ENHANCE SELECTIVITY OF NANOSECOND-
PULSED DBD PLASMA AGAINST TUMOR CELLS 
 
  
172 
 
 
 
ARTICLE 
Immune Cells Enhance Selectivity of Nanosecond-Pulsed 
DBD Plasma against Tumor Cells 
 
Abraham Lin1, Billy Truong1, Gregory Fridman1, Alexander Fridman1, Vandana Miller1 
 
1 Nyheim Drexel Plasma Institute, Drexel University, Philadelphia, USA 
 
 
173 
 
 
 
ABSTRACT 
Cancer immunotherapy is a promising strategy that engages the patient’s immune 
system to selectively kill cancer cells while sparing normal tissue. Treatment of 
macrophages with a nanosecond-pulsed dielectric barrier discharge directly enhanced their 
cytotoxic activity against tumor cells but not against normal cells. These results underscore 
the clinical potential of plasma for cancer immunotherapy. 
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Introduction 
Most chemotherapeutic agents and radiation used for treatment of cancers are not 
tumor specific, and rely on their differential toxicity against tumor and non-cancerous 
cells.(1) Damage occurs to both cancerous and normal cells, but normal tissue is better able 
to repair cellular damage and recover.(2, 3) The usefulness of many of these treatments is 
compromised by the serious side effects that result from their use.(4, 5) Since they are 
systemically administered, they are distributed to tissues throughout the body and may 
produce damage to susceptible organs.(1, 4, 6) In patients with incurable cancers where 
palliation of symptoms is the goal, the severity of side effects may be worse than the disease 
itself.(4, 7-9) Hence, the challenge of getting maximal therapeutic benefit but minimizing 
toxicity for anti-cancer therapies still remains.  
Non-equilibrium, atmospheric pressure plasma has been shown to exhibit 
comparable selectivity against tumor cells; therefore plasma development for cancer 
treatment has focused mainly on direct tumor cell killing, both in vitro and in vivo.(10-15) 
Ablative reduction of tumor masses has been demonstrated by most of these researchers. 
The involvement of the immune system in the resolution of this disease with plasma has 
largely been ignored.(5, 16, 17) For greatest clinical efficacy, plasma should a) selectively 
attack cancerous cells, b) preserve the integrity of surrounding normal tissue and c) engage 
the body’s natural innate and adaptive immunity against cancer.(18) Since the immune 
system is designed to discriminate between self and non-self,(19) tuning of plasma treatment 
to allow the immune system to retain this property could enhance the selectivity of both 
plasma and the immune system. The identification of non-self, danger signals is the 
function of antigen presenting cells (APCs) like macrophages and dendritic cells.(19-22) 
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Macrophages, originating from bone marrow progenitor cells, are key APCs.(20, 23) These 
progenitor cells develop into monocytes when released into the bloodstream and 
differentiate into tissue specific macrophages, displaying different phenotypes depending 
on the local environment.(24, 25) Activated pro-inflammatory macrophages secrete factors 
and cytotoxic substances, such as tumor necrosis factor α (TNF-α) and reactive oxygen and 
nitrogen species capable of killing cancerous cells.(26-28) Secretion of these factors can 
activate macrophages to exert their direct anti-tumor effects.(29-31) 
We have previously reported the enhancement of migration and anti-tumor function 
of macrophages in vitro by plasma (Table 1).(32-35) In vivo effects of plasma treatment 
include differentiation of hemocytes in the lymph organs 48 hours after plasma exposure 
of drosophila larvae.(36) But the effect of plasma activated macrophages on normal cells 
has not been examined.  
Table 1. Plasma has been reported to augment several macrophage functions. 
Macrophage Function where Plasma has Demonstrated Effect 
1) Cytokine Secretion (34) 
2) Migration to and from Immune Organs (35) 
3) Antigen Presentation to T and B Cells (37-40) 
4) Cancer Cell Killing (32, 38, 39) 
Macrophage Function where Plasma Effect has not been 
Demonstrated 
5) Recognition of Foreign Antigens (41, 42) 
6) Phagocytosis of Foreign Targets (41, 42) 
7) Recruitment of other Immune Cells (43) 
In this study, we tested the hypothesis that the selectivity of plasma effects 
against cancer can be enhanced via direct engagement of immune cells. We treated 
human macrophages (differentiated THP-1 monocytes) with a nanosecond-pulsed 
dielectric barrier discharge (nspDBD) plasma. Bekeschus et. al., has previously treated 
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THP-1 monocytes to study their redox modulation response to plasma.(44) We co-cultured 
macrophages with human lung carcinoma cells (A549) or normal lung epithelial cells 
(Beas2B), unexposed to plasma, in semi-permeable transwell inserts (Figure 1). This 
system separated the two cell types from direct contact but allowed for the exchange of 
soluble factors and signals in the media. Cancer cell viability was quantified 48 hours later 
to determine anti-tumor activity of macrophages.  
 
Figure 1. Transwell co-culture systems separated the macrophages and cancer cells from 
direct contact but allowed for the exchange of soluble factors and signals through the 
media. A) Differentiated THP-1 monocytes (M0 macrophages) were directly exposed to 
plasma to stimulate the release of anti-tumor factors. Non-plasma exposed A549 human 
lung carcinoma cells were cultured in the transwell inserts having membranes with 0.4 μm 
pores.   
Our results showed that plasma enhanced anti-tumor activity of macrophages 
through direct stimulation. While cancer cell viability decreased, normal cells remained 
unaffected. Therefore, further development of plasma to improve overall selectivity of 
treatment will provide a more efficacious and safe option for cancer immunotherapy.  
Results 
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Cancer Cells (A549) are More Sensitive to Plasma Compared to Immune Cells (THP-1) 
and Non-Cancerous Cells (Beas2B) 
Cancer cells, normal tissue, and immune cells such as dendritic cells and 
macrophages are all present in the tumor microenvironment,(45) and will be exposed to 
plasma during treatment of tumors. Therefore, plasma regimes should be developed to 
deliver maximum cytotoxicity to cancerous cells with minimal damage to other cells. In 
this study, we used a lung carcinoma cell line (A549), a normal lung epithelial cell line 
(Beas2B), and 1 phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 
macrophages (M0 macrophages) to represent the three cell types. We compared their 
susceptibility to plasma by measuring cell viability one hour after treatment. Cells seeded 
into 24-well plates one day prior to treatment were exposed to nspDBD plasma at 29 kV 
for 10 seconds. Frequency of pulses was adjusted to deliver a range of plasma energies. 
Following plasma exposure, viable cells were quantified with a Propidium Iodide 
(PI) exclusion assay. We observed that plasma had an energy-dependent effect on cell 
viability; at low treatment energy (50 mJ) there was minimal effect on cell viability for all 
three cell types (Figure 2). At higher energies, loss of viable A549 cells was greater than 
that of both normal lung epithelial cells and macrophages. This is consistent with previous 
reports and may be partially attributed to the different intracellular redox environments 
between normal and cancerous cells.(46-48) Based on these results, we selected 100 and 300 
mJ treatment for the subsequent experiment.  
178 
 
 
 
 
Figure 2. A549 lung carcinoma cells are more sensitive to plasma treatment compared to 
immune cells (THP-1) and normal lung epithelial cells (Beas2B). Cells were seeded into 
24-well plates one day prior to plasma treatment. A PI exclusion assay was performed 1 
hour post plasma treatment, and cell viability was determined by normalizing live cell 
counts to untreated controls. Data are shown as mean±SEM. *p<0.05, **p<0.05, 
***p<0.001 (Two Way ANOVA, Dunnett’s multiple comparison test). 
Plasma Directly Enhanced Anti-Tumor Activity of Macrophages  
To investigate whether plasma can directly stimulate the anti-tumor activity of 
macrophages, we co-cultured plasma-treated M0 macrophages with A549 cells in a 
transwell system for 48 hours (Figure 1). A549 viability following co-culture with 
macrophages not exposed to plasma was 58%. This served as our control for the baseline 
anti-tumor activity of macrophages in co-culture (represented in the figures as 0 mJ). Both 
100 mJ and 300 mJ plasma treatment of macrophages reduced A549 viability to less than 
43% (Figure 3). Co-culture of plasma-treated macrophages with the normal Beas2B 
epithelial cells did not affect their viability. Taken together, these results strongly indicate 
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that plasma can directly enhance cytotoxic activity of macrophages selectively against 
cancerous cells. 
 
Figure 3. Plasma enhanced anti-tumor activity of M0 macrophages. To determine whether 
plasma stimulated macrophages could selectively kill cancerous cells, macrophages were 
exposed to plasma and co-cultured with either A549 cancer cells or normal Beas2B lung 
epithelial cells. After 48-hour co-culture, both A549 and Beas2B cells were collected and 
viability was determined with a PI exclusion assay. Neither A549 nor Beas2B cells came 
in direct contact with plasma. Therefore, any observed killing effects are a result of secreted 
factors from macrophages. Data are shown as mean±SEM. *p<0.05, **p<0.05, 
***p<0.001 (One Way ANOVA, Dunnett’s multiple comparison test). 
Discussion 
Conventional treatments, such as chemotherapeutics and radiation, are only 
partially tumor specific and destroy cancer cells in the body, often at the expense of 
significant toxicity to normal tissue.(2, 4, 6) In contrast, immunotherapy is focused on 
activating the body’s natural defenses to selectively target tumors for therapeutic benefit 
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against cancer.(1, 16) This ensures that only cancer cells are destroyed by activated immune 
cells and the host’s normal cells remain healthy. 
Most recent advancements in plasma treatment of tumors have focused on 
optimization of ablative regimes and reduction of bystander effects on normal cells.(13, 49, 
50) By varying the energy deposited on target tissues, plasma regimes toxic to tumor cells 
and relatively safe for normal cells were identified for use. This may be done by varying 
treatment time, distance from source, carrier gases, voltage and frequency. However, in 
animal models of cancer treated at these regimes, successful reduction in tumor volumes 
and increased mean survival were associated with damage to surrounding normal tissue 
and tumor recurrence when treatment was discontinued. (13, 49, 50) We propose that moving 
away from ablative regimes of plasma for treatment, into regimes that promote stimulation 
of immune-mediated tumor cell killing may improve clinical outcomes and reduce 
damaging effects to neighboring tissue. Direct enhancement of immune cell function by 
plasma is an advantage of plasma for cancer immunotherapy.  
Plasma treatment of multiple human cell lines with our nspDBD system 
demonstrated that cancerous cells are more sensitive to plasma as compared to their normal 
counterparts even at lower energies (Figure 2). This further supports that plasma can be 
safely applied to induce cell death in cancerous cells, while minimizing damage to 
surrounding normal tissue. 
When macrophages were stimulated directly with plasma, they were more effective 
at killing A549 cells (Figure 3). The killing activity of plasma-activated macrophages is, 
at least in part, due to the release of tumor necrosis factor alpha (TNF-α),(34) a 
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proinflammatory cytokine known to be cytotoxic to cancerous cells.(51, 52) Kaushik, et. al. 
reported that macrophages treated with plasma released TNF-α, which reduced viability of 
A549 cells in co-culture. This effect was reversed by lenalidomide, a TNF-α specific 
inhibitor.(34) 
There was no effect of plasma-activated macrophages on the normal lung epithelial 
cell line, suggesting that macrophages maintain their selectivity to kill cancerous cells 
when stimulated with plasma. The different outcomes on normal and cancer cells may, in 
part, be attributed to their response to the released cytokines. TNF-α is strongly cytotoxic 
toward tumor cells but induces interleukin 6 (IL-6) and IL-8 secretion from Beas2B cells, 
the normal cells.(53, 54) Both these cytokines enhance cell survival and proliferation of 
normal epithelial/endothelial cell lines.(55-58) Taken together, this suggests that plasma-
mediated cancer therapy may be safely applied for direct augmentation of immune cell 
function while preserving selectivity (Figure 4). This is a significant advantage over 
radiation as APCs are among the most radiosensitive cells in the body.(59)  These effects 
are also observed in treatment of live whole organisms. Lee, et. al., reported that a single 
10 second treatment of Drosophila melanogaster larvae increased the numbers of fully 
differentiated hemocytes in the lymph organ within 48 hours.(36) Development of these 
larvae was followed and they achieved physiological and developmental milestones similar 
to untreated larvae. This further supports the safety of plasma for development of future 
clinical applications. 
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Figure 4. Plasma-stimulated macrophages exhibit selective killing of cancerous cells. 
Conclusion 
This study provides evidence that non-thermal plasma has two major advantages 
over current treatment modalities: (i) greater selectivity towards cancer cells and (ii) 
enhancement of anti-tumor activity of macrophages. Therefore, plasma has the potential to 
be an efficacious and safe cancer therapeutic option via engagement of the immune system. 
Materials 
Cell Culture and Plating 
Human lung carcinoma cells (A549, ATCC: CCL-185) and normal human lung 
epithelial cells (Beas2B, ATCC: CRL-9609) were a gift from Dr. Bela Peethambaran 
(University of the Sciences, Philadelphia, PA, USA). The Human monocyte cell line (THP-
1, ATCC:TIB-202) was a gift from Dr. Kara Spiller (Drexel University, Philadelphia, PA, 
US). All cells were cultured in RPMI 1640 with 10% fetal bovine serum and 1% 
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penicillin/streptomycin or RPMI 1640 with 10% heat inactivated fetal bovine serum and 
1% penicillin/streptomycin respectively (Corning Life Sciences, USA) and grown at 37oC 
with 5% CO2 in a humidified atmosphere.  
Cells were seeded at near confluency into 24-well plates (0.5 mL/well) one day 
prior to plasma treatment. A549 cells were plated at 3.0×105 cells/mL, Beas2B cells were 
plated at 4.0×105 cells/mL, and THP-1 cells were plated at 1.4×106 cells/mL. Before 
plasma treatment, cell culture media was removed and cells were washed twice with 
phosphate buffered saline (PBS). PBS from the second wash was removed right before 
plasma treatment and 0.5 mL of complete cell culture media was added immediately after 
plasma exposure. 
Differentiation of THP-1 Monocytes to M0 Macrophages 
THP-1 cells were differentiated into M0 macrophages, one day prior to 
experiments, by the addition of 0.5 µL of 100 µL/mL phorbol 12-myristate 13-acetate 
(PMA) (Sigma-Aldrich, USA) into the media of each well in the 24-well plate or 24-well 
insert. Cells were incubated overnight and PBS was used to wash differentiated cells before 
plasma treatment and co-culture.  
NspDBD Plasma Treatment Parameters 
Cells were treated with nspDBD plasma as described in previous publications 
(Figure 5).(32, 60) Briefly, we used a nanosecond pulser (FPB-20-05NM, FID GmbH, 
Germany) to produce 29 kV amplitude pulses, and an external function generator (TTI, 
TG5011 LXT) to control pulse frequency. Each treatment was fixed at 10 seconds and 
plasma was applied 1 mm above the cells. The energy of each pulse, measured in our 
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previous work,(60) was 0.9 mJ/pulse. Together with frequency and treatment time, the total 
plasma energy delivered to the cell was calculated. Plasma treatment parameters are listed 
in Table 2. 
Cell Viability Assay 
Cell viability was assessed with a Propidium Iodide (PI) (Thermo Fisher Scientific 
Inc., USA) exclusion assay. Damaged cell membranes allow for PI, a fluorescent agent, to 
penetrate into the cell and bind to DNA. One hour after plasma treatment, cells were 
detached with either 0.25% Trypsin, 0.1% EDTA in HBSS (Corning, USA) or 5 mM 
EDTA in PBS (EMD Millipore, USA) and stained with 100 μL/mL of propidium iodide 
(PI) (Invitrogen, USA). For co-culturing experiments, cells were collected and stained at 
48 hours post plasma and co-culture. An image cytometer (Nexcelom CBA Vision, 
Nexcelom Bioscience, USA) was used to quantify live cells. The FCS flow cytometry 
software (FCS 4.0, DeNovo Software, USA) was used to perform size gating. To determine 
viability, live cell counts for each treatment group was normalized to the average live cell 
counts of the untreated controls, and data are represented as a percentage of controls.  
Plasma-Treated Macrophages with Cancerous and Normal Cells 
THP-1 M0 macrophages were exposed to plasma and co-cultured with either A549 
or Beas2B cells. THP-1 monocytes were seeded into 24-well plates and differentiated into 
M0 macrophages with 0.5 μL of PMA (100 μL/mL) one day prior to plasma treatment. 
A549 and Beas2B cells were seeded spereately into transwell inserts (Corning Life 
Sciences, USA) at 0.3x105 cells/insert with 600 μL in the basal layer.  
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Cells were washed twice immediately before plasma treatment of M0 macrophages 
cells and 750 μL of complete THP-1 media was added immediately after. Inserts with either 
A549 cells or Beas2B cells were placed into the plasma treated wells and 750 μL of 
corresponding complete media was added. Media was changed the next day and cells 
remained in culture for an additional 24 hours before viability analysis.  
 
Figure 5. NspDBD plasma treatment system. High voltage pulses are delivered by a A) 
nanosecond pulser and with a function generator. B) A z-positioner was use to position the 
electrode above the cells in the 24-well plate. C) Plasma is generated in direct contact with 
cells. 
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Table 2 NspDBD Plasma Treatment Parameters 
Parameter Value 
Excitation Nanosecond pulsed 
Regime Uniform 
Voltage 29 kV 
Rise Time 2 ns 
Pulse Width 20 ns 
Gap Distance 1 mm 
Energy Per Pulse 0.9 mJ/pulse 
Frequency 5, 15, 30, 75 Hz 
Treatment Time 10 seconds 
Plasma Treatment Energies 50, 100, 300, 700 mJ 
Statistical Analysis 
Experiment was performed with a minimum of three replicates and repeated at least 
twice. Data are presented as mean±SEM. One-way ANOVA with post hoc Dunnett’s or 
Tukey’s multiple comparisons test and two-way ANOVA test with post hoc Sidak’s 
multiple comparisons test was performed in GraphPad Prism 6. p<0.05 was considered 
significant. 
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CHAPTER 9: CONCLUSION AND FUTURE WORK 
The use of non-thermal plasma for cancer immunotherapy has the potential to shift 
the current paradigm of plasma cancer treatment and be potentially advantageous for 
patients.  
Hypothesis: Plasma induces immunogenic cancer cell death through oxidative 
stress pathways, initiating antigen presenting cell recruitment followed by specific anti-
tumor T cell development. 
I. SUMMARY AND OVERALL CONCLUSIONS 
The purpose of this research was to: 
1) Explore the potential of non-thermal plasma to elicit immunogenic cell death 
2) Determine the underlying mechanisms of plasma-induced ICD  
3) Evaluate downstream anti-cancer immune responses.  
This would find application in cancer immunotherapy. To accomplish this, both in vitro 
and in vivo studies were conducted.  
I.1 IN VITRO RESULTS 
To summarize the results from in vitro studies, three cancer cell lines were treated 
with plasma: the A549 lung carcinoma cell line, the CNE-1 radiation-resistant 
nasopharyngeal cancer cell line and the CT26 colorectal cancer cell line. To identify 
whether plasma could elicit ICD, two DAMP signals were measured: secreted ATP and 
ecto-CRT. The same regime of plasma was identified to elicit ICD in all three treated cell 
lines as detected by emission of two DAMP signals: secreted ATP and ecto-CRT. This 
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indicates that induced ICD is a result of plasma stimulated processes and is not limited by 
cancer cell type. Following plasma treatment at the ICD-inducing regime, we observed 
increased intracellular ROS and upregulation of two ER stress response genes upstream of 
CRT emission, ATF4 and STC2. When intracellular ROS was attenuated with chemical 
agents, emission of ecto-CRT was also reduced. This suggested that plasma elicits ICD 
through known pathways associated with other ICD inducers (e.g. radiation and some 
chemotherapeutics): increased intracellular ROS with concomitant ER stress. 
The underlying interactions between plasma and cells required for ICD induction 
were also studied. Physical and gas barriers were engineered to systematically isolate and 
remove plasma components from treatment. When the plasma applicator was submerged 
in a liquid, the applied electric field is less than the dielectric strength of the medium, and 
therefore, electric fields were present during treatment but plasma was not generated. A 
quartz barrier was used to contain plasma constituents and only allow delivery of UV A, B 
and C to cells. Both, electric fields and plasma-generated UV had minimal effect on cell 
viability and ICD. A mesh barrier was used to only allow the delivery of long-lived, 
plasma-generated species to cells. While cell viability marginally recovered compared to 
our positive control (complete plasma discharged in air) (64% viable cells vs 50% 
respectively), DAMP emission was decreased significantly (CRT decreased from 27% to 
4% change from control and ATP went down from 87-fold to 17-fold). This strongly 
suggested that while long-lived species (e.g. H2O2, NO, O3, etc.) are important for cell 
death, charged and short-lived reactive species (e.g. 1O2, ∙OH, O2∙-, etc.) are required for 
initiating ICD. A pure nitrogen gas and pure oxygen gas barrier was used to determine the 
contribution of plasma-generated nitrogen and oxygen species, respectively. While plasma 
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discharge in nitrogen had negligible effects on cell viability and ICD, discharge in oxygen 
elicited responses that were similar to our positive control. Altogether, it is clear that the 
plasma-generated charged and short-lived ROS are the major contributors of ICD, though 
other synergistic effects are possible.  
I.2 IN VITRO ICD FOR IN VIVO PROTECTION 
Presently, the most accepted proof that a stimulus is a bona fide ICD inducer is 
through the use of a vaccination assay. CT26 colorectal cancer cells were treated with ICD-
inducing plasma and subcutaneously injected into the left flank of syngeneic Balb/c mice 
as a whole-cell vaccine. Untreated cells and cells treated with 50 μM of Cisplatin (a non-
ICD inducing chemotherapeutic) for 24 hours were used as negative controls. 
Mitoxantrone-treated cells served as our positive control.  Mice were then challenged with 
live CT26 cells on the contralateral flank one week after immunization. At the end of the 
study, mean tumor volumes of mice immunized with plasma-treated cells were 
significantly smaller than that of both negative controls. Furthermore, 3 out of the 10 mice 
in the plasma group did not develop tumors on the challenge site. In this study, contrary to 
literature, the animals in the positive control group developed tumors, and that data was 
not used in the analysis. While our data shows some protective effects of the plasma-
created vaccine, further optimization of vaccine creation and delivery is required. These 
experiments are needed and must be repeated to demonstrate that the plasma system can 
be fine-tuned to produce a regime for ICD induction.   
I.3 IN VIVO RESULTS 
To validate if ICD could be induced in vivo, experiments were performed on 
subcutaneous tumors in Balb/c mice. Plasma treatment resulted in the emission of CRT 
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and HMGB1 in the tumor. Furthermore, more CD11c+ and CD45+ immune cells were 
observed in the tumor microenvironment. There was a small amount of reversible 
histopathological damage in the skin at higher energy treatments. Plasma treatment was 
optimized by tuning treatment frequency, time and contact area to achieve DAMP emission 
and immune cell recruitment with minimal, reversible damage to normal tissue. In a 28 day 
study, we showed that plasma treatment of subcutaneous tumors, combined with 
administration of a cancer vaccine could enhance the development of cancer-specific 
splenic T cells. Our results also suggest that epitope spreading occurred which suggests 
that neoantigens were exposed. In our study, plasma alone did not appear to generate T 
cells but worked in combination with vaccine therapy, suggesting that plasma combination 
with other therapies may also provide beneficial outcomes. The plasma system parameters 
(frequency, duration, excitation, etc.) and the treatment parameters (e.g. number of 
treatments a week and days between treatments) also require further investigation to 
enhance therapeutic responses. Following immunological principles, effector T cells 
should systemically and specifically eliminate cancer in the patient, and the patient should 
develop memory T cells needed for long-term protection. These immunological events still 
remain to be tested.  
Altogether, our results support our hypothesis that plasma induces ICD and 
highlights the potential for clinical translation for cancer immunotherapy.  
II. FUTURE WORK 
This research can be further extended by examining some of the following aspects: 
197 
 
 
 
1. Long-Term Efficacy: A key test for systemic immunity against cancer would be the 
regression of untreated metastatic lesions following treatment of a single lesion. 
Such studies can provide the framework for better optimization of plasma systems 
and treatment protocols. More long term studies are required to validate cure rates 
in different tumor models. These should in parallel also examine the relevant 
immune responses. Comparison with studies in immunocompromised mice could 
be used to elucidate the specific role of different immune cells.  
2. Safety: While clinical efficacy is important, risk assessment must be performed 
before plasma becomes an acceptable clinical treatment. In the local treated areas, 
histological and histochemical analysis should be performed to detect any 
abnormalities or morphological changes. Additionally, genetic changes (DNA 
damage, mutations, etc.) should be monitored immediately and in long term follow-
up. Systemic changes in pro-inflammatory cytokines and tumor makers will also 
help in toxicity evaluation. Non-invasive imaging methods can be used for long-
term monitoring for neoplastic lesion development.  
3. Delineation of the specific plasma-generated ROS: Building off my previous 
experiments and existing literature in plasma chemistry and cancer pathology, 
plasma-generated species that may elicit ICD include singlet oxygen (1O2), 
hydroxyl radicals (∙OH), and superoxide radicals (O2∙-) [243-245]. To date, the 
influence of these species on ICD has not been investigated. Electron paramagnetic 
resonance (EPR) spectroscopy, the most direct method of radical detection in 
solution can be performed on liquid exposed to ICD-inducing regimes of plasma to 
delineate the contribution and concentration of these species [246]. The following 
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spin traps will be used: 1) 5,5-dimethyl-1-pyrroline N-oxide (DMPO) for ∙OH, 2) 
5-(diethoxyphosphoryl)-5-methy-1-pyrroline N-oxide (DEPMPO) for O2∙-, and 3) 
2,2,6,6-tetramethylpiperidine (TEMP) with and without sodium azide (NaN3) for 
1O2. The intensity of the EPR signal of TEMPO will give the concentration of 
O3/
1O2/O. Adding NaN3 to PBS, a 
1O2 scavenger, and comparing the EPR intensity 
of TEMPO after treatment without NaN3 will give the concentration of 
1O2 alone. 
To confirm that these radicals are the major effectors of plasma-induced ICD, EPR 
spectroscopy will be performed on liquid treated by plasma without short-lived 
species with the use of the copper mesh barrier, previously developed and shown 
to abrogate DAMP emission after plasma exposure [247]. This will not only 
provide deeper fundamental understanding of plasma-cell interactions for ICD but 
may also be used to further optimize plasma treatment sources for cancer 
immunotherapy.  
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